

APSR2021

The 25th Congress of the Asian Pacific Society of Respirology

OUR FUTURE



Digital Program Booklet

Hybrid Congress - Live Webinar on November 20-21, 2021
at/from the Kyoto International Conference Center

- On-demand on November 20 - December 21, 2021



Greeting from Local Congress Committees

Welcome to APSR 2021

It is with great pleasure that the 25th Congress of the Asian Pacific Society of Respiriology (APSR 2021) will take a place on 20th and 21st November 2021 for the first time as a hybrid event that will be held both in person in Kyoto and online around the world.

For APSR 2021, we are planning various programs in accordance with the theme of the congress, "Our Future." This does not simply refer to future development or young scientists. People see the world differently and have different feelings and sentiments depending on their age and level of experience. Different goals and tasks are set depending on their type of occupation, e.g., medical practitioner, researcher, manufacturer, or government officer, and different opinions and hopes can be brought together to broaden the path to the future. APSR 2021 provides opportunities for people of different ages, positions and occupations to discuss opinions, challenges and hopes from their respective viewpoints to explore future visions. At the same time, the congress will comprehensively examine and present "Our Future," i.e., the future of respiriology.

We will fully consider what we can do for "Our Future" as APSR 2021 in the shadow of the pandemic and strive to make it meaningful and successful. We will also carefully monitor the status of COVID-19 and make appropriate decisions as necessary.

We sincerely hope things will settle down soon and look forward to seeing you all in APSR 2021.

November 20-21, 2021



Shu Hashimoto
President of APSR 2021
Professor Emeritus, Nihon University



Kazuhisa Takahashi
Secretary General of APSR 2021
Juntendo University Faculty of Medicine and Graduate School of Medicine



Takeshi Kaneko
Chair of Program Committee of APSR 2021
Yokohama City University Graduate School of Medicine

Acknowledgment

Platinum Sponsor



Gold Sponsor



Silver Sponsor



Donation

CHEST M.I., INC
Healios K.K.

Co-sponsored Seminar

BIOMERIEUX
Bristol Myers Squibb
Broncus Medical
DAIKIN MEDICAL TECHNOLOGY(SUZHOU)CO.,LTD
Eli Lilly Japan K.K.
FUJIFILM Healthcare Corporation
Gilead Sciences K.K.
GlaxoSmithKline
Hill-Rom Services Pte Ltd
Japan Clean Air Association
Kyorin Pharmaceutical Co., Ltd.
MSD K.K.
Nikkeisha, Inc.
Nippon Kayaku Co., Ltd.
Olympus Corporation
ONO PHARMACEUTICAL CO., LTD
Takeda Pharmaceutical Company Limited.
Terumo Coporation
Trudell Medical International

Exhibition

AIR WATER MEDICAL Inc.
KONICA MINOLTA JAPAN, INC.
Olympus Corporation

Advertisement

TEIJIN PHARMA LIMITED.
Healios K.K.
MSD K.K.
Sumitomo Dainippon Pharma Co., Ltd.
Oxford Immunotec K.K.
Philips Japan, Ltd.

Grant

The Kyoto Convention & Visitors Bureau

Congress Committee

Central Congress Committee

Chairperson	Kazuto Matsunaga
President	Yoichi Nakanishi
President-Elect	David C L Lam
Treasurer	Yasuhiko Nishioka
Chairperson of the Research Committee	Young Whan Kim
Chairperson of the Education Committee	Philip Eng
Joint representative of the Editorial Office	Philip Bardin
Joint representative of the Editorial Office	Paul Reynolds
President of the previous congress	Chau Ngo Quy
President of the congress	Shu Hashimoto

Local Congress Committees

Honorary President	Michiaki Mishima	Saiseikai Noe Hospital/Professor Emeritus, Kyoto University
Honorary Advisor	Yoshinosuke Fukuchi	Professor Emeritus, Juntendo University Faculty of Medicine and Graduate School of Medicine
President	Shu Hashimoto	Professor Emeritus, Nihon University
Vice President	Toyohiro Hirai	Graduate School of Medicine Kyoto University
	Yoshinori Hasegawa	National Hospital Organization Nagoya Medical Center
	Akihiko Gemma	Graduate School of Medicine, Nippon Medical School
	Akihito Yokoyama	Kochi Medical School, Kochi University
Advisor	Toshihiro Nukiwa	Professor Emeritus, Tohoku University School of Medicine
	Yoichi Nakanishi	Kitakyushu City Hospital Organization

– Secretariat

Secretary General	Kazuhisa Takahashi	Juntendo University Faculty of Medicine and Graduate School of Medicine
Deputy Secretary General	Yasuhiro Gon	Nihon University School of Medicine
Executive Assistant	Norihiro Harada	Juntendo University Faculty of Medicine and Graduate School of Medicine
	Mari Hikichi	Nihon University School of Medicine

– Scientific Program Committees

Chair of Program Committee	Takeshi Kaneko	Yokohama City University Graduate School of Medicine
Vice-Chair of Program Committee	Yasuhiko Nishioka	Graduate School of Biomedical Sciences, Tokushima University
Program Committees	Tetsutaro Nagaoka	Juntendo University Faculty of Medicine and Graduate School of Medicine
	Shuichiro Maruoka	Nihon University School of Medicine
	Nobuaki Kobayashi	Yokohama City University Graduate School of Medicine
	Mari Hikichi	Nihon University School of Medicine

– Treasurer

Chair of Treasurer	Yuji Tohda	Kindai University Hospital
Vice-Chair of Treasurer	Masakazu Ichinose	Osaki Citizen Hospital
Treasurer Committees	Junichi Kadota	Nagasaki City Hospital Organization Nagasaki Harbor Medical Center
	Sakae Homma	Toho University Graduate School of Medicine
	Masayuki Hanaoka	Shinshu University School of Medicine
	Hideo Saka	National Hospital Organization Nagoya Medical Center
	Fumihiko Asano	Gifu Prefectural General Medical Center
	Nobuyuki Yamamoto	Wakayama Medical University

Keynote Lecture
 Presidential Lecture
 Award Lecture

Keynote Lecture

SATURDAY • NOVEMBER 20 13:20 - 14:00
 Room 1

Chair: Shu Hashimoto
 (Professor Emeritus, Nihon University, Japan)

KL The importance of the innate immune response in resilience against COVID-19

Speaker: Stephen Townley Holgate
 (University of Southampton, UK)

On-demand delivery date: November 22 - December 28, 2021

Presidential Lecture

SATURDAY • NOVEMBER 20 12:40 - 13:20
 Room 1

Chairs: Akihito Yokoyama
 (Kochi Medical School, Kochi University, Japan)
 Mari Hikichi
 (Nihon University School of medicine, Japan)

PL Our future; the path we're on

Speaker: Shu Hashimoto
 (Professor Emeritus, Nihon University, Japan)

On-demand delivery date: November 22 - December 28, 2021

Award Lecture 1: Michiyoshi Harasawa Memorial Award

SATURDAY • NOVEMBER 20 9:40 - 10:20
 Room 10

Chairs: Teresita de Guia
 (Philippine Heart Center, Philippines)
 Shoji Kudoh
 (Japan Anti-Tuberculosis Association, Japan)

AL1 A novel diagnostic and therapeutic strategy based on micro-aspiration

Speaker: Shinji Teramoto
 (Tokyo Medical University, Japan)

On-demand delivery date: November 22 - December 28, 2021

Award Lecture 2: Ann Janet Woolcock Memorial Award

SATURDAY • NOVEMBER 20 10:30 - 11:20
 Room 10

Chairs: Kim Young Whan
 (Konkuk University Medical Center, Republic of Korea)
 Arth Nana
 (Mahidol University, Thailand)

AL2 Biomarker research in lung cancer

Speaker: David CL Lam
 (University of Hong Kong, Hong Kong)

On-demand delivery date: November 22 - December 28, 2021

Expert View
Special Program

Expert View 1

On-demand

Chairs: Nobuoki Kohno
(Hiroshima Cosmopolitan University, Japan)
Kazuko Yamamoto
(Nagasaki University Graduate School of Biomedical Sciences, Department of Molecular Microbiology and Immunology, Japan)

EV1 Japanese guideline for diagnosis and treatment of COVID-19

Speaker: Yasuyuki Kato
(International University of Health and Welfare, Japan)

On-demand delivery date: November 20 - December 28, 2021

Expert View 2

On-demand

Chairs: Grace Sin-man Lam
(Pamela Youde Nethersole Eastern Hospital, Hong Kong)
Junichi Kadota
(Nagasaki City Hospital Organization Nagasaki Harbor Medical Center, Japan)

EV2 Overview of COVID-19

Speaker: Jiro Fujita
(University of the Ryukyus, Japan)

On-demand delivery date: November 20 - December 28, 2021

Expert View 3

On-demand

Chairs: Katsunori Yanagihara
(Nagasaki University, Japan)
Tetsutaro Nagaoka
(Juntendo University, Japan)

EV3 Incorporation of Molecular Diagnostics for Severe Pneumonia

Speaker: Richard G Wunderink
(Northwestern University Feinberg School of Medicine, USA)

On-demand delivery date: November 20 - December 28, 2021

Expert View 4

On-demand

Chairs: Celeste Mae L. Campomanes
(St. Luke's Medical Center, Philippines)
Shigeo Muro
(Nara Medical University, Japan)

EV4 Building a Walkable City and Infrastructure

Speaker: Shinya Kuno
(University of Tsukuba, Japan)

On-demand delivery date: November 20 - December 28, 2021

Expert View 5

On-demand

Chairs: Yasunari Miyazaki
(Tokyo Medical and Dental University, Japan)
Noboru Hattori
(Hiroshima University, Japan)

EV5 Host-Microbiome Interactions in the Pathogenesis of IPF

Speaker: Stavros Garantziotis
(National Institutes of Health, USA)

On-demand delivery date: November 20 - December 28, 2021

Expert View 6

On-demand

Chairs: Sita Andarini

(Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, University of Indonesia - Persahabatan Hospital, Jakarta, Indonesia)

Kazuhisa Takahashi

(Professor, Juntendo University, Graduate School of Medicine, Japan)

EV6 Advances in perioperative therapy: the new frontier**Speaker:** David P. Carbone

(The Ohio State University Comprehensive Cancer Center, USA)

On-demand delivery date: November 20 - December 28, 2021

Expert View 7

On-demand

Chairs: Kazuyoshi Imaizumi

(Fujita Health University, Japan)

Nobuaki Kobayashi

(Yokohama City University Graduate School of Medicine, Japan)

EV7 A Role of the Pathologist in Personalized Medicine for Lung Cancer Patient**Speaker:** Mari Mino-Kenudson

(Professor of Pathology, Harvard Medical School, MA, USA)

On-demand delivery date: November 20 - December 28, 2021

Expert View 8

On-demand

Chairs: Yuji Tohda

(Kindai University Hospital, Japan)

Takeshi Kaneko

(Yokohama City University, Japan)

EV8 A New Paradigm for the Management of Mild Asthma**Speaker:** Paul O'Byrne

(McMaster University, Canada)

On-demand delivery date: November 20 - December 28, 2021

Expert View 9

On-demand

Chairs: Kazuto Hirata

(Osaka City University Hospital, Japan)

Naomi Tsurikisawa

(Hiratsuka City Hospital, Japan)

EV9 Recent Advances in Severe asthma**Speaker:** Nizar N. Jarjour

(University of Wisconsin, Madison, USA)

On-demand delivery date: November 20 - December 28, 2021

Expert View 10

On-demand

Chairs: Hidenori Kage

(The University of Tokyo, Japan)

Mitsuhiro Yamada

(Tohoku University Hospital, Japan)

EV10 Approaches to lung endothelial cell repair in emphysema**Speaker:** Irina Petrache

(National Jewish Health, USA)

Closing Remarks:

Akira Koarai

(Tohoku University Graduate School of Medicine, Japan)

On-demand delivery date: November 20 - December 28, 2021

Expert View 11

On-demand

Chairs: Jane Bourke

(Monash University, Malaysia)

Sadatomo Tasaka

(Hirosaki University Graduate School of Medicine, Japan)

EV11 Survival Skills for an Academic Career**Speaker:** Lynn M Schnapp

(School of Medicine and Public Health, University of Wisconsin-Madison, USA)

On-demand delivery date: November 20 - December 28, 2021

Expert View 12

On-demand

Chairs: Natasha E Smallwood
(Alfred Hospital, Australia)
Toyohiro Hirai
(Department of Respiratory medicine, Graduate
School of Medicine, Kyoto University, Japan)

**EV12 Career Development and Gender
Equality to Achieve Sustainable Development**

Speaker: Tsuyako Nakamura
(Doshisha University, Japan)

On-demand delivery date: November 20 - December 28, 2021

Expert View 13

On-demand

Chairs: Yasutaka Nakano
(Shiga University of Medical Science, Japan)
Mayoko Tsuji
(Tokyo Women's Medical University, Japan)

EV13 Racial and ethnic disparities in respiratory health

Speaker: Neeta Thakur
(University of California, San Francisco, USA)

On-demand delivery date: November 20 - December 28, 2021

Expert View 14

On-demand

Chairs: Agus Dwi Susanto
(Department of Pulmonology and Respiratory Medicine, Faculty of Medicine Universitas Indonesia-Persahabatan Hospital, Indonesia)
Satoshi Konno
(Hokkaido University, Japan)

EV14 NHS pledges to go net zero carbon

Speaker: Nick Watts
(NHS, UK)

On-demand delivery date: November 20 - December 28, 2021

Expert View 15

On-demand

Chairs: Paul Reynolds
(Royal Adelaide Hospital, Australia)
Yasuhiko Nishioka
(Department of Respiratory Medicine and Rheumatology, The University of Tokushima, Japan)

EV15 The public health implications of the Paris Agreement: a model study

Speaker: Ian Hamilton
(The Lancet Countdown on Health and Climate Change, University College London, UK)

On-demand delivery date: November 20 - December 28, 2021

Expert View 16

On-demand

Chairs: Mitsuko Kondo
(Department of Respiratory Medicine, Tokyo Women's Medical University, Japan)
Shuichiro Maruoka
(Nihon University School of Medicine, Japan)

EV16 COVID-19 and its impact on the SDGs

Speaker: Mari Kosaka
(Tokai University, Japan)

On-demand delivery date: November 20 - December 28, 2021

Expert View 17

On-demand

Chair: Yasuhiro Gon
(Nihon University School of Medicine, Japan)

EV17 Deforestation and Zoonotic Disease

Speaker: Kimiko Okabe
(Forestry and Forest Products Research Institute, Japan)

On-demand delivery date: November 20 - December 28, 2021

Special Program 1

SUNDAY • NOVEMBER 21

9:00 - 10:30

Room 1

SP1 History, Present, and future of the APSR**Chairs:** Michiaki Mishima

(Saiseikai Noe Hospital/Professor Emeritus, Kyoto University, Japan)

Kwun M Fong

(University of Queensland Thoracic Research Centre, The Prince Charles Hospital, Australia)

Yoshinori Hasegawa

(National Hospital Organization Nagoya Medical Center, Japan)

Speakers:**1. The launch and early history of the APSR**

Yoshinosuke Fukuchi

(Juntendo University, Japan)

2. Present Status

Yoichi Nakanishi

(Kitakyusyu City Hospital Organization, Japan)

3. Future

David CL Lam

(University of Hong Kong, HKSAR, Hong Kong)

On-demand delivery date: November 24 - December 28, 2021

Special Program 2

SUNDAY • NOVEMBER 21

16:20 - 17:50

Room 1

SP2 Message and lecture by representatives of sister society and president of 26th congress of APSR**Chairs:** Albert Lim Yick Hou

(President of 27th Congress of the APSR (Singapore Thoracic Society), Senior Consultant, Department of Respiratory & Critical Care Medicine, Tan Tock Seng Hospital, Singapore)

Toshihiro Nukiwa

(Tohoku University, Sendai, Japan)

Akihito Yokoyama

(Kochi University, Japan)

Speakers:**1. Pulmonary embolism in patients with COVID-19**

Marc Humbert

(President of the ERS, South Paris University, France)

2. Sleep medicine in COVID-19 pandemic

Anita Simonds

(Past President of the ERS, National Heart and Lung Institute, Imperial College London, UK)

3. COPD management in COVID-19 pandemic

Ki-Suck Jung

(Hallym University College of Medical, South Korea)

4. Restarting Respiratory Clinical Research in the era of the COVID-19 pandemic

Gregory P. Downey

(President-elect of the ATS, University of Colorado Denver Anschutz Medical campus, USA)

On-demand delivery date: November 24 - December 28, 2021

Congress Symposium

Congress Symposium 1

SATURDAY · NOVEMBER 20

8:30 - 10:00

Room 6

CS1 Current topics on clinical and basic aspects in COVID-19 in Asia Pacific Region-1

Chairs: Philip Eng
(Mt Elizabeth Hospital, Rep of Singapore)
Yuji Fujikura
(National Defense Medical College, Japan)

Speakers:

- 1. Japan COVID-19 Task Force: a nation-wide consortium to elucidate host genetics of COVID-19**
Ho Namkoong
(Keio University School of Medicine, Japan)
- 2. Differential diagnosis of pneumonias in the COVID-19 era: insights from multicenter cohort study in Japan**
Isao Ito
(Kyoto University, Japan)
- 3. ECMO cohort study in Korea**
Kuk-Hui Son
(Gachon University Gil Medical Center, Gachon University, Korea)
- 4. A multi-center study on the safety and efficacy of remdesivir for patients with moderate to severe COVID-19 in three hospitals in Indonesia**
Erlina Burhan
(Indonesian Society of Respiriology, Indonesia)
- 5. Summary**
Tomoo Kishaba
(Okinawa Chubu Hospital, Japan)

On-demand delivery date: November 24 - December 28, 2021

Congress Symposium 2

SATURDAY · NOVEMBER 20

10:10 - 11:40

Room 6

CS2 Current topics on clinical and basic aspects in COVID-19 in Asia Pacific Region-2

Chairs: Yuanlin Song
(Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai Respiratory Research Institute Shanghai Key Laboratory of lung inflammation and injury, China)
Hirofumi Chiba
(Sapporo Medical University, Japan)

Speakers:

- 1. Long-term effects of COVID-19 in a cohort with both community and hospital management**
Anthony Byrne
(St Vincent's Hospital Sydney Heart Lung Clinic Department of Thoracic Medicine and St Vincent's Clinical School University of New South Wales Faculty of Medicine, Australia)
- 2. COVID-19 and interstitial pneumonia**
Takashi Ogura
(Kanagawa Cardiovascular Respiratory Center, Japan)
- 3. COVID-19 and Stress-induced asthma**
Shuichiro Maruoka
(Nihon University, Japan)
- 4. ABCDEF Bundle and Supportive ICU Practices for Patients With Coronavirus Disease 2019 Infection**
Keibun Liu
(Critical Care Research Group, The Prince Charles Hospital, QLD, Australia)
- 5. Summary**
Makoto Ishii
(Keio University School of Medicine, Japan)

On-demand delivery date: November 24 - December 28, 2021

Congress Symposium 3

SATURDAY • NOVEMBER 20

15:10 - 16:40

Room 6

CS3 Our Future [Part 1] 1) Gender equality and career development in medicine

Chairs: Philip Bardin
(Monash University and Medical Centre, Australia)
Etsuko Tagaya
(Tokyo Women's Medical University, Japan)

Speakers:

- 1. Future we want in academia**
Mari Hikichi
(Nihon University School of Medicine, Japan)
- 2. Building our future: shaping a medical culture where both men and women can thrive**
Jane Latimer
(University of Sydney, Australia)
- 3. Gender equality in medicine - why we should all be champions for change**
Adam Andrew Castricum
(Australasian College of Sport and Exercise Physicians, Australia / New Zealand)
- 4. Creating organizations that promote gender equality and women's career development**
Masumi Takeuchi
(Kobe University, Japan)
- 5. Summary**
Mary Sau-Man Ip
(The University of Hong Kong, Hong Kong)

On-demand delivery date: November 24 - December 28, 2021

Congress Symposium 4

SATURDAY • NOVEMBER 20

16:45 - 17:50

Room 6

CS4 Our future [Part 2] 2) Learn and apply sociology of the work environment

Chair: Hisako Matsumoto
(Kindai University, Japan)

Speakers:

- 1. Work-Life balance**
Katsuhiko Hirasawa
(Nihon University College of Commerce, Japan)

2. A study on Human Resources of Public Health in the Post-COVID Era

Liu Li
(Department of Neurology of The First Affiliated Hospital ChongQing Medical University, China)

3. Women's career and work-life integration

Tsuyako Nakamura
(Doshisha University, Japan)

On-demand delivery date: November 24 - December 28, 2021

Congress Symposium 5

SUNDAY • NOVEMBER 21

9:00 - 10:30

Room 5

CS5 Think about refractory asthma; Treatment position of oral corticosteroids and biologics

Chairs: Christopher Lai
(The Chinese University of Hong Kong, Hong Kong)
Koichi Fukunaga
(Keio University School of Medicine, Department of Medicine, Pulmonary Division, Japan)

Speakers:

- 1. Pathophysiology of refractory asthma and goals to aim for**
Yasuhiro Gon
(Division of Respiratory Medicine, Nihon University School of Medicine, Japan)
- 2. Clinical findings, problems and visions for OCS in the treatment of refractory asthma**
Fanny Wai San Ko
(The Chinese University of Hong Kong, Hong Kong)
- 3. Current and future positioning of biologics in the treatment of refractory asthma**
Hiroto Matsuse
(Toho University Ohashi Medical Center, Japan)
- 4. Summary**
Tamotsu Ishizuka
(University of Fukui, Japan)

On-demand delivery date: November 24 - December 28, 2021

Congress Symposium 6

SUNDAY • NOVEMBER 21

9:00 - 10:30

Room 6

CS6 Progress and future directions for Immunotherapy for lung cancer (tentative)**Chairs:** Chong-Kim Liam

(Division of Respiratory Medicine, Department of Medicine, University Malaya Medical Centre, Malaysia)

Kazuhisa Takahashi

(Juntendo University, Graduate School of Medicine, Japan)

Speakers:**1. Current evidence of immune checkpoint inhibitors in the treatment of NSCLC**

Myung-Ju Ahn

(Sungkyunkwan University, South Korea)

2. Current status of Immunotherapy

Kentaro Tanaka

(Kyusyu University, Japan)

3. Future perspective of Immunotherapy

Aaron S. Mansfield

(Mayo Clinic College of Medicine and Science, USA)

4. Summary

Koichi Takayama

(Kyoto Prefectural University of Medicine, Japan)

On-demand delivery date: November 24 - December 28, 2021

Congress Symposium 7

SUNDAY • NOVEMBER 21

9:00 - 10:30

Room 7

CS7 Reconsideration of regulating eosinophils**Chairs:** James G. Martin

(McGill University, Canada)

Makoto Nagata

(Saitama Medical University, Japan)

Speakers:**1. Asthma-mediated resolution of inflammatory rheumatoid arthritis via regulatory eosinophils**

Aline Bozec

(Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Germany)

2. Eosinophils, airway nerves, and cough

Akio Niimi

(Nagoya City University, Japan)

3. Inflammatory tissue-derived eosinophils

Jun Miyata

(National Defense Medical College, Japan)

4. Summary

Akio Niimi

(Nagoya City University, Japan)

On-demand delivery date: November 24 - December 28, 2021

Congress Symposium 8

SUNDAY • NOVEMBER 21

9:00 - 10:30

Room 8

CS8 Impact of environmental factor on respiratory system**Chairs:** Anna Nolan

(New York University School of Medicine, USA)

Takafumi Suda

(Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Japan)

Speakers:**1. Impact of climate change on human health**

Yasushi Honda

(University of Tsukuba, Japan)

2. Metabolomics of World Trade Center-Lung Injury: a machine learning approach

Anna Nolan

(New York University School of Medicine, USA)

3. Summary

Nobukazu Fujimoto

(Okayama Rosai Hospital, Japan)

On-demand delivery date: November 24 - December 28, 2021

Congress Symposium 9

SUNDAY • NOVEMBER 21

12:40 - 14:10

Room 4

CS9 Palliative care in respiratory diseases

Chairs: David C Currow
(University of Wollongong, Australia)
Toru Tsuda
(Kirigaoka Tsuda Hospital, Japan)

Speakers:

- 1. Palliative oxygen for breathlessness**
David C Currow
(University of Wollongong, Australia)
- 2. Opioids for dyspnea in COPD**
Nicholas T. Vozoris
(University of Toronto, Canada)
- 3. Palliative care in lung cancer**
Akira Inoue
(Tohoku University School of Medicine, Japan)
- 4. Palliative treatment in severe respiratory disease**
Magnus P Ekström
(Lund University, Sweden)
- 5. Summary**
Ryo Tachikawa
(Kobe City Medical Center General Hospital, Japan)

On-demand delivery date: November 24 - December 28, 2021

Congress Symposium 10

SUNDAY • NOVEMBER 21

12:40 - 14:10

Room 5

CS10 Telemedicine in respiratory care: current status and future

Chairs: Chang-Keun Kim
(Asthma and Allergy Center, Inje University SanggyePaik Hospital, Korea)
Kazuo Chin
(Nihon University of Medicine, Japan)

Speakers:

- 1. Tele-monitoring of CPAP in sleep disorders in Japan**
Toru Oga
(Kawasaki Medical University, Japan)

2. The current situation of telemedicine in respiratory diseases in Korea

Jung Yeon Shim
(Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Korea)

3. Current status of e-health for respiratory diseases in Taipei

Chien-Hua Tseng
(Taipei Medical University-Shuang-Ho hospital, Taiwan)

4. Remote-Monitoring of Home Non-Invasive Ventilation

Chris Carlin
(NHS Greater Glasgow & Clyde, UK)

On-demand delivery date: November 24 - December 28, 2021

Congress Symposium 11

SUNDAY • NOVEMBER 21

12:40 - 14:10

Room 6

CS11 Management of underlying diseases causing severe COVID-19

Chairs: Ngo Quy Chau
(Tam Anh General hospital, Viet Nam)
Kazuto Matsunaga
(Yamaguchi University, Japan)

Speakers:

- 1. Working diagnosis and initial management of COPD during the COVID-19 pandemic**
Yoko Shibata
(Department of Pulmonary Medicine, Fukushima Medical University School of Medicine, Japan, Japan)
- 2. New Strategic Approach to COPD management**
Ian A. Yang
(The Prince Charles Hospital and The University of Queensland, Australia)
- 3. Management of COPD in COVID-19 pandemic**
Digambar Behera
(Postgraduate Institute of Medical Education and Research, and Fortis Health Care, India)
- 4. Summary**
Kazuhisa Asai
(Osaka City University, Japan)

On-demand delivery date: November 24 - December 28, 2021

Congress Symposium 12

SUNDAY • NOVEMBER 21

16:20 - 17:50

Room 6

CS12 To end tuberculosis epidemic in global

Chairs: Erlina Burhan
(Indonesian Society of Respiriology, Indonesia)
Takeshi Kaneko
(Yokohama City University, Japan)

Speakers:

- 1. Global scale-up of tuberculosis preventive treatment: progress, challenges and recommended actions**
Dennis Falzon
(World Health Organization, Global TB Programme, Switzerland)
- 2. Treatment for latent tuberculosis infection in low- and middle-income countries: progress and challenges with implementation and scale-up.**
Erlina Burhan
(Indonesian Society of Respiriology, Indonesia)
- 3. Community-wide Screening for Tuberculosis in a High-Prevalence Setting**
Jennifer Ann M. Wi
(Lyceum Northwestern FQ Duque College of Medicine, Philippines)
- 4. Emerging concerns about latent tuberculosis infection in the COVID-19 era**
Nobuaki Kobayashi
(Yokohama City University Graduate School of Medicine, Japan)
- 5. Summary**
Toshiaki Kikuchi
(Niigata University Graduate School of Medical and Dental Sciences, Japan)

On-demand delivery date: November 24 - December 28, 2021

Congress Symposium 13

SUNDAY • NOVEMBER 21

16:20 - 17:50

Room 7

CS13 Single-cell analysis symposium

Chairs: Martijn C Nawijn
(University Medical Center Groningen, Netherlands)
Kazuyo Moro
(Osaka University, Japan)

Speakers:

- 1. The Human Lung Cell Atlas**
Martijn C Nawijn
(University Medical Center Groningen, Netherlands)
- 2. Intelligent Image-Activated Cell Sorting**
Keisuke Goda
(University of Tokyo, Japan)
- 3. Single-cell analysis and the innate lymphoid cells**
Kazuyo Moro
(Osaka University, Japan)
- 4. Summary**
Takuji Suzuki
(Chiba University, Japan)

On-demand delivery date: November 24 - December 28, 2021

Congress Symposium 14

SUNDAY • NOVEMBER 21

16:20 - 17:50

Room 8

CS14 Current topics and future perspectives in Asian Pacific Region

Chairs: Faisal Yunus
(University of Indonesia - Persahabatan Hospital, Indonesia)
Kazuma Kishi
(Toho University Medical Center Omori Hospital, Japan)

Speakers:

- 1. Lung cancer**
Fariz Nurwidya
(Universitas of Indonesia, Indonesia)
- 2. Treatment of Cancer associated thrombosis**
Jin Zhang
(General Hospital of Ningxia Medical University, China)
- 3. Interstitial pneumonia**
Jin Jin
(Beijing Hospital, China)

4. COPD

Tomotaka Kawayama
(Kurume University School of Medicine, Japan)

5. Summary

Yasunari Miyazaki
(Tokyo Medical and Dental University, Japan)

On-demand delivery date: November 24 - December 28, 2021

Assembly Symposium

Assembly Symposium 1: Clinical Respiratory Medicine

SATURDAY • NOVEMBER 20 8:30 - 10:00

Room 7

AS1 Haemoptysis with radiological clinical correlation

Chairs: Dushantha Madegedara
(National Hospital, Kandy, Sri Lanka)
Naozumi Hashimoto
(Nagoya University, Japan)

Speakers:

- 1. Educational Lecture: Indwelling pleural catheter management in malignant pleural effusion**

EL Speaker: Rajesh Thomas
(Sir Charles Gairdner Hospital and University of Western Australia, Australia)

- 2. Pathophysiological basis of Haemoptysis**
Koji Sakamoto
(Nagoya University, Japan)

- 3. How to investigate patients with Haemoptysis**
Dushantha Madegedara
(National Hospital, Kandy, Sri Lanka)

- 4. Radiological investigations in Haemoptysis**
Bhavin Jankharia
(Picture This, Mumbai, India)

On-demand delivery date: November 25 - December 28, 2021

Assembly Symposium 2: Cell and Molecular Biology

SATURDAY • NOVEMBER 20 10:10 - 11:40

Room 7

AS2 Hot topics in respiratory research

Chairs: Hidenori Kage
(The University of Tokyo, Japan)
Takuji Suzuki
(Chiba University, Japan)

Speakers:

- 1. Educational Lecture: TBD**

EL Speaker: Akihisa Mitani
(The University of Tokyo Hospital, Japan)

2. Cell type- and region-specific mucin and CFTR expression in the airway

Kenichi Okuda
(Cystic Fibrosis/Pulmonary Research and Treatment Center, School of Medicine, University of North Carolina at Chapel Hill, USA)

3. Role of p300 in the cigarette smoke-induced impaired immune response in macrophages

Chul-Gyu Yoo
(College of Medicine, Seoul National University, South Korea)

4. Targeting Supernumerary Centrosomes to Combat Lung Cancer

Masanori Kawakami
(The University of Tokyo, Japan)

On-demand delivery date: November 25 - December 28, 2021

Assembly Symposium 3: Clinical Allergy & Immunology

SATURDAY • NOVEMBER 20 15:10 - 16:40

Room 7

AS3 Current Topics in Asthma

Chairs: Janet Rimmer
(St Vincents Clinic, Australia)
Takashi Iwanaga
(Kindai University Hospital, Japan)

Speakers:

- 1. Educational Lecture: Difficult to treat and severe asthma in adults**

EL Speaker: Takashi Iwanaga
(Kindai University Hospital, Japan)

- 2. Severe T2-high asthma in the biologics era**
Ian Pavord
(University of Oxford, UK)

- 3. Asthma and covid-19 mortality**
Christine Jenkins
(The George Institute for Global Health, Australia)

- 4. ILC2 regulatory network and asthma**
Koichi Fukunaga
(Keio University of Medicine, Japan)

On-demand delivery date: November 25 - December 28, 2021

Assembly Symposium 4: Environmental & Occupational Health and Epidemiology

SATURDAY • NOVEMBER 20

8:30 - 10:00

Room 8

AS4 Emerging occupational and environmental interstitial lung diseases

Chairs: Woo Jin Kim
(Kangwon National University, Korea)
Kazuhiro Yatera
(University of Occupational and Environmental Health, Japan)

Speakers:**1. Educational Lecture: Air pollution and respiratory diseases**

EL Speaker: Kazuhiro Yatera
(University of Occupational and Environmental Health, Japan)

2. Silicosis, a re-emerging occupational ILD

Deborah H Yates
(University of NSW, Australia)

3. Humidifier disinfectant related lung diseases

Jun-Pyo Myong
(Seoul St. Mary's Hospital, College of Medicine, the Catholic University of Korea, Republic of Korea)

4. Recent advances in occupational and environmental ILD

Yasuo Morimoto
(University of Occupational and Environmental Health, Japan)

On-demand delivery date: November 25 - December 28, 2021

Assembly Symposium 5: Respiratory Infections (non-tuberculous)

SATURDAY • NOVEMBER 20

10:10 - 11:40

Room 8

AS5 Novel approaches on treatment of respiratory infectious disease

Chairs: Chieh Liang Wu
(Taichung Veterans General Hospital, Taiwan)
Masaki Fujita
(Fukuoka University Hospital, Japan)

Speakers:**1. Educational Lecture: Management of critically ill patients with influenza**

EL Speaker: Shih-Chi Ku
(National Taiwan University Hospital, Taiwan)

2. Possibility of treating infectious diseases by intervention to host susceptibility factors

Takuro Sakagami
(Kumamoto University, Japan)

3. Cell-based therapy on infectious disease-mechanism and efficacy

Jae Woo Lee
(University of California, San Francisco, USA)

4. Development of trans-airway and oral vaccines against respiratory viral infections using effective mucosal adjuvant SF10 based on human pulmonary surfactant

Hiroshi Kido
(Tokushima University, Institute of Advanced Medical Sciences, Japan)

On-demand delivery date: November 25 - December 28, 2021

Assembly Symposium 6: Tuberculosis

SATURDAY • NOVEMBER 20

15:10 - 16:40

Room 8

AS6 Artificial Intelligence in TB Diagnostics

Chairs: Charles Y. Yu
(De La Salle Medical and Health Sciences Institute, Philippines)
Jennifer Ann M. Wi
(Lyceum Northwestern FQ Duque College of Medicine, Philippines)

Speakers:**1. Educational Lecture: Message to TB clinicians. Evidence and techniques for proper sampling to ensure bacteriological TB confirmation for the treatment based on drug susceptibility test results**

EL Speaker: Jin Takasaki
(National Center for Global Health and Medicine, Japan)

2. Should This be part of Screening?

Jacob H Creswell
(Stop TB Partnership, Switzerland)

3. Role of X-ray for detection of TB

Ikushi Onozaki
(Research Institute of Tuberculosis, Japan)

4. Innovations in X-Ray and Artificial Intelligence Computer-Aided Detection (CAD) Software for TB Response-experience from the field and procurement availability

Zhi Zhen Qin

(Stop TB Partnership / United Nations Office for Project Services, Switzerland)

On-demand delivery date: November 25 - December 28, 2021

Assembly Symposium 7: Respiratory Neurobiology and Sleep

SUNDAY • NOVEMBER 21

9:00 - 10:30

Room 2

AS7 Alternative treatments for obstructive sleep apnea

Chairs: Danny J. Eckert

(College of Medicine and Public Health, Flinders University, Australia)

Yoshitaka Oku

(Hyogo College of Medicine, Japan)

Speakers:

1. Educational Lecture: Respiratory control during sleep - from bench to bedside

EL Speaker: Yoshitaka Oku

(Hyogo College of Medicine, Japan)

2. Nasal airway stent

Makoto Satoh

(University of Tsukuba, Moriya Keiyu Hospital, Japan)

3. Pharmacological interventions for obstructive sleep apnea

Danny J. Eckert

(College of Medicine and Public Health, Flinders University, Australia)

On-demand delivery date: November 25 - December 28, 2021

Assembly Symposium 8: Critical Care Medicine

SUNDAY • NOVEMBER 21

9:00 - 10:30

Room 3

AS8 Critical Illness in Cancer Patients

Chairs: Rex Chin-Wei Yung

(IONIQ Sciences Inc, USA, Johns Hopkins University (retired), USA)

Akihiko Gemma

(Nippon Medical School, Japan)

Speakers:

1. Educational Lecture: Management and problem of oncologic emergency in advanced lung cancer

EL Speaker: Kyoichi Kaira

(Saitama Medical university, International Medical Center, Japan)

2. Overview

Rex Chin-Wei Yung

(IONIQ Sciences Inc, Johns Hopkins University (retired), USA)

3. Clinical Question 1: Clinical problems in the treatment for advanced lung cancer with interstitial pneumonia: focusing on the pulmonary toxicity of cytotoxic anticancer agents and immune checkpoint inhibitors

Motoyasu Kato

(Juntendo University Graduate School of Medicine, Japan)

4. Clinical Question 2: Manifestation and management of toxicities of target therapy in cancer patients with critical illness

Jia-Yih Feng

(Taipei Veterans General Hospital, Taiwan)

5. Summary

Akihiko Gemma

(Nippon Medical School, Japan)

On-demand delivery date: November 25 - December 28, 2021

Assembly Symposium 9: Bronchoscopy and Interventional Techniques

SUNDAY • NOVEMBER 21

9:00 - 10:30

Room 4

AS9 Mediastinal staging - state of the art in the era of lung ablation

Chairs: Phan Nguyen
(Royal Adelaide Hospital, Australia)
Fumihiro Asano
(Gifu Prefectural General Medical Center, Japan)

Speakers:**1. Educational Lecture: EBUS**

EL Speaker: Takahiro Nakajima
(Dokkyo Medical University, Japan)

2. Bronchoscopic lung cancer ablation - are we ready for prime time?

Kazuhiro Yasufuku
(Division of Thoracic Surgery, Toronto General Hospital, UHN, University of Toronto, Canada)

3. EBUS-TBNA and EUS-B-FNA: From staging to re-biopsy in Lung cancer

Chih-Yen Tu
(China Medical University Hospital, Taiwan)

4. EBUS staging - how to improve reach and yield

Masahide Oki
(National Hospital Organization Nagoya Medical Center, Japan)

On-demand delivery date: November 25 - December 28, 2021

Assembly Symposium 10: Paediatric Lung Disease

SUNDAY • NOVEMBER 21

12:40 - 14:10

Room 1

AS10 Paediatric Respiratory Potpourri

Chairs: Jessie de Bruyne
(University of Malaya Medical Centre, Malaysia)
Shigemi Yoshihara
(Department of Pediatrics, Dokkyo Medical University, Japan)

Speakers:**1. Educational Lecture: Viral infections and pre-school asthma**

EL Speaker: Shigemi Yoshihara
(Department of Pediatrics, Dokkyo Medical University, Japan)

2. Running a Respiratory Service in the light of COVID

Teoh Oon Hoe
(KK Women's and Children's Hospital, Singapore)

3. Respiratory therapy for children using Biphase Cuirass Ventilation

Kuniyuki Okada
(OKADA Kodonomori Clinic, Saitama Medical University, Japan)

On-demand delivery date: November 25 - December 28, 2021

Assembly Symposium 11: Respiratory Structure and Function

SUNDAY • NOVEMBER 21

12:40 - 14:10

Room 2

AS11 Physiological assessment of airway by oscillometry

Chairs: Gregory G King
(Royal North Shore Hospital, Australia)
Hajime Kurosawa
(Tohoku University, Japan)

Speakers:**1. Educational Lecture: Lung and chest wall mechanics**

EL Speaker: Troy J Cross
(The University of Sydney, Australia)

2. Overview and perspective

David A. Kaminsky
(University of Vermont Larner College of Medicine, USA)

3. Clinical application in asthma

Gregory G King
(Royal North Shore Hospital, Sydney, Australia)

4. Clinical application in COPD

Toshihiro Shirai
(Shizuoka General Hospital, Japan)

On-demand delivery date: November 25 - December 28, 2021

Assembly Symposium 12: Interstitial Lung Disease

SUNDAY • NOVEMBER 21

12:40 - 14:10

Room 3

AS12 Beyond current treatment of IPF

Chairs: Arata Azuma
(Nippon Medical School, Japan)
Takafumi Suda
(Second Division, Department of Internal Medicine,
Hamamatsu University School of Medicine, Japan)

Speakers:**1. Educational Lecture: Current anti-fibrotic treatment of IPF, real-world**

EL Speaker: Arata Azuma
(Nippon Medical School, Japan)

2. New pharmacologic agents for treatment of IPF

Martin Kolb
(McMaster University, Canada)

3. Current treatment of IPF: Unsolved Issues and future directions

Moo Suk Park
(Yonsei University College of Medicine, Severance
Hospital, Republic of Korea)

4. Anti-fibrotic treatment of PF-ILD beyond IPF

Takafumi Suda
(Second Division, Department of Internal Medicine,
Hamamatsu University School of Medicine, Japan)

On-demand delivery date: November 25 - December 28, 2021

Assembly Symposium 13: COPD

SUNDAY • NOVEMBER 21

16:20 - 17:50

Room 2

AS13 Precision medicine in COPD

Chairs: Chin Kook Rhee
(Seoul St. Mary's Hospital, The Catholic University
of Korea, South Korea)
Kazuto Matsunaga
(Yamaguchi University, Japan)

Speakers:**1. Educational Lecture: No more waiting for COPD patients**

EL Speaker: Kazuto Matsunaga
(Yamaguchi University, Japan)

2. Early and Pre-COPD

Bartolome Celli
(Harvard Medical School, USA)

3. Identification of COPD exacerbation prone

Diahn-Warnng Perng
(Taipei Veterans General Hospital, Taipei, Taiwan)

4. Factors associated with clinical course of COPD

Masaru Suzuki
(Hokkaido University, Japan)

On-demand delivery date: November 25 - December 28, 2021

Assembly Symposium 14: Lung Cancer

SUNDAY • NOVEMBER 21

16:20 - 17:50

Room 3

AS14 Advances in lung cancer in the Asia Pacific: Overcoming Resistance in NSCLC

Chairs: Kwun M Fong
(University of Queensland Thoracic Research Centre,
The Prince Charles Hospital, Australia)
Sita Andarini
(University of Indonesia, Indonesia)

Speakers:**1. Educational Lecture: Targeted lung cancer screening**

EL Speaker: Jin-Yuan Shih
(National Taiwan University Hospital, Taiwan)

2. The evolution of lung cancer

Kwun M Fong
(University of Queensland Thoracic Research Centre,
The Prince Charles Hospital, Australia)

3. Lung cancer treatment landscape in Asia: overcoming resistance

Koichi Hagiwara
(Jichi Medical University, Japan)

4. Immunotherapy and beyond for NSCLC

Terufumi Kato
(Kanagawa Cancer Center, Japan)

On-demand delivery date: November 25 - December 28, 2021

Assembly Symposium 15: Pulmonary Circulation

SUNDAY • NOVEMBER 21

16:20 - 17:50

Room 4

AS15 Topics of hypoxia induced pulmonary hypertension

Chairs: Silvia Ulrich
(University Hospital Zurich, Switzerland)
Masayuki Hanaoka
(First Department of Medicine, Shinshu University
School of Medicine, Japan)

Speakers:**1. Educational Lecture: Hypoxic pulmonary vasoconstriction**

EL Speaker: Yoshiteru Morio
(Tokyo National Hospital, Japan)

2. Hypoxia and pulmonary hypertension

Silvia Ulrich
(University Hospital Zurich, Switzerland)

3. High Altitude Pulmonary Hypertension (HAPH)

Talant Sooronbaev
(Kyrgyz-Swiss High Altitude Medical and Research
Center, Kyrgyz Republic)

4. Experimental and clinical approach for pulmonary hypertension due to lung disease

Masayuki Hanaoka
(First Department of Medicine, Shinshu University
School of Medicine, Japan)

On-demand delivery date: November 25 - December 28, 2021

Assembly Symposium 16: Asthma

SUNDAY • NOVEMBER 21

16:20 - 17:50

Room 5

AS16 Biologics for the management of asthma

Chairs: Kang-Yun Lee
(Taipei Medical University, Taiwan)
Jun Miyata
(Division of Infectious Diseases and Respiratory
Medicine, Department of Internal Medicine, Na-
tional Defense Medical College, Japan)

Speakers:**1. Educational Lecture: Biologics for the management of asthma**

EL Speaker: Nobuaki Miyahara
(Dpt of Medical Technology, Okayama University
Academic Field of Health Sciences, Japan)

2. Biologics and irritant asthma

James G. Martin
(McGill University, Canada)

3. Diverse phenotypes and selection of the biologics in asthma

Hae-Sim Park
(Ajou University Medical Center, Republic of Korea)

4. Predictive and Response Biomarkers for Biologics in Asthma

Norihiro Harada
(Juntendo University, Japan)

On-demand delivery date: November 25 - December 28, 2021

Emerging Talent Symposia

Emerging Talent Symposia 1

SATURDAY • NOVEMBER 20 8:30 - 9:25

Room 1

ETS1 Lung development and regeneration

Chairs: Tatsuya Nagano
(Kobe University Graduate School of Medicine, Japan)
Mitsuru Morimoto
(RIKEN Center for Biosystems Dynamics Research, Japan)

Speakers:

- 1. Lung development and regeneration**
Mitsuru Morimoto
(RIKEN Center for Biosystems Dynamics Research, Japan)
- 2. Genetic and cellular mechanisms that underlie the complex orchestration of alveolar morphogenesis**
Nan Tang
(National Institute of Biological Sciences, Beijing, China)
- 3. Advances in human lung generation**
Munemasa Mori
(Columbia Center for Human Development, Columbia University Medical Center, USA)

On-demand delivery date: November 26 - December 28, 2021

Emerging Talent Symposia 2

SATURDAY • NOVEMBER 20 8:30 - 9:25

Room 2

ETS2 Potential platforms for understanding the mechanism of lung diseases

Chairs: Shimpei Gotoh
(Kyoto University, Japan)
Elisa Herawati
(Sebelas Maret University, Indonesia)

Speakers:

- 1. iPS cell-based disease modelling of primary ciliary dyskinesia**
Naoyuki Sone
(Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Japan)

2. Fast AI-Enabled Cell Tracking and Migration Analysis for High-Throughput Drug Screening

Alphons R Gwatimba
(Telethon Kids Institute, Australia)

3. In vivo and in vitro models of functional airway epithelium

Elisa Herawati
(Sebelas Maret University, Indonesia, Indonesia)

On-demand delivery date: November 26 - December 28, 2021

Emerging Talent Symposia 3

SATURDAY • NOVEMBER 20 8:30 - 9:25

Room 3

**ETS3 Insights into pathophysiology of respiratory illnesses
The pathophysiological findings from COVID-19**

Chairs: Masaki Yamamoto
(Yokohama City University Medical Center, Japan)
Yen Hsiang Huang
(Taichung Veterans General Hospital, Taiwan)

Speakers:

- 1. COVID-19 Lung Sequelae: Clinical Updates**
Matsuo So
(Department of Medicine, Icahn School of Medicine at Mount Sinai, USA)
- 2. The pathophysiological findings from COVID-19**
Masaki Yamamoto
(Yokohama City University Medical Center, Japan)

On-demand delivery date: November 26 - December 28, 2021

Emerging Talent Symposia 4

SATURDAY • NOVEMBER 20 8:30 - 9:25

Room 4

ETS4 Prognosis of interstitial lung diseases

Chairs: Kensuke Kataoka
(Tosei General Hospital, Japan)
Nicole S. Goh
(Austin Hospital, Australia)

Speakers:

- 1. Prognosis of acute exacerbation of interstitial lung diseases.**
Kensuke Kataoka
(Tosei General Hospital, Japan)

2. Prognosis of interstitial lung disease associated with systemic sclerosis.

Nicole S. Goh
(Austin Hospital, Australia)

3. Prognosis of interstitial lung disease associated with rheumatoid arthritis. OR Prognosis of idiopathic pulmonary fibrosis.

Song Yee Kim
(Division of Pulmonology, Department of Internal Medicine, Yonsei University College of Medicine, Republic of Korea)

On-demand delivery date: November 26 - December 28, 2021

Emerging Talent Symposia 5

SATURDAY • NOVEMBER 20 8:30 - 9:25
Room 5

ETS5 Up-to-date knowledge of management of NTM pulmonary disease

Chairs: Kozo Morimoto
(Fukujuji Hospital, Japan Anti-Tuberculosis Association, Japan)
Jing Zhang
(Associate Director, Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University, China)

Speakers:

- 1. Clinical phenotype of bronchiectasis with NTM pulmonary disease. The story in Japan.**
Takanori Asakura
(Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Japan)
- 2. Natural course of NTM pulmonary disease. When to start treatment to whom?**
Kyung-Wook Jo
(Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea)
- 3. Treatment of NTM pulmonary disease. Current recommendation and future direction**
Andrew Burke
(The Prince Charles Hospital, Australia)

On-demand delivery date: November 26 - December 28, 2021

Emerging Talent Symposia 6

SATURDAY • NOVEMBER 20 9:30 - 10:25
Room 1

ETS6 Bronchopulmonary dysplasia in adult: the early origins of adult lung disease

Chairs: Chiharu Ota
(Tohoku University Hospital, Japan)
Shannon J Simpson
(Telethon Kid Institute, Australia)

Speakers:

- 1. Bronchopulmonary dysplasia-from the neonatologist's point of view**
Fumihiko Namba
(Saitama Medical Center, Saitama Medical University, Japan)
- 2. Bronchopulmonary dysplasia-from the pathologist's point of view**
Ryoko Saito-Koyama
(Department of Pathology, Tohoku University Graduate School of Medicine, Japan)
- 3. Bronchopulmonary dysplasia-from the pulmonologist's point of view**
Shannon J Simpson
(Telethon Kid Institute, Australia)

On-demand delivery date: November 26 - December 28, 2021

Emerging Talent Symposia 7

SATURDAY • NOVEMBER 20 9:30 - 10:25
Room 2

ETS7 CPAP adherence across the world

Chairs: Motoo Yamauchi
(Nara Medical University, Japan)
Naricha Chirakalwasan
(Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand)

Speakers:

- 1. Real World Data for CPAP Adherence in Japan**
Eriko Hamada
(Nara Medical University, Japan)
- 2. Efficacy of a telemonitoring system in CPAP therapy**
Worawat Chumpangern
(Faculty of medicine, Khon Kaen university, Thailand)

3. Real world data for CPAP adherence in the US

Sanjay R. Patel
(University of Pittsburgh, USA)

On-demand delivery date: November 26 - December 28, 2021

Emerging Talent Symposia 8

SATURDAY • NOVEMBER 20 9:30 - 10:25

Room 3

ETS8 Multidisciplinary approaches for pleural effusions

Chairs: Takeshi Saraya
(Kyorin University School of Medicine, Department of Respiratory Medicine, Japan)
Hoang Anh Duc
(Respiratory Center - Bach Mai hospital, Hanoi Medical University, Hanoi, Viet nam)

Speakers:

1. Clinical Features and Prognosis of Nontuberculous Mycobacterial Pleuritis

Kazuma Yagi
(Keio University School of Medicine, Division of Pulmonary Medicine, Department of Medicine, Japan)

2. Diagnostic method for malignant pleural effusion distinguishing malignant mesothelioma from lung cancer using pleural carcinoembryonic antigen and hyaluronic acid levels

Takeshi Saraya
(Kyorin University School of Medicine, Department of Respiratory Medicine, Japan)

3. Ultrasound for respiratory disorders: Pleural effusions, Covid-19, and more

Taro Minami
(Care New England Medical Group, The Warren Alpert Medical School of Brown University, USA)

On-demand delivery date: November 26 - December 28, 2021

Emerging Talent Symposia 9

SATURDAY • NOVEMBER 20 9:30 - 10:25

Room 4

ETS9 Frontiers in pulmonary hypertension

Chairs: Ayako Shigeta
(Chiba University, Japan)
Kuo Yang Wang
(China Medical University Hospital, Taiwan)

Speakers:

1. Inflammatory biomarkers and characteristics in Japanese CTEPH patients

Akira Naito
(Graduate School of Medicine, Chiba University, Japan)

2. Pulmonary hypertension in interstitial lung diseases

Ping-Hung Kuo
(Department of Internal Medicine (chest medicine), National Taiwan University Hospital, Taiwan)

3. Is Nintenedab Effective as a Treatment for Pulmonary Hypertension?—Pros and Cons—

Tetsutaro Nagaoka
(Juntendo University, Japan)

On-demand delivery date: November 26 - December 28, 2021

Emerging Talent Symposia 10

SATURDAY • NOVEMBER 20 9:30 - 10:25

Room 5

ETS10 Basophils and mast cells in airway diseases

Chairs: Keiko Wakahara
(Nagoya University Graduate School of Medicine, Japan)
Hiroki Kabata
(Keio University School of Medicine, Japan)

Speakers:

1. Basophils in COPD

Sho Shibata
(Tokyo Medical and Dental University, Japan)

2. Sputum mast cell/basophil gene expression in severe asthma

Michael Fricker
(University of Newcastle, Australia)

3. ILC2 and basophils in asthma

Takahiro Matsuyama
(Department of Pulmonary Medicine, Graduate
School of Medical and Dental Sciences, Kagoshima
University, Japan)

On-demand delivery date: November 26 - December 28, 2021

Emerging Talent Symposia 11

SATURDAY • NOVEMBER 20 10:30 - 11:25
Room 1

ETS11 Mitochondria in lung disease

Chairs: Kenji Mizumura
(Nihon University School of Medicine, Japan)
Jin Woo Song
(Asan Medical Center, University of Ulsan College
of Medicine, South Korea)

Speakers:

- 1. Mitochondria in COPD**
Kenji Mizumura
(Nihon University School of Medicine, Japan)
- 2. Mitochondria in IPF**
Jin Woo Song
(Asan Medical Center, University of Ulsan College
of Medicine, South Korea)
- 3. Mitochondrial DNA in lung disease**
Suzanne Cloonan
(Trinity College, Dublin, Ireland and Weill Cornell
Medicine, USA)

On-demand delivery date: November 26 - December 28, 2021

Emerging Talent Symposia 12

SATURDAY • NOVEMBER 20 10:30 - 11:25
Room 2

ETS12 Minding Sex/Gender as a Biological Variable in Lung Disease

Chairs: Mari Hikichi
(Nihon University School of Medicine, Japan)
Annalicia Vaughan
(Centenary UTS Center for Inflammation, Australia)

Speakers:

- 1. Intrstitial pneumonia**
Mari Hikichi
(Nihon University School of Medicine, Japan)

2. Sex-based difference in disease behavior of COPD and asthma

Fanny Wai San Ko
(The Chinese University of Hong Kong, Hong Kong)

3. Importance of including sex and gender in biomedical research

Neeloffer Mookherjee
(University of Manitoba, Canada)

On-demand delivery date: November 26 - December 28, 2021

Emerging Talent Symposia 13

SATURDAY • NOVEMBER 20 10:30 - 11:25
Room 3

ETS13 Secondary Infections in COVID-19 patients

Chairs: Kazuko Yamamoto
(Nagasaki University Hospital, Japan)
Romanee Chaiwarith
(Chiang Mai University, Thailand)

Speakers:

- 1. Bacterial and fungal infection in COVID-19 patients- experience from Japan**
Kazuko Yamamoto
(Nagasaki University Hospital, Japan)
- 2. Secondary infections in HIV-positive COVID-19 patients**
Romanee Chaiwarith
(Chiang Mai University, Thailand)
- 3. Mucormycosis in COVID-19 patients- experience from India**
Atul K Patel
(Infectious Diseases Clinic, Ahmedabad, India)

On-demand delivery date: November 26 - December 28, 2021

Emerging Talent Symposia 14

SATURDAY • NOVEMBER 20

10:30 - 11:25

Room 4

ETS14 Various aspects of asthma**Chairs:** Norihiro Harada

(Juntendo University Faculty of Medicine and Graduate School of Medicine, Japan)

Takashi Iwanaga

(Kindai University Hospital, Japan)

Speakers:**1. Steroid-resistant asthma**

Tomohito Takeshige

(Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Japan)

2. Microbiome in asthma

Steven L Taylor

(South Australian Health and Medical Research Institute, Australia)

3. Regulatory and IgE + B cells in asthma

John-Paul Oliveria

(McMaster University, Canada)

On-demand delivery date: November 26 - December 28, 2021

Emerging Talent Symposia 15

SATURDAY • NOVEMBER 20

10:30 - 11:25

Room 5

ETS15 From the Bench of Young Basic Researchers - Development of New Therapeutic Targets for Pulmonary Hypertension**Chairs:** Sachiko Kuriyama

(Juntendo University, Japan)

Lei Wang

(Second Affiliated Hospital of Xi'an Jiaotong University, China)

Speakers:**1. Periostin contribute to the development of vascular remodeling via enhanced M2 macrophage migration in pulmonary arterial hypertension**

Takashi Yoshida

(Juntendo University, Japan)

2. The role of PD-1/PD-L1 pathway in hypoxic pulmonary hypertension and its possible mechanism

Lei Wang

(Second Affiliated Hospital of Xi'an Jiaotong University, China)

3. Gut microbiota in pulmonary hypertension

Takayuki Jujo

(Department of Respiriology, Graduate School of Medicine, Chiba University, Japan)

On-demand delivery date: November 26 - December 28, 2021

Emerging Talent Symposia 16

SATURDAY • NOVEMBER 20

15:05 - 16:00

Room 1

ETS16 Microenvironment in lung: The Disruption of Homeostasis in Lung Disease**Chairs:** Atsuyasu Sato

(Respiratory Medicine, Kyoto University, Japan)

Nakwon Kwak

(Seoul National University Hospital, South Korea)

Speakers:**1. Lung Regeneration and Microenvironment**

Atsuyasu Sato

(Respiratory Medicine, Kyoto University, Japan)

2. COPD pathogenesis and microenvironment

Nakwon Kwak

(Seoul National University Hospital, South Korea)

3. Disease Pathogenesis and Microenvironment in IPF

Rachel S. Knipe

(Massachusetts General Hospital, USA)

On-demand delivery date: November 26 - December 28, 2021

Emerging Talent Symposia 17

SATURDAY • NOVEMBER 20

15:05 - 16:00

Room 2

ETS17 2nd line treatment for EGFR-positive NSCLC: beyond PD after osimertinib**Chairs:** Yukari Tsubata

(Shimane University, Japan)

Fariz Nurwidya

(University of Indonesia, Indonesia)

Speakers:**1. Treatment for EGFR-positive NSCLC**

Motoko Tachihara

(Kobe University Graduate School of Medicine, Japan)

2. Role of ICI for EGFR-positive NSCLC

Satoshi Ikeda

(Kanagawa Cardiovascular and Respiratory Center, Japan)

3. Acquired resistance mutation after treatment of osimertinib

Fariz Nurwidya

(University of Indonesia, Indonesia)

On-demand delivery date: November 26 - December 28, 2021

Emerging Talent Symposia 18

SATURDAY • NOVEMBER 20

15:05 - 16:00

Room 3

ETS18 Comprehensive analysis with liquid biopsy on lung cancer**Chairs:** Naoko Aragane

(Saga University Hospital, Japan)

Wang Chun Kwok

(Queen Mary Hospital, Hong Kong)

Speakers:**1. Clinical usefulness of NGS with liquid biopsy**

Chiho Nakashima

(Saga University, Japan)

2. Plasma EGFR mutation status by ddPCR in patients with suspected lung cancer -a prospective study in Hong Kong

Lynn Yim Wah Shong

(Kwong Wah Hospital, Hong Kong)

3. TBD

Luan Van Pham

(108 Military Central Hospital, Vietnam)

On-demand delivery date: November 26 - December 28, 2021

Emerging Talent Symposia 19

SATURDAY • NOVEMBER 20

15:05 - 16:00

Room 4

ETS19 Lung epithelial regeneration: the necessary approach for the future treatment of pulmonary fibrosis**Chairs:** Seidai Sato

(Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Japan)

Amornpun Wongkarnjana

(King Chulalongkorn Memorial Hospital, Thailand)

Speakers:**1. Novel senolytic drug ARV-825 promotes self-renewal of alveolar type 2 cells in lung**

Seidai Sato

(Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Japan)

2. The models and platforms to study about epithelial regeneration of the lungs in lung fibrosis

Harshana Bandara Lansakara Mudiyansele

(National Hospital for Respiratory Diseases-Welisara, Sri Lanka)

3. Intrinsic BMP inhibitor Gremlin regulates lung alveolar progenitor cell proliferation and differentiation

Toyoshi Yanagihara

(Hamanomachi Hospital, Japan)

On-demand delivery date: November 26 - December 28, 2021

Emerging Talent Symposia 20

SATURDAY • NOVEMBER 20

16:05 - 17:00

Room 1

ETS20 Chronic airway diseases revisited 2021**Chairs:** Masaru Suzuki

(Hokkaido University, Japan)

Hye Yun Park

(Samsung Medical Center, South Korea)

Speakers:**1. Reconsideration of COPD, asthma, and their overlap**

Masaru Suzuki

(Hokkaido University, Japan)

2. Significance of eosinophils in COPD

Hye Yun Park

(Samsung Medical Center, Korea)

3. Significance of bronchiectasis as a chronic airway disease

Sei Won Lee
(Asan Medical Center, South Korea)

On-demand delivery date: November 26 - December 28, 2021

Emerging Talent Symposia 21

SATURDAY • NOVEMBER 20 16:05 - 17:00

Room 2

ETS21 Management of lung cancer in the next decade

Chair: Takehito Shukuya
(Juntendo University, Japan)

Speakers:

1. Chemotherapy for lung cancer in the next decade

Yasushi Goto
(National Cancer Center Hospital, Japan)

2. Radiotherapy for lung cancer in the next decade

Hideyuki Harada
(Shizuoka Cancer Center, Japan)

3. Biomarker analysis for lung cancer in the next decade

Junya Fujimoto
(The University of Texas MD Anderson Cancer Center, USA)

On-demand delivery date: November 26 - December 28, 2021

Emerging Talent Symposia 22

SATURDAY • NOVEMBER 20 16:05 - 17:00

Room 3

ETS22 Future in oncoimmunology against thoracic cancer

Chairs: Nobuaki Kobayashi
(Yokohama City University Graduate School of Medicine, Japan)
Zhang Xiaotong
(Department of Respiratory Disease, Peking Union Medical College, Beijing, China)

Speakers:

1. Synthetic oligonucleotides for cancer immunotherapy

Nobuaki Kobayashi
(Yokohama City University Graduate School of Medicine, Japan)

2. Challenges for the establishment of biomarkers for immunotherapy in lung cancer

Zhang Xiaotong
(Department of Respiratory Disease, Peking Union Medical College, Beijing, China)

3. For a better understanding of immune checkpoint inhibitors from clinical trials

Niels Reinmuth
(Asklepios Kliniken GmbH & Co., Germany)

On-demand delivery date: November 26 - December 28, 2021

Emerging Talent Symposia 23

SATURDAY • NOVEMBER 20 16:05 - 17:00

Room 4

ETS23 Nation-wide multicenter studies for Chronic Obstructive Pulmonary Disease

Chairs: Susumu Sato
(Graduate school of medicine, Kyoto University, Japan)
Yeon-Mok Oh
(Asan Medical Center, South Korea)

Speakers:

1. Knowledges from COPD cohort studies in Japan

Naoya Tanabe
(Kyoto University, Japan)

2. Knowledges from COPD cohort studies in Korean

Chin Kook Rhee
(Seoul St. Mary's Hospital, The Catholic University of Korea, South Korea)

On-demand delivery date: November 26 - December 28, 2021

Emerging Talent Symposia 24

SATURDAY • NOVEMBER 20 17:05 - 18:00

Room 1

ETS24 Challenges to prevent and control the outbreak of COVID-19 and other respiratory tract infections in different countries

Chairs: Yuichiro Shindo
(Nagoya University Hospital, Japan)
Yeming Wang
(China-Japan Friendship Hospital, China)

Speakers:

- 1. Epidemiological characteristics and therapeutic challenges in COVID-19 in Japan**
Yuichiro Shindo
(Nagoya University Hospital, Japan)
- 2. Epidemiological characteristics and therapeutic/preventive challenges in COVID-19 in other Asian areas (China, Korea, etc)**
Yeming Wang
(China-Japan Friendship Hospital, China)
- 3. Epidemiological characteristics and therapeutic/preventive challenges in COVID-19 in European countries**
James D. Chalmers
(University of Dundee, UK)

On-demand delivery date: November 26 - December 28, 2021

Emerging Talent Symposia 25

SATURDAY • NOVEMBER 20 17:05 - 18:00

Room 2

ETS25 The development of a novel therapeutic strategy for lung cancer; from bench to bedside

Chairs: Tadaaki Yamada
(Kyoto Prefectural University of Medicine, Japan)
In-Jae Oh
(Chonnam National University Hwasun Hospital, South Korea)

Speakers:

- 1. Overcoming drug tolerance to ALK inhibitor in ALK positive lung cancer**
Keiko Tanimura
(Kyoto Prefectural University of Medicine, Japan)

2. EGFR-TKIs resistance promotes immune escape in lung cancer via increased PD-L1 expression

Wei Wang
(Nanfang Hospital, Southern Medical University, China)

3. Co-Mutation in splicing factor with EGFR mutations limits sensitivity to EGFR-TKIs~Why are EGFR-TKIs less effective against EGFR L858R?~

Shigeki Nanjo
(Kanazawa University, Japan / UCSF, USA)

On-demand delivery date: November 26 - December 28, 2021

Emerging Talent Symposia 26

SATURDAY • NOVEMBER 20

17:05 - 18:00

Room 3

ETS26 How to detect driver mutations of lung cancer in clinical practice-current status and efforts-

Chairs: Motoko Tachihara
(Kobe University Graduate School of Medicine, Japan)
Satoru Miura
(Niigata Cancer Center Hospital, Japan)

Speakers:

- 1. Current Status and Initiatives at Matsusaka Municipal Hospital**
Yoichi Nishii
(Matsusaka Municipal Hospital Respiratory Center, Japan)
- 2. Detection of oncogenic driver mutations in the United States**
Adam Fox
(The Medical University of South Carolina, USA)

On-demand delivery date: November 26 - December 28, 2021

Emerging Talent Symposia 27

SATURDAY • NOVEMBER 20

17:05 - 18:00

Room 4

ETS27 Review of BAL in Interstitial Lung Disease diagnosis**Chairs:** Yuko Waseda

(University of Fukui, Japan)

Sun Mi Choi

(Seoul National University Hospital, Seoul, Republic of Korea)

Speakers:**1. Morphological evaluation of BAL**

Yuko Waseda

(University of Fukui, Japan)

2. Evaluation of liquid component of BAL

Sun Mi Choi

(Seoul National University Hospital, Seoul, Republic of Korea)

3. Evaluation of cellular component of BAL

Sara Tomassetti

(Careggi University Hospital, Florence, Italy)

On-demand delivery date: November 26 - December 28, 2021

Luncheon Seminar
Coffee Break Seminar
Meet the Expert
Sponsored Lecture
Sponsored Symposium

Luncheon Seminar 1

SATURDAY • NOVEMBER 20 11:40 - 12:30

Room 1

LS1 Pathophysiology and treatment of COPD patients

Chair: Kazuto Matsunaga
(Department of Respiratory Medicine and Infectious Disease, Yamaguchi University, Japan)

Speakers:

1. Understanding the pathophysiology of COPD and the importance of anti-M3R treatment

Atsuyasu Sato
(Department of Respiratory Medicine, Kyoto University, Japan)

2. Precision medicine in Asian COPD patients

Chin Kook Rhee
(Seoul St. Mary's Hospital, The Catholic University of Korea, Korea)

*Co Sponsored by
Boehringer Ingelheim*

Luncheon Seminar 2

SATURDAY • NOVEMBER 20 11:40 - 12:30

Room 2

Chair: Terufumi Kato
(Department of Thoracic Oncology, Kanagawa Cancer Center, Japan)

LS2 Cancer Immunotherapy for NSCLC~ Thinking about the optimal first-line treatment~

Speaker: Tatsuya Yoshida
(Department of Thoracic Oncology, Department of Experimental Therapeutics, National Cancer Center Hospital, Japan)

*Co Sponsored by
Chugai Pharmaceutical Co., Ltd.*

Luncheon Seminar 3

SATURDAY • NOVEMBER 20 11:40 - 12:30

Room 3

Chair: Shigeo Muro
(Nara Medical University, Department of Respiratory Medicine, Japan)

LS3 COPD Treatment Strategy based on the latest study

Speaker: Ichiro Kuwahira
(Tokai University Tokyo Hospital, Pulmonary Medicine, Japan)

*Co Sponsored by
AstraZeneca K.K.*

Luncheon Seminar 4

SATURDAY • NOVEMBER 20 11:40 - 12:30

Room 4

Chair: Koichiro Asano
(Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine, Japan)

LS4 Type2 inflammation in asthma

Speaker: Koichi Fukunaga
(Pulmonary Division, Department of Medicine, Keio University School of Medicine, Japan)

*Co Sponsored by
Sanofi K. K.*

Luncheon Seminar 5

SATURDAY • NOVEMBER 20 11:40 - 12:30

Room 5

LS5 Asthma New Treatment Pathway

Chair: Yuji Tohda
(Kindai University Hospital, Japan)

Speakers:

1. Pharmacological management with LAMA in asthma patients

Etsuko Tagaya
(Respiratory Medicine, Tokyo Women's Medical University, Japan)

2. Anti-IL-5 Therapy for Severe Asthma -From Real World Data

Takuro Sakagami
(Respiratory Medicine, Kumamoto University, Japan)

*Co Sponsored by
GlaxoSmithKline*

Coffee Break seminar 1

SATURDAY • NOVEMBER 20 14:10 - 15:00
Room 1

Chair: Yasuhiko Nishioka
(Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Japan)

CBS1 Progressive fibrosing ILD: the world beyond IPF

Speaker: Martin Kolb
(McMaster University and St. Joseph's Healthcare, Hamilton, Ontario, Canada)

*Co Sponsored by
Boehringer Ingelheim*

Coffee Break seminar 2

SATURDAY • NOVEMBER 20 14:10 - 15:00
Room 2

Chair: Yohei Doi
(Departments of Microbiology and Infectious Diseases, Fujita Health University Hospital, Japan)

CBS2 Hospitalized COVID-19 Patients: Current Concepts in the Management

Speaker: David Alain Wohl
(Institute of Global Health and Infectious Diseases, The University of North Carolina at Chapel Hill, USA)

*Co Sponsored by
Gilead Sciences K.K*

Coffee Break seminar 3

SATURDAY • NOVEMBER 20 14:10 - 15:00
Room 3

Chair: Akihiko Gemma
(Nippon Medical School, Japan)

CBS3 New treatment strategies for driver mutation-positive NSCLC

Speaker: Hidehito Horinouchi
(Department of Thoracic Oncology, National Cancer Center Hospital, Japan)

*Co Sponsored by
Eli Lilly Japan K.K.*

Coffee Break seminar 4

SATURDAY • NOVEMBER 20 14:10 - 15:00
Room 4

Chair: Yoshihiro Nishimura
(Kobe University, Division of Respiratory Medicine, Japan)

CBS4 BEST PRACTICES FOR RESPIRATORY SYNDROMIC TESTING IN COVID-19 ERA AND POST-COVID FUTURE

Speaker: Hitoshi Honda
(Tokyo Metropolitan Tama Medical Center, Division of Infectious Disease, Japan)

*Co Sponsored by
BIOMERIEUX*

Meet the Expert 1

SUNDAY • NOVEMBER 21 8:00 - 8:50
Room 1

Chair: Masashi Bando
(Division of Pulmonary Medicine, Department of Medicine, Jichi Medical University, Tochigi, Japan)

ME1 IPF practice based on guidelines and experience in Japan

Speaker: Yasuhiro Kondoh
(Deputy Director, Department of Respiratory Medicine and Allergy, Tosei General Hospital, Aichi, Japan)

*Co Sponsored by
Boehringer Ingelheim*

Meet the Expert 2

SUNDAY • NOVEMBER 21 8:00 - 8:50

Room 2

Chair: Akihito Yokoyama
(Kochi Medical School, Kochi University, Japan)

ME2 Remaining challenges of biologics in severe asthma treatment

Speaker: Hisako Matsumoto
(Kindai University Faculty of Medicine, Japan)

Co Sponsored by
AstraZeneca K.K.

Meet the Expert 3

SUNDAY • NOVEMBER 21 8:00 - 8:50

Room 3

Chair: Hiromasa Inoue
(Kagoshima University, Department of Pulmonary Medicine, Graduate school of Medical and Dental Sciences, Japan)

ME3 Airway obstruction in asthma

Speaker: Kazuto Matsunaga
(Yamaguchi University, Department of Respiratory Medicine and Infectious Disease, Graduate School of Medicine, Japan)

Co Sponsored by
Novartis Pharma K.K.

Meet the Expert 4

SUNDAY • NOVEMBER 21 8:00 - 8:50

Room 4

Chair: Sakae Honma
(Toho University, Department of Advanced and Integrated Interstitial Lung Diseases Research, Japan)

ME4 Current research aimed at overcoming clinical questions of thoracic malignancies

Speaker: Takehito Shukuya
(Juntendo University, Department of Respiratory Medicine, Japan)

Co Sponsored by
TAIHO PHARMACEUTICAL CO., LTD.

Meet the Expert 5

SUNDAY • NOVEMBER 21 8:00 - 8:50

Room 5

Chair: Naoko Aragane
(Department of Respiratory Medicine, Saga University Hospital/Saga University Hospital Cancer Center, Japan)

ME5 Comprehensive Genomic Profiling for non-small cell lung cancer treatment

Speaker: Eiji Iwama
(Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Japan)

Co Sponsored by
Chugai Pharmaceutical Co., Ltd.

Sponsored Lecture 1

SUNDAY • NOVEMBER 21 10:40 - 11:30

Room 1

Chair: Kazuhisa Takahashi
(Juntendo University, Department of Respiratory Medicine, Japan)

SL1 Multi-disciplinary strategies to improve lung cancer treatment

Speaker: Hiroyuki Yasuda
(Keio University, Division of Pulmonary Medicine, Japan)

Co Sponsored by
TAIHO PHARMACEUTICAL CO., LTD.

Sponsored Lecture 2

SUNDAY • NOVEMBER 21 10:40 - 11:30

Room 2

Chair: Isamu Okamoto

(Research Institute for Diseases of the Chest Graduate School of Medical Sciences, Kyushu University, Japan)

SL2 The current role of ICI in NSCLC Treatment**Speaker:** Kentaro Tanaka

(Department of Respiratory Medicine, Kyushu University Hospital, Japan)

*Co Sponsored by
MSD K.K.***Sponsored Lecture 3**

SUNDAY • NOVEMBER 21 10:40 - 11:30

Room 3

Chair: Takeshi Kaneko

(Department of Pulmonology, Yokohama City University Graduate School of Medicine, Japan)

SL3 Selection of inhaled medications based on asthma symptoms**Speaker:** Hisako Matsumoto

(Kindai University Faculty of Medicine, Department of Respiratory Medicine & Allergology, Japan)

*Co Sponsored by
Novartis Pharma K.K.***Sponsored Lecture 4**

SUNDAY • NOVEMBER 21 10:40 - 11:30

Room 4

Chair: Makoto Nishio

(Thoracic Medical Oncology Department, Cancer Institute Hospital of JFCR, Japan)

SL4 Biomarker-Driven Therapy for NSCLC: Focus on ALK**Speaker:** Yasushi Goto

(Department of Thoracic Oncology, National Cancer Center Hospital, Japan)

*Co Sponsored by
Chugai Pharmaceutical Co., Ltd.***Sponsored Lecture 5**

SUNDAY • NOVEMBER 21 10:40 - 11:30

Room 5

Chair: Akio Niimi

(Nagoya City University Graduate School of Medical Sciences, Department of Respiratory Medicine, Allergy and Clinical Immunology, Japan)

SL5 Updates in Asthma : Device, Drug & Disease**Speaker:** Omar S Usmani

(Imperial College London, UK)

*Co Sponsored by
Kyorin Pharmaceutical Co., Ltd.***Sponsored Lecture 6**

SUNDAY • NOVEMBER 21 11:40 - 12:30

Room 1

Chair: Yuichiro Ohe

(Department of Thoracic Oncology, National Cancer Center Hospital, Japan)

SL6 Progress of the treatment for squamous cell lung cancer in Japan**Speaker:** Terufumi Kato

(Department of Thoracic Oncology, Kanagawa Cancer Center, Japan)

*Co Sponsored by
Nippon Kayaku Co., Ltd.***Sponsored Lecture 7**

SUNDAY • NOVEMBER 21 11:40 - 12:30

Room 2

Chair: Takeshi Kaneko

(Respiratory Medicine, Yokohama City University, Japan)

SL7 Role of LAMA in asthma treatment**Speaker:** Satoshi Konno

(Respiratory Medicine, Hokkaido University, Japan)

*Co Sponsored by
GlaxoSmithKline*

Sponsored Lecture 8

SUNDAY • NOVEMBER 21

11:40 - 12:30

Room 3

SL8 Airway Clearance Management with Oscillatory Airway Clearance Therapy on COVID Patients/COVID RESPIRATORY CARE-Addressing Sputum and Airway Clearance**Speakers:**

Huiqing Ge

(Department of Respiratory Therapy, Sir Run Run Shaw Hospital affiliated to ZheJiang University Medical College Hospital, China)

Alexander Michael

(Division of Pulmonary and Critical Care Medicine in Northwestern Medical Group, Illinois, USA)

*Co Sponsored by
Hill-Rom Services Pte Ltd***Sponsored Lecture 9**

SUNDAY • NOVEMBER 21

11:40 - 12:30

Room 4

SL9 Lung Cancer - Access and Ablation**Chairs:** Lam Bing

(Hong Kong Sanatorium & Hospital, Hong Kong)

Lee Pyng

(National University Hospital, Singapore)

Speakers:**1. Full Lung Access with Archimedes**

Terence Tam

(Queen Mary Hospital, Hong Kong)

2. Bronchoscopic RF Ablation Study to Treat Lung Cancer

Shiyue Li

(The First Affiliated Hospital of Guangzhou Medical University, China)

3. VAPORIZE Study - Bronchoscopic Lung Cancer Ablation With Vapor

Daniel Steirfort

(Royal Melbourne Hospital, Australia)

*Co Sponsored by
Broncus Medical***Sponsored Lecture 10**

SUNDAY • NOVEMBER 21

11:40 - 12:30

Room 5

SL10 The validity of the oxygen inhalation for severe COVID-19 patients and home oxygen therapy in China**Chair:** Shu Hashimoto

(Nihon University, Japan)

Speakers:**1. Oxygen inhalation is their essential therapy for severe COVID-19 patients**

Yuanlin Song

(Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, China)

2. Home oxygen therapy, our activity for apply to the public medical insurance in China.

Satoshi Ueda

(DAIKIN MEDICAL TECHNOLOGY (SUZHOU) CO., LTD, Japan)

*Co Sponsored by
DAIKIN MEDICAL TECHNOLOGY (SUZHOU) CO., LTD***Sponsored Lecture 11**

SUNDAY • NOVEMBER 21

14:20 - 15:10

Room 1

Chair: Makoto Nishio

(Thoracic Medical Oncology Department, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Japan)

SL11 Landscape of ICI treatment in NSCLC and its pitfall**Speaker:** Yasushi Goto

(Department of Thoracic Oncology, National Cancer Center Hospital, Japan)

*Co Sponsored by
MSD K.K.*

Sponsored Lecture 12

SUNDAY • NOVEMBER 21 14:20 - 15:10

Room 2

Chair: Akio Niimi

(Graduate School of Medical Sciences Department of Respiratory Medicine, Allergy and Clinical Immunology Nagoya City University, Japan)

SL12 Effects of biologics on Type 2 Inflammation in Severe Asthma**Speaker:** Toshiyuki Koya

(Department of Respiratory Medicine and Infectious Diseases, Niigata University Medical & Dental Hospital, Japan)

*Co Sponsored by
Sanofi K. K.*

Sponsored Lecture 13

SUNDAY • NOVEMBER 21 14:20 - 15:10

Room 3

SL13 Evidence of coil embolization for hemoptysis**Chairs:** Hideo Ishikawa

(Hemoptysis and Pulmonary-Circulation Center, Eishinkai Kishiwada Rehabilitation Hospital, Japan)

Yoshihisa Kodama

(Department of Radiology, Teine Keijinkai Hospital, Japan)

Speakers:**1. Clinical approach for Hemoptysis**

Takashi Niwa

(Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Japan)

2. Bronchial Artery Embolization for hemoptysis-----Cutting-edge based on Real World Data & our Research

Hideo Ishikawa

(Hemoptysis and Pulmonary Circulation Center, Eishinkai Kishiwada Rehabilitation Hospital, Japan)

*Co Sponsored by
Terumo Coporation*

Sponsored Lecture 14

SUNDAY • NOVEMBER 21 14:20 - 15:10

Room 4

Chair: Hiromasa Inoue

(Pulmonary Medicine, Kagoshima University, Japan)

SL14 Treatment of Severe Eosinophilic Asthma with anti IL-5 antibody**Speaker:** Hiroshi Kanazawa

(Respiratory Medicine, Osaka City University, Japan)

*Co Sponsored by
GlaxoSmithKline*

Sponsored Lecture 15

SUNDAY • NOVEMBER 21 14:20 - 15:10

Room 5

Chair: Masahiro Seike

(Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Japan)

SL15 Optimizing treatment for ALK-positive non-small cell lung cancer in 2021: a focus on Brigatinib.**Speaker:** Yoshitaka Zenke

(Department of Thoracic Oncology, National Cancer Center Hospital East, Japan)

*Co Sponsored by
Takeda Pharmaceutical Company Limited.*

Sponsored Lecture 16

SUNDAY • NOVEMBER 21

15:20 - 16:10

Room 1

SL16 Challenges and Innovations in AI Technology for Respiratory Disease Imaging - From Data Acquisition and Processing to Interpretation

Chair: Shigeo Muro
(Department of Respiratory Medicine, Nara Medical University, Japan)

Speakers:

- 1. AI-driven Dose Reduction and Optimization of Chest CT Imaging Workflow**
Hisaya Hagiwara
(Image Diagnostics Sales Department, Diagnostic Systems Sales Division, FUJIFILM Healthcare Corporation, Japan)
- 2. State-of-the-art Technology in the Chest Area of AI Technology "REiLI" Developed by FUJIFILM**
Kozue Ito
(IT Solution Division, Medical Business Division, FUJIFILM Corporation, Japan)
- 3. Recent Advances in Quantitative CT Analysis of Airway and Parenchyma in COPD and IPF**
Naoya Tanabe
(Department of Respiratory Medicine, Kyoto University, Japan)

Co Sponsored by
FUJIFILM Healthcare Corporation

Sponsored Lecture 17

SUNDAY • NOVEMBER 21

15:20 - 16:10

Room 2

SL17 New Era of Bronchoscopy

Chair: Fumihiko Asano
(Gifu Prefectural General Medical Center, Japan)

Speakers:

- 1. Advancements in Peripheral Bronchoscopy**
Yuji Matsumoto
(National Cancer Center Hospital, Japan)
- 2. New Era of Bronchoscopy**
Vallandramam R. Pattabhi Raman
(Royal Care Super Specialty Hospital, India)

Co Sponsored by
Olympus Corporation

Sponsored Lecture 18

SUNDAY • NOVEMBER 21

15:20 - 16:10

Room 3

Chair: Hirotsugu Kenmotsu
(Division of Thoracic Oncology, Shizuoka Cancer Center, Japan)

SL18 The Current Status of Dual-Immuno-therapy in Non-Small Cell Lung Cancer Treatment

Speaker: Satoru Miura
(Department of Internal Medicine, Niigata Cancer Center Hospital, Japan)

Co Sponsored by
Bristol Myers Squibb/ONO PHARMACEUTICAL CO., LTD

Sponsored Lecture 19

SUNDAY • NOVEMBER 21

15:20 - 16:10

Room 4

Chair: Kazuhiko Nakagawa
(Department of Medical Oncology, Kindai University, Faculty of Medicine, Japan)

SL19 Updates in Immunotherapy for First-Line Treatment of NSCLC

Speaker: Hidehito Horinouchi
(Department of Thoracic Oncology, National Cancer Center Hospital, Japan)

Co Sponsored by
MSD K.K.

Sponsored Lecture 20

SUNDAY • NOVEMBER 21

15:20 - 16:10

Room 5

Chair: Akio Niimi

(Nagoya City University Graduate School of Medical Sciences, Department of Respiratory Medicine, Allergy and Clinical Immunology, Japan)

SL20 Patient-centred inhaler device selection**Speaker:** Omar Usmani

(National Heart and Lung Institute, Imperial College London, UK)

*Co Sponsored by
Trudell Medical International*

Sponsored Symposium 1

SATURDAY • NOVEMBER 20

18:00 - 19:30

Room 6

SS1 Progressive fibrosing interstitial lung diseases (PF-ILD) -Disease concept, Monitoring, Treatment.**Chairs:** Takafumi Suda

(Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Japan)

Yoshikazu Inoue

(Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Japan)

Speakers:**1. Emerging concept and pathogenesis of PF-ILD**

Yoshikazu Inoue

(Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Japan)

2. Diagnosis and monitoring of CTD-ILD

Masataka Kuwana

(Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Japan)

3. Impact of treatment of PF-ILD

Vincent Cottin

(National Reference Centre for Rare Pulmonary Diseases, Louis Pradel University Hospital and Claude Bernard University, France)

*Co Sponsored by
Boehringer Ingelheim*

Sponsored Symposium 2

SATURDAY • NOVEMBER 20

18:00 - 19:30

Room 7

SS2 Treatment Strategies for Achieving Asthma Management Goals**Chairs:** Hiromasa Inoue

(Department of Pulmonary Medicine, Kagoshima University, Japan)

Masakazu Ichinose

(Academic Center of Osaki Citizen Hospital, Japan)

Speakers:**1. The role of IgE and IL-13 in type 2 inflammation**

Koichiro Takahashi

(Division of Respiratory Medicine, Saga University Hospital, Japan)

2. Immune cell network inducing innate immunity-mediated type 2 inflammation and its regulatory mechanism

Hiroki Kabata

(Division of Pulmonary Medicine, Department of Medicine, Keio University school of Medicine, Japan)

3. Treatment of severe asthma with consideration of airflow limitation, symptoms, and exacerbations

Kazuto Matsunaga

(Department of Respiratory Medicine and Infectious Disease, Graduate School of Medicine, Yamaguchi University, Japan)

*Co Sponsored by
Sanofi K. K.*

Sponsored Symposium 3

SATURDAY • NOVEMBER 20

18:00 - 19:30

Room 8

SS3 Solving Social Problems through Partnerships between Medicine and Industry**Chair:** Shu Hashimoto

(President, Japan Clean Air Association; President, 25th Asia Pacific Respiratory Society, Japan)

Speakers:**1. Opening remarks****Aim and background of this project**

Shu Hashimoto

(President, Japan Clean Air Association; President, 25th Asia Pacific Respiratory Society, Japan)

2. Keynote Speech**Kubota's Challenges and Solutions to Social Issues**

Tsuyako Nakamura

(Faculty of Global Communication, Doshisha University, Japan)

3. Lecture ①**Proper use of antimicrobial agents, a limited medical resource, to achieve the SDGs in medicine**

Yuichi Yamazaki

(General Manager, Precision Equipment Business Unit, Kubota Corporation, Japan)

4. Lecture ②**Proper use of antimicrobial agents, a limited medical resource, to achieve the SDGs in medicine**

Katsunori Yanagihara

(Nagasaki University Graduate School of Biomedical Sciences Head, Laboratory Medicine, Nagasaki University Hospital, Japan)

5. Round Table Discussion

Shu Hashimoto

(President, Japan Clean Air Association; President, 25th Asia Pacific Respiratory Society, Japan)

Tsuyako Nakamura

(Faculty of Global Communication, Doshisha University, Japan)

Yuichi Yamazaki

(General Manager, Precision Equipment Business Unit, Kubota Corporation, Japan)

Katsunori Yanagihara

(Nagasaki University Graduate School of Biomedical Sciences Head, Laboratory Medicine, Nagasaki University Hospital, Japan)

Atsushi Suzuki

(Director, Economic Sustainability Consortium, Japan)

Keisuke Kurose

(Japan Clean Air Association, Japan)

*Co Sponsored by***Japan Clean Air Association Nikkeisha, Inc.****Sponsored Symposium 4**

SUNDAY • NOVEMBER 21

18:00 - 19:30

Room 1

SS4 Current Status and Future Perspectives of Treatment Strategy in Lung Cancer (NSCLC/SCLC)**Chair:** Kazuhisa Takahashi

(Juntendo University Hospital, Juntendo University Faculty of Medicine & Professor and Chairman, Graduate School of Medicine Division of Respiratory Medicine, Japan)

Speakers:**1. CASPIAN study and share of IMFIZNI clinical experience for SCLC**

Niels Reinmuth

(Department of Pulmonary Oncology, Asklepios Lung Clinic Munich-Gauting Gauting, Germany)

2. Current landscape of targeted therapy in NSCLC

Myung-Ju Ahn

(Section of Hematology-Oncology, Department of Medicine, Samsung Medical Center Sungkyunkwan University School of Medicine, Korea)

*Co Sponsored by
AstraZeneca K.K.***Sponsored Symposium 5**

SUNDAY • NOVEMBER 21

18:00 - 19:30

Room 2

SS5 Endobronchial Ultrasound in Asia - Past, Present and Future**Chairs:** Noriaki Kurimoto

(Shimane University Hospital, Japan)

David Fielding

(Royal Brisbane and Women's Hospital, Australia)

Speakers:**1. History of EBUS**

Noriaki Kurimoto

(Shimane University Hospital, Japan, Japan)

2. Current Practice and Challenges of EBUS in Korea

Jung Seop Eom

(Pusan National University Hospital, Korea)

3. Current Practice and Challenges of EBUS in Thailand

Anan Wattanathum

(Phramongkutklao Hospital, Bangkok, Thailand)

4. Current Practice and Challenges of EBUS

Wahju Aniwidyaningsih
(Persahabatan Hospital, Indonesia)

5. Closing remarks

David Fielding
(Royal Brisbane and Women's Hospital, Australia)

Co Sponsored by
Olympus Corporation

Sponsored Symposium 6

SUNDAY • NOVEMBER 21

18:00 - 19:30

Room 3

SS6 Treatable Traits approach for the management of obstructive airways diseases

Chair: David Leather
(GlaxoSmithKline Global Medical, UK)

Speakers:

1. Introduction to Treatable traits

Neil Barnes
(GlaxoSmithKline Global Medical, UK)

2. Using Treatable traits in clinical practice

Alvar Agusti
(Medicine, University of Barcelona, Spain)

Co Sponsored by
GlaxoSmithKline

Oral Session

Oral Session 1

SATURDAY • NOVEMBER 20

8:30 - 9:20

Room 9

O1 Clinical Respiratory Medicine 1**Chair:** Roland LEUNG

(The Chinese University of Hong Kong, Hong Kong)

- O1-1 The 1-minute sit-to-stand test to help detect exertional desaturation during the 6-minute walk test in interstitial lung disease patients with normal resting blood oxygen levels.**

Keiji Oishi

(Department of Medicine and Clinical Science, Graduate School of Medicine, Yamaguchi University, Japan)

- O1-2 Protein C activity as a potential prognostic factor for nursing home-acquired pneumonia**

Issei Oi

(Kyoto University, Japan)

- O1-4 Prognosis of Japanese patients with late-onset non-infectious pulmonary complications after hematopoietic stem cell transplantation registered for lung transplantation**

Naoya Ikegami

(Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Japan)

- O1-5 A gentlemen with exertional dyspnea following allogeneic Bone marrow transplantation (BMT): A case report of chronic pulmonary graft versus host disease (GVHD) manifest as bronchiectasis.**

Niranjan Chandramal

(National hospital of Sri Lanka, Sri Lanka)

On-demand delivery date: November 30 - December 28, 2021

Oral Session 2

SATURDAY • NOVEMBER 20

9:30 - 10:20

Room 9

O2 Clinical Respiratory Medicine 2**Chair:** Chao-Chi HO

(National Taiwan University Hospital, Taipei, Taiwan)

- O2-1 Elevated levels of induced-sputum IL-36 gamma and osteopontin in the elderly with dysphagia.**

Yasuyuki Taooka

(Department of internal medicine, Akiota hospital, Japan)

- O2-2 Development and Implementation of an Aspiration Pneumonia Diagnostic Algorithm for the practical application of the JRS guidelines**

Yuki Yoshimatsu

(Iizuka Hospital, Japan)

- O2-3 Novel non-invasive point of care sputum test for early identification of Pseudomonas aeruginosa airway infection**

Dharmika Leshan Wannigama

(Antimicrobial Resistance and Stewardship Research Unit, Department of Microbiology, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Thailand)

- O2-4 Prevalence, characteristics, risk factors and disease course of ulcerative colitis-related pulmonary manifestations.**

Mitsuhiro Moda

(NHO Kinki-Chuo Chest Medical Center, Japan)

- O2-5 Impacts of nebulised GM-CSF treatment in autoimmune Pulmonary Alveolar Proteinosis: A systematic review and meta-analysis**

Maitri Munsif

(Department of Respiratory and Sleep Medicine, Austin Health, Melbourne, Australia, Institute for Breathing and Sleep, Austin Health, Australia)

On-demand delivery date: November 30 - December 28, 2021

Oral Session 3

SATURDAY • NOVEMBER 20

8:30 - 9:30

Room 10

O3 Cell and Molecular Biology

Chair: Atsuyasu Sato
(Respiratory Medicine, Kyoto University, Japan)

- O3-1 Role of reactive persulfide species in influenza virus-induced lung inflammation.**
Tomohiro Ichikawa
(Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Japan)
- O3-2 Transplantation of lung progenitors derived from human induced pluripotent stem cells into the murine lungs**
Satoshi Ikeo
(Kyoto University, Japan)
- O3-3 MiR-21 regulates the proliferation and apoptosis of human bronchial epithelial cells by targeting PARP-1**
Qian Zhang
(Department of Respiratory and Critical Care Medicine, The Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University, China (Mainland))
- O3-4 In-silico Cross-validation Unveiled Genomic Mortality Signatures of CC5 and CC8 MRSA Obtained from the Intensive Care Patients**
Irandi Putra Pratomo
(Pulmonology Staff Group, Universitas Indonesia Hospital, Universitas Indonesia, Depok - Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia)
- O3-5 Fast AI-Enabled Cell Tracking and Migration Analysis for High-Throughput Drug Screening**
Alphons Gwatimba
(Telethon Kids Institute, Australia)
- O3-6 The Pulmonary Endothelium Plays a Critical Role in the Fibrotic Response to Lung Injury through S1PR1 and ROCK Mediated Cytoskeletal Rearrangements**
Rachel S. Knipe
(Massachusetts General Hospital, USA)

On-demand delivery date: November 30 - December 28, 2021

Oral Session 4

SATURDAY • NOVEMBER 20

10:30 - 11:20

Room 9

O4 Clinical Allergy and Immunology

Chair: Janet Rimmer
(St Vincents Clinic, Sydney, Australia)

- O4-1 Reactive sulfur species are involved in the regulation of innate immunity of type 2 airway inflammation**
Ayumi Suzuki
(Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Japan)
- O4-2 Serum albumin in furry animals as a cross-reactive component may causes more severe allergic symptoms**
Zhifeng Huang
(Department of Allergy and Clinical Immunology, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China, China (Mainland))
- O4-3 Deletion of ELOVL fatty acid elongase 6 (Elovl6) aggravates allergic airway inflammation through promoting the ceramide and sphingosine-1-phosphate signaling pathway**
Kazufumi Yoshida
(Department of Pulmonary Medicine, Faculty of Medicine, University of Tsukuba, Japan)
- O4-4 A synthetic oligonucleotide consisting of a poly-guanosine sequence suppresses phytohemagglutinin-induced IL-10 from human peripheral blood mononuclear cells.**
Yuna Sugiura
(Yokohama City University Graduate School of Medicine, Japan)
- O4-5 Combination of Tryptase and IL-33 in Bronchoalveolar Lavage Fluid May Predict the Types of Eosinophilic Pneumonia and Disease Recurrence**
Tomohiro Akaba
(Tokyo Women's Medical University, Japan)

On-demand delivery date: November 30 - December 28, 2021

Oral Session 5

SATURDAY • NOVEMBER 20

15:10 - 16:00

Room 9

O5 Environmental and Occupational Health and Epidemiology**Chair:** Jun-Pyo Myong

(Seoul St. Mary's Hospital, College of Medicine, the Catholic University of Korea, Republic of Korea)

O5-1 The Peak Expiratory Flow Rate and Respiratory Health of Children 7 to 18 years-old living near the Inayawan Landfill Site, Cebu City, Philippines

Philip Hester Gilbuena

(Chong Hua Hospital, Philippines)

O5-2 Factors affecting Compliance to COVID-19 Infection Prevention and Control Measures and its Effects on the Risk of COVID-19 Infection among Physicians in a Tertiary Government Hospital

Sta. Ana Charry Mae

(East Avenue Medical Center, Philippines)

O5-3 Traffic-related air pollution and respiratory health: a cross-sectional study among adolescents in Vietnam.

Hong Le

(Faculty of Medicine, The University of Queensland, Australia, Australia)

O5-4 The effects of smoking cessation therapy on pulmonary function and predictive factor of the FEV1 increase.

Masaaki Iwabayashi

(Department of Respiratory Medicine, Kobe City Medical Center West Hospital, Japan)

O5-5 Current smoking by socioeconomic status in a representative Japanese population

Minh Nguyen

(Emory University, United States of America)

On-demand delivery date: November 30 - December 28, 2021

Oral Session 6

SATURDAY • NOVEMBER 20

15:10 - 16:00

Room 10

O6 Respiratory Infections (non-tuberculous) 1**Chair:** Yuanlin Song

(Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University Shanghai Respiratory Research Institute Shanghai Key Laboratory of lung inflammation and injury, China)

O6-1 A multi-epitope peptide rOmp22 encapsulated in chitosan-PLGA nanoparticles as vaccine candidate against Acinetobacter baumannii infection

Xingran Du

(The Second Affiliated Hospital of Nanjing Medical University, China (Mainland))

O6-2 A novel broad-spectrum peptide therapy for acute and chronic lung infections with multidrug-resistant gram-negative bacteria

Dhammika Leshan Wannigama

(Antimicrobial Resistance and Stewardship Research Unit, Department of Microbiology, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Thailand)

O6-3 Bioinformatics analysis of high-throughput sequencing to identify key genes and signaling pathways in Vero E6 cells infected by SARS-CoV-2

Ye-Ling Liu

(Department of Clinical Medicine, The Third Clinical School of Guangzhou Medical University, Guangzhou, China (Mainland))

O6-4 Treatment outcomes of COVID-19 patients in Hong Kong's first designated Infection Control Centre and the impact of emergent SARS-CoV-2 mutant strains from imported cases

Charles Wong

(Department of Medicine, Pamela Youde Nethersole Eastern Hospital, HKSAR, Hong Kong)

O6-5 Genome-wide association study in patients with pulmonary Mycobacterium avium complex disease

Ho Namkoong

(Department of Infectious Diseases, Keio University School of Medicine, Japan)

On-demand delivery date: November 30 - December 28, 2021

Oral Session 7

SATURDAY • NOVEMBER 20

16:10 - 17:00

Room 10

O7 Respiratory Infections (non-tuberculous) 2

Chair: Chieh Liang Wu
(Taichung Veterans General Hospital, Taiwan)

- O7-1 Structural differentiation of the spike glycoprotein from SARS-CoV-2 COVID-19 variants of concern compared to other human-infecting coronaviruses: A computational study with clinical implications**
Marni Cueno
(Nihon University School of Dentistry, Japan)
- O7-2 Subunit Immunization with outer membrane protein potentially protects broadly against multidrug-resistant gram-negative bacillus**
Naoki Iwanaga
(Department of Respiratory Medicine, Nagasaki University Hospital, Japan)
- O7-3 A potential novel prognostic sputum biomarker for chronic *Pseudomonas aeruginosa* biofilm pulmonary infection**
Dhammika Leshan Wannigama
(Antimicrobial Resistance and Stewardship Research Unit, Department of Microbiology, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Thailand)
- O7-4 Early life respiratory infections perturb lung function in adulthood**
Laith Harb
(Telethon Kids Institute, Australia)
- O7-5 The role of increasing TIM3 on T cells in patients with nontuberculous mycobacterial lung disease: from immune cell dysfunction to clinical severity**
Chin-Chung Shu
(National Taiwan University Hospital, Taiwan)

On-demand delivery date: November 30 - December 28, 2021

Oral Session 8

SATURDAY • NOVEMBER 20

17:10 - 18:00

Room 10

O8 Respiratory Infections (non-tuberculous) 3

Chair: Masaki Fujita
(Fukuoka University Hospital, Japan)

- O8-1 Microbiology and treatment outcomes of pleural infection in a tertiary hospital in Hong Kong: a 10-year review**
Charles Wong
(Department of Medicine, Pamela Youde Nethersole Eastern Hospital, HKSAR, Hong Kong)
- O8-2 Clinical impact by phenotyping empyema based on pleural fluid culture positivity and appearance: a 7-year retrospective analysis**
Ka Pang Chan
(Department of Medicine & Therapeutics, Chinese University of Hong Kong, Hong Kong; Department of Medicine & Therapeutics, Prince of Wales Hospital, Hong Kong, Hong Kong)
- O8-3 The effectiveness of the combined use of remdesivir and regdanvimab (CT-P59) in patients with severe COVID-19: A single center retrospective study**
Aram Choi
(Ulsan University Hospital, University of Ulsan College of Medicine, Korea)
- O8-4 Determination of Antibody Titers of Filipino Healthcare Workers after COVID-19 Vaccination (Sinovac and AstraZenica) - A Preliminary Report**
Marian Dimabuyu
(Center for Thoracic and Critical Care Medicine, Cardinal Santos Medical Center, Philippines)
- O8-5 Prevalence of acute myocardial injury among COVID-19 patients in Persahabatan Hospital, Jakarta**
Hendra Wahyuni
(Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, University of Indonesia, Indonesia)

On-demand delivery date: November 30 - December 28, 2021

Oral Session 9

SATURDAY • NOVEMBER 20

16:10 - 17:00

Room 9

O9 Tuberculosis 1

Chair: Lalaine L. Mortera
(Manila Central University Hospital, Philippines)

- O9-1 Urticaria—a Major Systemic Drug Reaction under 1HP Tuberculosis Prevention in Non-HIV Population**
Jann-Yuan Wang
(National Taiwan University Hospital, Taiwan)
- O9-2 Gut Microbiota Signature can Distinguish Latent TB Infection Among Poorly Diabetic Patients**
Hung-Ling Huang
(Kaohsiung Medical University Hospital, Taiwan)
- O9-3 Artificial intelligence-assisted pathological screening of acid-fast bacilli may be useful for early detection of mycobacteriosis.**
Yoshiaki Zaizen
(Division of Respiriology, Neurology and Rheumatology, Department of Medicine, Kurume University School of Medicine, Japan)
- O9-4 The Effects of Active Hexose Correlated Compound (AHCC) on Levels of CD4+ and CD8+ in Human Immunodeficiency Virus (HIV) Infected Tuberculosis Patients**
Jamaluddin Madolangan
(Pulmonology, Medicine Study Program, Post Graduate School Hasanuddin University, Makassar, Indonesia, Indonesia)
- O9-5 Factors Affecting Time to Sputum Culture Conversion with Drug Resistant Tuberculosis using Short-term and Longer Regimen in Indonesia**
Galoeh Adyasiwi
(Departement of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Indonesia, Indonesia)

On-demand delivery date: November 30 - December 28, 2021

Oral Session 10

SATURDAY • NOVEMBER 20

17:10 - 18:00

Room 9

O10 Tuberculosis 2

Chair: Jennifer Ann M. Wi
(Lyceum Northwestern FQ Duque College of Medicine, Philippines)

- O10-1 Community-led tuberculosis and COVID-19 risk communication in the Vietnamese migrant population in Japan**
Sangnim Lee
(Department of Epidemiology and Clinical Research, The Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, Japan)
- O10-2 Collaboration of Professional Organization as Public-Private Mix Practice in Tuberculosis Control in Padang City, West Sumatera**
Russilawati Russilawati
(Faculty of Medicine, Universitas Andalas, Indonesia)
- O10-3 Echographic septation: a useful diagnostic indicator discriminating tuberculous from malignant pleural effusion**
Sze Shyang Kho
(Division of Respiratory Medicine, Sarawak General Hospital, Malaysia)
- O10-4 Effectiveness of intravenous isoniazid and ethambutol administration in patients with drug-susceptible pulmonary tuberculosis with TB-meningoencephalitis and HIV co-infection in the intensive phase of treatment**
Dmytro Butov
(Kharkiv National Medical University, Ukraine)
- O10-5 Usage of addictive agents and alcohol among patients infected with tuberculosis**
Harshana Bandara
(Senior Registrar in Respiratory Medicine, Welisara, Sri Lanka)

On-demand delivery date: November 30 - December 28, 2021

Oral Session 11

SUNDAY • NOVEMBER 21

8:50 - 9:40

Room 9

O11 COPD 1**Chair:** Chin Kook Rhee

(Seoul St. Mary's Hospital, The Catholic University of Korea, South Korea)

O11-1 Siglec-1-negative alveolar macrophages are associated with COPD exacerbation and may represent pro-inflammatory phenotypes

Takuya Saito

(Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Japan)

O11-2 Anomalous Epithelial Variations and Ectopic Inflammatory Response in Chronic Obstructive Pulmonary Disease

Naoaki Watanabe

(Division of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Japan)

O11-3 Risk factors of rapid lung function decline in COPD patients of real world

Hyun Woo Lee

(Division of Respiratory and Critical Care, Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Korea)

O11-4 Association of preserved ratio impaired spirometry with mortality risk: the Hisayama Study

Yasuyoshi Washio

(Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Japan)

O11-5 IVC 'mis' -guided fluids? An evaluation of the effect of different PEEP on the IVC indices of COPD patients on NIV.

Mihir Gangakhedkar

(All India Institute of Medical Sciences Rishikesh, India)

On-demand delivery date: November 30 - December 28, 2021

Oral Session 12

SUNDAY • NOVEMBER 21

9:50 - 10:40

Room 9

O12 COPD 2**Chair:** Hao-Chien Wang

(National Taiwan University Hospital, Taiwan)

O12-1 Pulmonary hyperinflation and the risk of COPD exacerbation: analysis from KOCOSS Cohort

Youlim Kim

(Hallym University Chuncheon Sacred Heart Hospital, Korea)

O12-2 Effectiveness of empirical anti-pseudomonal antibiotics in recurrent COPD exacerbation: A multicenter retrospective cohort study

Akihiro Shiroshita

(Ichinomiyanishi Hospital, Japan)

O12-3 Epithelial mesenchymal transition (EMT) is an active process in smokers, patients with small airway disease and COPD: implications for small airway fibrosis and obliteration

Wenyang Lu

(Respiratory Translational Research Group, Department of Laboratory Medicine, School of Health Sciences, University of Tasmania, Launceston, Tasmania 7248, Australia, Australia)

O12-4 Comprehensive analysis of allergen-specific IgE in COPD: mite-specific IgE specifically related to the diagnosis of asthma-COPD overlap

Hikaru Toyota

(Teikyo University School of Medicine, Japan)

O12-5 Insulin-resistance as an activator of inflammation in the comorbid course of chronic obstructive pulmonary disease and metabolic syndrome

Olga Tanchenko

(Amur State Medical Academy, Russia)

On-demand delivery date: November 30 - December 28, 2021

Oral Session 13

SUNDAY • NOVEMBER 21

8:50 - 9:50

Room 10

O13 Lung Cancer 1**Chair:** Emily Stone

(St Vincent's Hospital Sydney, University of NSW, Australia)

O13-1 High PD-L1 expression influenced the clinical outcomes of osimertinib in treatment naïve advanced EGFR -mutant non-small-cell lung cancer patients

Yen-Hsiang Huang

(National Chung Hsing University, Taiwan)

O13-2 Two Year Follow-up Data of First-Line Pembrolizumab for Advanced NSCLC Patients with PD-L1 TPS of 50% or Greater

Yuichi Tambo

(Kanazawa University Hospital, Japan)

O13-3 The ratio of T790M to EGFR-activating mutation predicts response of osimertinib in 1st or 2nd generation EGFR-TKI-refractory NSCLC

Motohiro Tamiya

(Department of Thoracic Oncology, Osaka International Cancer Institute, Japan)

O13-4 Comprehensive analysis of aquaporin superfamily in lung adenocarcinoma

Guofu Lin

(The Second Affiliated Hospital of Fujian Medical University, China (Mainland))

O13-5 The Characteristic of Acquired Resistance (T790M mutation) using plasma ct-DNA in EGFR-TKI treatment of Adenocarcinoma Lung Patients

Muhammad Harbi Praditya

(Department of Pulmonology and Respiratory Medicine, Adam Malik General Hospital -- Faculty of Medicine Universitas Sumatera Utara, Indonesia)

On-demand delivery date: November 30 - December 28, 2021

Oral Session 14

SUNDAY • NOVEMBER 21

9:50 - 10:40

Room 10

O14 Lung Cancer 2**Chair:** Sita Andarini

(Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, University of Indonesia - Persahabatan Hospital, Jakarta, Indonesia)

O14-1 Comparing effectiveness of FDA approved first-line treatments for patients with advanced NSCLC and high PD-L1 Expression

Faiza Ahmed

(Larkin Community Hospital, United States of America)

O14-2 Chemotherapy versus chemo-immunotherapy as first-line treatment in patients with extensive-stage small-cell lung cancer- A systematic review and meta-analysis

Ching-Yi Chen

(E-Da Hospital, Taiwan)

O14-3 Diagnostic and dynamic circulating methylated DNA markers for non-small cell lung cancer

Shu-Yung Lin

(Department of Internal Medicine, National Taiwan University Hospital, Taiwan)

O14-4 Immunological contribution in the development of lung cancer with pulmonary fibrosis

Tatsuki Nishioka

(Department of Immunology, Nara Medical University, Japan)

O14-5 Pulmonologists and molecular biomarker testing for patients with advanced non-small cell lung cancer

Adam Fox

(The Medical University of South Carolina, USA)

On-demand delivery date: November 30 - December 28, 2021

Oral Session 15

SUNDAY • NOVEMBER 21

12:40 - 13:30

Room 7

O15 Lung Cancer 3

Chair: David CL Lam
(University of Hong Kong, Hong Kong)

O15-1 Evaluation of CXCL12 expression in the microenvironment of non-small cell lung cancer

Yurie Kogue
(Department of Respiratory Medicine, Suzuka Chuo General Hospital, Japan)

O15-2 Comparison of Treatment Duration in Developing Drug Resistance to EGFR-TKI, Pemetrexed, and Combination Treatment in NSCLC in vitro

Eshat Fahmida Haque
(Department of Internal Medicine, Division of Medical Oncology & Respiratory Medicine, Faculty of Medicine, Shimane University, Japan)

O15-3 The immunoproteasome as a potential therapeutic target in cisplatin-resistant small cell and non-small cell lung cancer

Tatsuaki Shoji
(Hokkaido University, Japan)

O15-4 The efficacy of Gefitinib as a first-line therapy in elderly patients with advanced non-small cell lung cancer with EGFR mutations

Luan Pham
(Department of Respiratory Medicine, 108-Military Central Hospital, Ha Noi, Vietnam, Viet Nam)

O15-5 Relationship between PD-L1 expression, common driver mutations and cigarette smoking in patients with non-small cell lung cancer

Chong Kin Liam
(Department of Medicine, Faculty of Medicine, University of Malaya, Malaysia)

On-demand delivery date: November 30 - December 28, 2021

Oral Session 16

SUNDAY • NOVEMBER 21

12:40 - 13:30

Room 8

O16 Asthma 1

Chair: Phan Thu Phuong
(Hanoi Medical University, Vietnam)

O16-1 Intergenerational effects of passive smoking in fathers on offspring's asthma: A longitudinal cohort study

Jiacheng Liu
(The University of Melbourne, Australia)

O16-2 The role of 27-hydroxycholesterol in the pathogenesis of bronchial asthma

Tatsunori Ito
(Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Japan)

O16-3 Incidence and risk factors of recurrence/ flares of allergic bronchopulmonary mycosis

Jun Tanaka
(Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine, Japan)

O16-4 Grape seed proanthocyanidin extract ameliorates glucocorticoid insensitivity in severe asthma

Qian Zhang
(Department of Respiratory and Critical Care Medicine, The Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University, China (Mainland))

O16-5 Asthma persistence is associated with gender, age and inhaled corticosteroid treatment and history of disease exacerbations in Chinese children

Ting Fan Leung
(Department of Paediatrics, The Chinese University of Hong Kong, Hong Kong)

On-demand delivery date: November 30 - December 28, 2021

Oral Session 17

SUNDAY • NOVEMBER 21

13:30 - 14:20

Room 8

O17 Asthma 2**Chair:** Shih-Lung Cheng

(Division of Pulmonary Medicine, Far Eastern Memorial Hospital, Taiwan)

O17-1 Asthma Status During COVID-19 Pandemic

Nesia Priandari

(Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Indonesia, Indonesia)

O17-2 Performance of GINA score against ACT in defining asthma control and predicting unplanned healthcare utilization

Andrew Li

(National University Hospital, Singapore)

O17-3 Reasons for uncontrolled asthma in patients attending a difficult-to-treat asthma clinic

Chee Kuan Wong

(University of Malaya, Malaysia)

O17-4 Novel predictive biomarkers for mepolizumab treatment in patients with severe asthma

Hitoshi Sasano

(Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Japan)

O17-5 Soluble TIM-4 levels in serum are associated with severe asthma phenotype

Yuki Tanabe

(Juntendo University, Japan)

On-demand delivery date: November 30 - December 28, 2021

Oral Session 18

SUNDAY • NOVEMBER 21

13:30 - 14:20

Room 7

O18 Respiratory Neurobiology and Sleep**Chair:** Yoshitaka Oku

(Hyogo College of Medicine, Japan)

O18-1 Information-motivation-behavioral skills intervention increases the CPAP adherence in old OSAHS patients

Yina Wang

(Department of Geriatrics, The Second Xiangya Hospital of Central South University, China (Mainland))

O18-2 Breathing irregularities before sleep onset on polysomnography in patients with heart diseases

Soshi Okamoto

(Tokyo University, Japan)

O18-3 Analysis of nocturnal desaturation waveform by using algorithm in the patients with idiopathic pulmonary fibrosis.

Yuichiro Yasuda

(Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Japan)

O18-4 Non-invasive ventilation improves persistent tachycardia in a case of mitochondrial myopathy.

Glenn Yong

(Tan Tock Seng Hospital, Singapore)

O18-5 Sleep apnea and academic performance: A study on medical students using the Berlin Questionnaire

Riana Putri Moegandi

(Undergraduate Programme, Faculty of Medicine, Universitas Indonesia, Indonesia)

On-demand delivery date: November 30 - December 28, 2021

Oral Session 19

SUNDAY • NOVEMBER 21

12:40 - 13:30

Room 9

O19 Critical Care Medicine**Chair:** Tatsuma Fukuda

(Toranomon Hospital, Tokyo, Japan)

O19-1 Non-invasive ventilation vs early intubation for acute hypoxaemic respiratory failure: A single-centre propensity-matched cohort study.

Dilip Jayasimhan

(Intensive Care Unit, Waikato District Health Board, New Zealand, Department of Respiratory Medicine and Respiratory Research Unit, Waikato District Health Board, New Zealand)

O19-2 Clinical utility of serum heme oxygenase-1 for evaluating oxidative stress in patients with lung injury

Ryo Nagasawa

(Department of Pulmonology, Yokohama City University Graduate School of Medicine, Japan)

O19-3 The outcomes of evolving treatment regimens among COVID-19 confirmed severe and critical cases admitted at the Lung Center of the Philippines

Honeylet Chan-Reyes
(Lung Center of the Philippines, Philippines)

O19-4 Pilot Mobile Assisted Ventilation Services (MOVES) in acute general medical wards (AGMW) during winter surge in QEH

Pik Kee Maggie Lit
(Nurse Consultant (Respiratory) department of Medicine, Queen Elizabeth Hospital, HAHO, HK, Hong Kong)

O19-5 Sepsis, cardiovascular events and short-term mortality risk in critically ill patients

Sharlene Ho
(Tan Tock Seng Hospital, Singapore)

On-demand delivery date: November 30 - December 28, 2021

Oral Session 20

SUNDAY • NOVEMBER 21 13:30 - 14:20

Room 9

O20 Bronchoscopy and Interventional Techniques

Chair: Chih-Yen Tu
(Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, China Medical University Hospital, China)

O20-1 Spinal cord infarction after bronchial artery embolization using coils for hemoptysis: a single-center retrospective analysis of 3046 procedures

Hideo Ishikawa
(Hemoptysis and Pulmonary-Circulation Center, Eishinkai Kishiwada Rehabilitation Hospital, Japan)

O20-2 Validation of factors make cryobiopsy more effective for peripheral pulmonary lesions: results of the MINERVA registry

Yuji Matsumoto
(Department of Endoscopy, Respiratory Endoscopy Division/Department of Thoracic Oncology, National Cancer Center Hospital, Japan)

O20-3 Multiple pulmonary function measurement system for guiding interventional bronchoscopy

Hiroki Nishine
(Division of Respiratory and Infectious Diseases, Department of Internal Medicine, St. Marianna University School of Medicine, Japan)

O20-4 Diagnostic yield and the number of tumor cells of ultrathin bronchoscopy for peripheral lung lesions: a comparison with thin bronchoscopy

Atsuhiko Yatani
(Kobe University Graduate School of Medicine, Japan)

O20-5 The microbiology of postobstructive pneumonia in patients with malignancy endobronchial lesions

Chia-Hung Chen
(China Medical University Hospital, Taiwan)

On-demand delivery date: November 30 - December 28, 2021

Oral Session 21

SUNDAY • NOVEMBER 21 16:20 - 17:10

Room 9

O21 Paediatric Lung Disease

Chair: Anne Goh
(KK Women's and Children's Hospital, Singapore)

O21-1 Pediatric lung transplantation in Korea: A single center experience

Ji Soo Park
(Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea, Korea)

O21-2 Relationship between wheezing and developmental trajectory of nasopharyngeal microbiome in Chinese toddlers

Ting Fan Leung
(Department of Paediatrics, The Chinese University of Hong Kong, Hong Kong)

O21-3 Comparing admission days of tracheostomized children admitted with bTAR-TIs 6-month before and after home respiratory care training

Prakarn Tovichien
(Division of Pulmonology, Department of Pediatrics, Siriraj Hospital Mahidol University, Thailand)

O21-4 A case report of bronchiolitis obliterans in a child post hydrocarbon inhalation in Angkor Hospital for Children

Khenuoy Um
(MD, Pediatric respiratory fellow in Angkor Hospital for Children, Cambodia)

O21-5 Bronchiolitis obliterans in an asthmatic diagnosed child at the chest clinic, Angkor Hospital for Children

Sokchinda Kong
(Angkor Hospital for Children, Cambodia)

On-demand delivery date: November 30 - December 28, 2021

Oral Session 22

SUNDAY • NOVEMBER 21 17:10 - 18:00

Room 9

O22 Respiratory Structure and Function

Chair: Gregory G King
(Royal North Shore Hospital, Sydney, Australia)

O22-1 Parenchymal destruction in asthma : Fixed airflow obstruction and lung function trajectory

Kaoruko Shimizu
(Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Japan)

O22-2 Oscillometry in single lung transplantation for interstitial lung disease demonstrates abnormal respiratory reactance: results of a multi-center cross-sectional study

Joan Pei Yun Sim
(Lung Transplant & Thoracic Medicine Unit, St Vincent's Hospital, Sydney Australia; St Vincent's Clinical School, The University of New South Wales, Sydney Australia, Australia)

O22-3 Cohort differences in spirometry indices in healthy Singapore Chinese adults

Gin Tsen Chai
(Department of Respiratory and Critical Care Medicine, Tan Tock Seng Hospital, Singapore)

O22-4 Dynamic-Forced Expiratory CT as a Useful Protocol for Severe ECAC.

DANIEL HERNANDEZ-ROJAS
(Mayo Clinic Florida Division of Pulmonary, Allergy and Sleep Medicine, United States of America)

O22-5 Complete Pulmonary function profiles of 267 Post Covid patients with exertional dyspnea in Bangladesh

Islam Mohammad Azharul
(Square Hospital, Bangladesh)

On-demand delivery date: November 30 - December 28, 2021

Oral Session 23

SUNDAY • NOVEMBER 21

12:40 - 13:30

Room 10

O23 Pulmonary Circulation

Chair: Nobuhiro Tanabe
(Chibaken Saiseikai Narashino Hospital, Japan)

O23-1 Clinical features of novel phenotype in pulmonary hypertension along with mild lung parenchymal change without severe ventilatory impairment

Tadasu Okaya
(Chiba University Hospital, Japan)

O23-2 Clinical characteristics of pulmonary arterial hypertension and co-existing lung disease: analysis of the data from National Research Project of Intractable Disease in Japan

Rika Suda
(Department of Respiratory, Graduate School of Medicine, Chiba University, Department of Respiratory Medicine, Chibaken Saiseikai Narashino Hospital, Japan)

O23-3 Elevated betaine is associated with poor prognosis of patients with pulmonary hypertension

Yicheng Yang
(Fuwai Hospital, China (Mainland))

O23-4 An elusive cause of dyspnea

Gin Tsen Chai
(Department of Respiratory and Critical Care Medicine, Tan Tock Seng Hospital, Singapore)

O23-5 Taiwan Cohort - Registry of Chronic Thromboembolic Pulmonary Hypertension (TREC): A Preliminary Study

Ching-Lung LIU
(Division of Chest, Department of Internal Medicine, MacKay Memorial Hospital, Taiwan)

On-demand delivery date: November 30 - December 28, 2021

Oral Session 24

SUNDAY • NOVEMBER 21

16:20 - 17:10

Room 10

O24 Interstitial Lung Disease 1

Chair: Arata Azuma
(Nippon Medical School, Japan)

- O24-1 Regulation of SMAD7 and SOCS1 through metabolic and epigenetics coordination by mesenchymal stem cell-derived humoral factor STC1 induces anti-fibrotic and anti-inflammatory effects in lung injuries**
Shinya Ohkouchi
(Tohoku University, Japan)
- O24-2 The role of circulatory high-mobility group box 1 for predicting checkpoint inhibitor pneumonitis caused by anti-PD-1/PD-L1 antibody monotherapy**
Kakuhiro Yamaguchi
(Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Japan)
- O24-3 The Role of Mitochondria-Dependent Metabolic Reprogramming in the Pathogenesis of Pulmonary Fibrosis**
Kai Yazaki
(University of Tsukuba, Japan)
- O24-4 Impact of medication burden on tolerability of disease-targeted therapy and survival in interstitial lung disease**
Yet H Khor
(Department of Respiratory and Sleep Medicine, Austin Health, Heidelberg, Victoria, Australia, Institute for Breathing and Sleep, Heidelberg, Victoria, Australia, Faculty of Medicine, University of Melbourne, Melbourne, Victoria, Australia)
- O24-5 Altered megakaryocyte and platelet parameters in idiopathic pulmonary fibrosis**
Shigeki Saito
(Tulane University, United States of America)

On-demand delivery date: November 30 - December 28, 2021

Oral Session 25

SUNDAY • NOVEMBER 21

17:10 - 18:00

Room 10

O25 Interstitial Lung Disease 2

Chair: Yuko Waseda
(University of Fukui, Japan)

- O25-1 Increased expression of Angiotensin-converting enzyme 2 (ACE2), TMPRSS2 and Furin in idiopathic pulmonary fibrosis (IPF) and lymphangioleiomyomatosis (LAM) patients' lung tissue: implications for COVID -19**
Wenyong Lu
(Respiratory Translational Research Group, Department of Laboratory Medicine, School of Health Sciences, University of Tasmania, Launceston, Tasmania 7248, Australia, Australia)
- O25-2 Assessment of alveolar-capillary membrane permeability using aerosol scintigraphy indiffuse cutaneous systemic sclerosis - a cross sectional study**
MUNIZA BAI
(DEPARTMENT OF PULMONARY MEDICINE, JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH, India)
- O25-3 Clinical characteristics in patients who clinically diagnosed with idiopathic pleuroparenchymal fibroelastosis using new Japanese clinical diagnostic criteria**
Toshihiko Ohni
(Juntendo University Graduate School of Medicine, Japan)
- O25-4 A real-world study of the safety and efficacy of low-dose nintedanib for idiopathic pulmonary fibrosis**
Soichiro Soma
(Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Japan)
- O25-5 The end of the road for patients with interstitial lung disease, are we doing enough?**
Juanita Lestari
(Department of Respiratory and Critical Care Medicine, Tan Tock Seng Hospital, Singapore, Singapore)

On-demand delivery date: November 30 - December 28, 2021

Poster Session

Poster Session 1

On-demand

P1 Clinical Respiratory Medicine**P1-1 Role of early intrapleural fibrinolytic therapy for thoracic empyema: an analysis of the nationwide inpatient database**

Hiroyuki Tamiya

(The Department of Respiratory Medicine, The University of Tokyo Hospital, Japan)

P1-2 Correlations in physical symptoms, blood biochemical findings, and chest CT images in an early phase of COVID-19 patient

Satoshi Fukuda

(Department of General medicine, International University of Health and Welfare, Shioya Hospital, Japan)

P1-3 Prescribing oxygen: an audit of prescribing and delivery practices at two tertiary hospitals in Melbourne, Australia

Jayne Roberts

(Department of Respiratory & Sleep Disorders Medicine, Western Health. Department of Respiratory Medicine, Northern Hospital, Australia)

P1-4 Computed tomographic volumetry in the diagnosis of lung inflation disorders in patients with pulmonary-mediastinal sarcoidosis

Andrey V. Ilin

(Far Eastern Scientific Center of Physiology and Pathology of Respiration, Russia)

P1-5 The cytokine balance of allergic bronchopulmonary aspergillosis (ABPA) and chronic pulmonary aspergillosis (CPA)

Yuya Ito

(Department of Respiratory Medicine, Nagasaki University Hospital, Japan)

P1-6 Clinical effectiveness of cefoperazone-sulbactam versus piperacillin-tazobactam for the treatment of pneumonia in the elderly population

Chun-Ta Huang

(Department of Internal Medicine, National Taiwan University Hospital, Taiwan)

P1-8 Impact on inhalation adherence of asthma and COPD patients during the COVID-19 pandemic

Eriko Fukutani

(Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Japan)

P1-9 Predictive factor of high-flow nasal oxygen failure in covid-19 patients at tertiary hospital in Jakarta

Wahyu Soebekti

(Department of Pulmonology and respiratory medicine, Faculty of medicine, University of Indonesia, Indonesia)

P1-10 Indicators of the pituitary-thyroid system in asthma patients with cold airway hyperresponsiveness without manifestation of thyroid lesion, living in endemic goiter area

Victor P. Kolosov

(Far Eastern Scientific Center of Physiology and Pathology of Respiration, Russia)

P1-11 Acute Pulmonary Complications Following Cosmetic Silicone Breast Injections: 2 Rare Cases

Nai-Chien Huan

(Respiratory Department, Sultanah Aminah Hospital, Malaysia)

P1-12 Eosinophilic Granulomatosis with Polyangiitis (Churg Strauss Syndrome) Presenting as Acute Polyneuropathy Mimicking Guillain-Barre Syndrome - A Case Report

Marian Dimabuyu

(Center for Thoracic and Critical Care Medicine, Cardinal Santos Medical Center, Philippines)

P1-13 Effect of Bromhexine among COVID-19 Patients - A Meta-Analysis

Martin Kristoffer Ogbac

(Perpeual Help Medical Center - Las Piñas, Philippines)

P1-14 Venous blood gases versus Arterial blood gases in the titration of acute non-invasive ventilation.

Maurice Lam

(Department of Respiratory and Sleep Medicine St. George Hospital, Sydney, Australia)

P1-15 Chest X-Ray Improvement in COVID-19 Moderate Symptoms with Remdesvir and Favipiravir : A Comparative study

Arief Riadi Arifin

(Indonesia Society of Respirology, Indonesia)

P1-16 VAP bundle for Chronic Ventilator Ward Patients in TB and Chest Unit of Grantham Hospital

Wing Kin Law

(Grantham Hospital, Hospital Authority, Hong Kong)

- P1-17 A case of radio-insensitive SMARCA4-deficient thoracic undifferentiated carcinoma with severe right heart failure**
Shotaro Ito
(Department of Respiratory Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Japan)
- P1-18 Whole-lung lavage for Pulmonary Alveolar Proteinosis in Australia - safety and efficacy at a single centre**
Hugh Buzacott
(Alfred Hospital, Department of Respiratory Medicine, Australia)
- P1-19 Thoracic endometriosis diagnosed with the aid of the pleuroscopy**
Boon Hau Ng
(Respiratory Unit, Department of Medicine, Pusat Perubatan Universiti Kebangsaan Malaysia, Malaysia)
- P1-20 Adulthood presentation of congenital pulmonary airway malformation type-1**
Abbas El-Hajj Hussein
(Department of Respiratory Medicine, St George Hospital, Australia)
- P1-21 The effectiveness of 5 days antibiotic therapy on patients hospitalized for community acquired pneumonia**
WAI HENG CHEW
(Universiti Kebangsaan Malaysia Medical Center, Faculty of Medicine, Department of Internal Medicine, Kuala Lumpur, Malaysia., Malaysia)
- P1-22 The prevalence and clinical significance of pleural fluid detected by chest MRI: a cross-sectional study in a medical checkup setting.**
Kensuke Fukuda
(Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Japan)
- P1-23 Effects of early nutrition therapy combined with early pulmonary rehabilitation on ADL performance in elderly patients with pneumonia**
Yuichi Murakawa
(Department of Rehabilitation Technology, Sanuki Municipal Hospital, Japan)
- P1-24 Correlation of Chest CT Findings and Severity of Coronavirus Disease (COVID-19) Infections in Patients admitted at Chinese General Hospital and Medical Center**
Jennifer Siy
(Chinese General Hospital and Medical Center, Philippines)
- P1-25 Impact of Isolated Calf Deep Vein Thrombosis on Clinical manifestation**
YON JU RYU
(College of Medicine, Ewha Womans University, Korea)
- P1-26 Cytokines secreted by PC9-MET and PC9 cells may worsen COVID-19**
Md Mohiuddin
(Department of Respiratory Medicine, Kanazawa University, Japan)
- P1-27 THE IMPACT OF ELECTRONIC SMOKING SYSTEMS ON THE BRONCHOPULMONARY SYSTEM**
Tatiana Luchnikova
(Amur State Medical Academy, Russia)
- P1-28 Erector spinae muscle radiographic density predicts survival after lung transplantation**
Yohei Oshima
(Rehabilitation Unit, Kyoto University Hospital, Japan)
- P1-29 Clinical characteristics of Preserved Ratio Impaired Spirometry in Japan**
Shinichiro Miura
(Department of Molecular and Internal Medicine, Institute of Biomedical & Health Sciences, Hiroshima University, Japan)
- P1-30 Sleep architecture of short sleep time in patients with obstructive sleep apnea: a retrospective single-facility research**
Shuhei Nozawa
(First Department of Medicine, Shinshu University School of Medicine, Japan)
- P1-31 A randomized crossover exploratory study comparing the effect of an auto-demand oxygen delivery system with that of a normal demand oxygen delivery system**
Takehiro Otoshi
(Kobe University Graduate School of Medicine, Japan)
- P1-32 A case report of a fatal pulmonary tumour emboli.**
Rivindi Watthayalage
(RACP, Australia)
- P1-33 Careful history taking detects underlying disorders of initially unknown causes of aspiration pneumonia**
Yuki Yoshimatsu
(Iizuka Hospital, Japan)

- P1-34** **Passive Microwave Radiometry as a early screening diagnostic of pneumonia due to Coronavirus infection 2019 Lung Complications in Kyrgyzstan**
Batyr Osmonov
(Educational-Scientific Medical Center, Kyrgyz State Medical Academy (KSMA), Kyrgyz Republic)
- P1-35** **A case of chronic type II respiratory failure due to Bethlem myopathy**
Masato Morita
(Tottori University Hospital, Department of Respiratory Medicine and Rheumatology, Japan)
- P1-36** **Multicenter study elucidating factors associated with sequelae of discharged COVID-19 patients in Japan**
Takahiro Ando
(Department of Respiratory Medicine, Tokyo Medical and Dental University, Japan)
- P1-37** **Correlation of the effectiveness of hemodialysis and pleuropulmonary findings by thoracic ultrasound in patients with chronic kidney disease**
Alvarez Martinez Natalia
(Hospital Universitario de Monterrey, Mexico)
- P1-38** **Impact of cisplatin and pemetrexed on VEGFR-1 on inducing anticancer effects in KRAS-dependent A549 cells**
Md Mohiuddin
(Department of Respiratory Medicine, Kanazawa University, Japan)
- P1-39** **Paclitaxel induces growth inhibition in gefitinib-resistant PC9-MET cells by down-regulating MDM2 and activating p53**
Md Mohiuddin
(Department of Respiratory Medicine, Kanazawa University, Japan)
- P1-40** **Pig bronchus: A rare tracheobronchial anomaly causing lung collapse and recurrent pneumonia**
Thilini Muthukumarana
(Senior Registrar in Paediatric Pulmonology, Sri Lanka)
- P1-41** **IMPACT OF RESPIRATORY FAILURE SERVICE ON MANAGEMENT OF ACUTE HYPERCAPNIC RESPIRATORY FAILURE IN LIVERPOOL HOSPITAL**
Khine Khine Yin Mon
(Sydney, Australia. Department of Respiratory Medicine, Liverpool Hospital, Australia)
- P1-42** **Use of indwelling pleural catheters as a palliative care intervention for malignant pleural effusions at Queen Elizabeth Hospital, Woolwich**
Grace Tan
(Lewisham and Greenwich NHS Trust, United Kingdom)
- P1-43** **Inter-hospital collaboration of sleep services programs between Kowloon Hospital (KH) and Queen Elizabeth Hospital (QEH)**
Maggie Pik Kee Lit
(Nurse Consultant (Respiratory) Respiratory Division, Department of Medicine, Queen Elizabeth Hospital, Hong Kong)
- P1-44** **Pulmonary amyloidosis due to IgG lambda myeloma - An unusual presentation**
Syed Ahmad
(Consultant Respiratory Physician, Chorley and South Ribble Hospital, United Kingdom, United Kingdom)
- P1-45** **Resolving Persistent Bilateral Pneumothorax without Performing Video-Assisted Thoracoscopic Surgery (VATS): A Case Report**
Charry Mae Sta. Ana
(East Avenue Medical Center, Philippines)
- P1-46** **A Case of Bronchial Obstruction due to Pulmonary Hypertension**
Sampath Liyanage
(Senior Registrar in Respiratory Medicine, Sri Lanka)
- P1-47** **Clinical characteristics of severe COVID19 patients**
Yuki Kuwahara
(Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University Hospital, Saga, Japan, Japan)
- P1-48** **Metabolism of traditional Chinese medicine in the treatment of allergic rhinitis**
Mengli ZHANG
(Guangzhou Medical University, China (Mainland))
- P1-49** **General Practitioner and Specialists Perceptions of Clinical Pathways for Management of Chronic Breathlessness in Primary Care**
Anthony Paulo Sunjaya
(Respiratory Group, The George Institute for Global Health, UNSW Sydney, Australia)
- P1-50** **Radiological Findings of EVALI: a Systematic Review**
Raissa Barreto Lima
(Bahia School of Medicine and Public Health, Brazil)

- P1-51 Status of palliative care in respiratory disease before and after Covid-19 outbreak**
Shunsuke Okumura
(Asahikawa Medical University Hospital, Japan)
- P1-52 Successful case of non-HIV pneumocystis pneumonia treated with extracorporeal membrane oxygenation (ECMO)**
Kazuhiro Abe
(Tokyo women's medical university, Japan)
- P1-53 The combination of sarcoid lymphadenopathy and cystic formation of the mediastinum: ways to optimize radiation diagnostics**
Anatoliy V. Lenshin
(Far Eastern Scientific Center of Physiology and Pathology of Respiration, Russia)
- P1-54 Paclitaxel impedes G1 phase progression in gefitinib-resistant non-small-cell lung cancer**
Md Mohiuddin
(Department of Respiratory Medicine, Kanazawa University, Japan)
- P1-55 Pulmonary function after Nintedanib treatment in post-COVID-19 pulmonary fibrosis**
Lomanta Jan Michael Jesse
(Philippine General Hospital, Philippines)
- P1-56 A case of pulmonary alveolar proteinosis with severe respiratory failure improved by segmental lung lavage with fiberoptic bronchoscopy under general anesthesia**
Yu Matsumoto
(Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Japan)
- P1-57 Kartagener's syndrome: A case report of a lady with poorly resolving asthma**
Niranjan Chandramal
(National hospital of Sri Lanka, Sri Lanka)
- P1-58 Successful treatment of complex multiloculated chylothorax with single low dose intrapleural Alteplase**
Wan Awatif Wan Mohd Zohdi
(Respiratory Unit, Department of Medicine, Pusat Perubatan Universiti Kebangsaan Malaysia, Malaysia)
- P1-59 Co-relation of Age, Sex, diffusion and volume defects with HRCT chest scoring in Post COVID patients with exertional breathlessness in Bangladesh**
Haq Masrura
(Square Hospital, Bangladesh)
- P1-60 An innocent vascular ring in an adult asthmatic patient; incidental balanced type double aortic arch**
Harshana Bandara
(Senior Registrar in Respiratory Medicine, Welisara, Sri Lanka)
- P1-61 RESEARCH OF RESPIRATORY SEQUELAE IN COVID 19 PATIENTS AT 3 MONTHS**
Ghislaine Tsemo
(French Society of respiratory diseases, France)
- P1-62 Elderly sarcoidosis in Japan**
Keiuske Watanabe
(Department of Pulmonology, Yokohama City University Graduate School of Medicine, Japan)
- P1-63 Respiratory responses during two minutes walking in late-stage elderly people**
Masahiro Satake
(Department of Physical Therapy, Akita University Graduate School of Health Sciences, Japan)
- P1-64 A case of misdiagnosis of pulmonary hamartoma**
Anna Lau
(Tan Tock Seng Hospital, Singapore)
- P1-65 Two cases of Castleman's disease with lung lesions controlled by tocilizumab**
Sanami Ozaki
(Kawaguchi Municipal Medical Center, Japan)
- P1-66 Metastatic pulmonary calcification mimicking miliary pulmonary tuberculosis: A case report**
Thian Chee Loh
(Department of Medicine, Faculty of Medicine, University of Malaya, Malaysia)
- P1-67 Silicosis, tuberculosis and dermatomyositis - are they connected?**
Sharlene Ho
(Respiratory and Critical Care Medicine, Tan Tock Seng Hospital, Singapore)
- P1-68 Association between Smoking and Physical Fitness Measured Using 6-Minutes Walking Test in Nonstaff Employee University of Indonesia, Depok: A Cross-sectional Study**
Hilma Nur Faiza
(Faculty of Medicine Universitas Indonesia, Indonesia)
- P1-69 Acquired Esophago-Airway fistula in Adults: A Case Report**
Rachelle Dela torre-Mangente
(Philippine College of Chest Physician, Philippines)

- P1-70 Yokukansan and in-hospital mortality in patients with pneumonia**
Akira Yokoyama
(Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Japan)
- P1-71 Breath-Actuated Inhalation Therapy: Survey Of physicians' Perception (INTROSPECT) in Nepal**
Ramesh Chokhani
(Norvic International Hospital, Nepal)
- P1-72 A Case of Lung Intravascular Large B Cell Lymphoma Developed with Acute Respiratory Failure: Usefulness of Corticosteroid Rescue Prior to Define Diagnosis**
Mayoko Tsuji
(Department of Respiratory Medicine, Tokyo Women's Medical University, Japan)
- P1-73 Dry needling and orthopnea: A case of bilateral, atraumatic phrenic nerve demyelination.**
Sarbroop Dhillon
(Sleep & Respiratory Fellow, West Australian Sleep Disorders Research Institute, Australia)
- P1-74 COVID-19 in renal transplant recipients in a resource poor setting: a case series**
Malika Udugama
(National Hospital for respiratory diseases, Sri Lanka)
- P1-75 Shrinking lung treatment responding to Cyclophosphamide pulses - A case report**
Sugeesha Wickramasinghe
(Senior Clinical Fellow in Respiratory Medicine, Chorley and South Ribble Hospital, United Kingdom, United Kingdom)
- P1-76 Rare endobronchial squamous papilloma causing recurrent pneumonia**
Nik Nuratiqah Nik Abeer
(Respiratory Unit, Department of Medicine, Pusat Perubatan Universiti Kebangsaan Malaysia, Malaysia)
- P1-77 Long-COVID syndrome associated with COVID-19 pneumonia**
Naho Furusho
(Nihon University School of Medicine, Department of Internal Medicine, Division of Respiratory Medicine, Japan)
- P1-78 Descriptive analysis of patients attending an outpatient post covid-19 clinic in a tertiary care hospital in sri lanka**
Uditha Udumulla
(Demonstrator, Faculty of Medicine, Sabaragamuwa University of Sri Lanka, Sri Lanka)
- P1-79 Diaphragm dysfunction developed after COVID-19 infection without pneumonia**
Elizaveta Sheludko
(Far Eastern Scientific Center of Physiology and Pathology of Respiration, Russia)
- P1-80 Clinical analysis of lung bullas with spontaneous regression after abscess**
Sotaro Shikano
(Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Japan)
- P1-81 Malignant Pleural Effusion in a Newly-diagnosed Multiple Myeloma Patient**
Mara Angeli Kiocho
(Perpetual Help Medical Center Las Pinas, Philippines)
- P1-82 Successful Treatment of Bilateral Diaphragmatic Paralysis From HIV Associated Axonal Polyneuropathy with Bilevel Positive Airway Pressure - A Case report**
Mohd Zhafran Zainal Abidin
(Universiti Teknologi MARA (UiTM), Malaysia)
- P1-83 A Case Report of Primi 30 Weeks of Pregnancy with Covid-19 Pneumonia with Dengue Fever.**
Anarul Islam
(General Medical Council, Bangladesh)
- P1-84 Airway Management Training for nursing staff of TB and Chest Unit, Grantham Hospital**
Chung Yin Kan
(Grantham Hospital, Hospital Authority, Hong Kong)
- P1-85 Knowledge, Awareness and Practices of Nurses and Respiratory Therapists Regarding Administering Inhaler Gadget Education to Admitted Patients Prescribed with an Inhaler Device**
Melanie Sanchez
(University of Santo Tomas Hospital, Philippines)
- P1-86 Prone positioning treatment for COVID-19 ARDS patients with pneumomediastinum and subcutaneous emphysema during treatment of mechanical ventilation. : a two cases report**
Masako Ichikawa
(Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Japan)
- P1-87 Dyspnea Eight Years Post Craniopharyngioma Resection**
Faisal Abushullaih
(National Guard Hospital in Dammam, Saudi Arabia)

- P1-88 Persistent Bilateral Unprovoked Pulmonary Embolism - A Case of Chronic Thromboembolic Pulmonary Hypertension in a Young Lady with Seronegative Antiphospholipid Syndrome**
Muhammad Farid Mohd Fauad
(Universiti Teknologi MARA, Malaysia)
- P1-89 Postural herniation of a skeletal muscle hemangioma through intercostal space**
Richa Tyagi
(King George's Medical University, India)
- P1-90 Increased risk of suicide attempt among patients receiving blood transfusion: The good, the bad and the ugly**
Weisyu Hu
(China Medical University Hospital, Taiwan)
- P1-91 Two cases of polypharmacy-associated aspiration pneumonia: a possible role of aging lung**
Shinji Teramoto
(Tokyo Medical University hachioji medical center, Japan)
- P1-92 Para-spinal neurilemmoma with an atypical thoracic discomfort- An undescribed entity**
Sugeesha Wickramasinghe
(Senior Clinical Fellow in Respiratory Medicine, Chorley and South Ribble Hospital, Chorley, United Kingdom, United Kingdom)
- P1-93 A case of lung mass with bifurcation that was difficult to differentiate from lung cancer.**
Yasuhito Nagata
(Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Japan)
- P1-94 The challenges of patients that with home using long term Oxygen therapy under Coronavirus pandemic**
Leung Sin Man Kerrie
(Hospital Authority, Hong Kong)
- P1-95 It runs in the family: Case series of severe and critical COVID-19 in three family members**
Archangel Manuel
(Lung Center of the Philippines, Quezon city, Philippines)

Poster Session 2

On-demand

- P2 Cell and Molecular Biology**
- P2-1 Antifibrotic effect of lung-resident progenitor cells with high aldehyde dehydrogenase activity**
Hiroshi Takahashi
(Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan, Japan)
- P2-2 Mesenchymal stem cells cultured in serum-free medium suppress murine bleomycin-induced pulmonary fibrosis by enhancing regulatory T cell induction**
Shun Takao
(Department of Molecular and Internal Medicine, Graduate School of Biomedical & Health Sciences, Hiroshima University, Japan)
- P2-3 Isolation and Characterization of Lymphatic Endothelial Cells from Lung Tissues affected by Lymphangioliomyomatosis**
Koichi Nishino
(Division of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Japan)
- P2-4 miR103a-3p in extracellular vesicles from FcεRI-aggregated human mast cells enhances IL-5 production by group 2 innate lymphoid cells**
Shota Toyoshima
(Center for Medical Education, Nihon University School of Medicine, Japan)
- P2-5 TGF-β-induced epithelial-mesenchymal transition and tumor-promoting effects in CMT64 cells are reflected in the transcriptomic signature of human lung adenocarcinoma**
Naoya Miyashita
(Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Japan)
- P2-6 Folliculin Haploinsufficiency Causes Cellular Dysfunction of Pleural Mesothelial Cells**
Shouchi Okamoto
(Division of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Japan)
- P2-7 Alleviation of mouse LPS-induced lung injury by CD26/DPP4 deficiency**
Syun Sato
(Department of Respiratory, Graduate School of Medicine, Chiba University, Japan)

- P2-8 Exosomal micro RNA-146a derived from human lung fibroblasts could modulate cyclooxygenase 2 gene expression.**
Fumihiko Makino
(Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Japan)
- P2-9 Soluble ST2 enhances IL-33-induced neutrophilic airway inflammation: a potential mechanism of neutrophilic asthma**
Masato Watanabe
(Department of Respiratory Medicine, Kyorin University Faculty of Medicine, Japan)
- P2-10 Role of MAP3K19 in allergic airway inflammation of asthma**
Yuuki Sandhu
(Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Japan)
- P2-11 Application of conditional reprogramming culture to analyze Japanese primary ciliary dyskinesia**
Atsushi Kurokawa
(Department of Respiratory Medicine, Tokyo Women's Medical University, Japan)
- P2-12 Drug resistance is associated with upregulation of metabolic enzymes in malignant pleural mesothelioma.**
Yuzo Sato
(Institute for Advanced Biosciences, Keio University, Japan)
- P2-13 Cold-shock proteins are upregulated in asthma patients with cold airway hyperresponsiveness and provoke increase in MUC5AC expression under cooling**
Denis Naumov
(Far Eastern Scientific Center of Physiology and Pathology of Respiration, Russia)
- P2-14 Oxytocin receptor is a promising therapeutic target of malignant mesothelioma**
Ichidai Tanaka
(Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Japan)
- P2-15 An hTERT/Cdk4 -immortalized normal human bronchial epithelial cell line is highly resistant to mutant KRAS-induced senescence**
Nao Muraki
(Division of Host Defense Sciences, Dept. of Integrated Health Sciences, Nagoya University Graduate School of Medicine, Japan)
- P2-16 Inflammatory cytokine derived from inflammasome in tumor-associated macrophages enhances malignant potential of malignant pleural mesothelioma**
Daisuke Horio
(Department of Respiratory Medicine and Hematology, Hyogo College of Medicine, Japan)
- P2-17 Nintedanib inhibits epithelial-mesenchymal transition in A549 alveolar epithelial cells through regulation of the TGF- β /Smad pathway**
Wira Winardi
(Department of Respiratory Medicine, Juntendo University, Graduate School of Medicine, Japan)
- P2-18 Establishment of Acquired Pemetrexed-Resistant MPM Cell Lines and Evaluation of An IGF-1R Inhibitor Picropodophyllin for MPM Treatment**
Rong Sun
(Department of Internal Medicine, Division of Medical Oncology & Respiratory Medicine, Faculty of Medicine, Shimane University, Izumo, Japan, Japan)
- P2-19 The effect of X-ray irradiation and glucocorticoid on the barrier function in rat alveolar epithelial cells**
Naokata Kutsuzawa
(Division of Pulmonary Medicine, Department of Medicine Tokai University School of Medicine, Japan)
- P2-20 Propylene glycol and glycerol, components of e-cigarettes and heated tobacco products, damage epithelial cells in human airways.**
Moegi Komura
(Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Japan)
- P2-21 PI3-kinase delta differentially regulates antiviral interferon-induced expression of programmed death 1 ligand 1 and ligand 2 in human primary bronchial epithelial cells**
Tomohiro Ogawa
(Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Japan)
- P2-22 Imaging changes and immune-checkpoint expression on T cells in bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis**
Yasuaki Kotetsu
(Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Japan)

- P2-23 Hypercapnia accelerates adipogenesis: a novel role of high CO₂ in exacerbating obesity**
Kazutetsu Aoshiba
(Department of Respiratory Medicine, Tokyo Medical University Ibaraki Medical Center, Japan)
- P2-24 Ways to tackle the highly transmissible Delta virus**
Ching Ho Szeto
(Wong Tai Sin Hospital, Hong Kong)
- P2-25 Iron mediates cigarette smoke-induced ACE2 expression in bronchial epithelial cells**
Kenji Mizumura
(Division of Respiratory Medicine, Nihon University School of Medicine, Japan)
- P2-26 Effect of lycopene on lung aging and oxidative stress in senescence-accelerated mouse P1 Strain**
Kengo Koike
(Division of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Japan)
- P2-27 Identification of inhibitors targeting heat shock protein 47 for the development of anti-fibrotic therapeutics**
Daisuke Okuno
(Department of Respiratory Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Japan)
- P2-28 Targeting EMT by suppression of LSD1 in malignant pleural mesothelioma**
Aditya Wirawan
(Department of Respiratory Medicine, Juntendo University, Graduate school of Medicine and Faculty of Medicine, Japan)
- P2-29 Short-term Intermittent Cigarette Smoke Exposure Enhances the Stemness of Alveolar Type 2 Cells through activation of fatty acid oxidation**
Hidehiro Irie
(Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Japan)
- P2-30 Resolvin E3 attenuates profibrotic factor production via its action on macrophages**
Masakiyo Yatomi
(Division of Allergy and Respiratory Medicine, Integrative Center of Internal Medicine, Gunma University Hospital, Japan)
- P2-31 Expression of programmed death ligand 1 (PD-L1) in thymoma**
Avisseena Dutha Pratama
(Division of Pulmonology and Critical Disease, Department of Internal Medicine, Faculty of Medicine Diponegoro University-Dr. Kariadi Hospital, Semarang, Indonesia, Indonesia)
- P2-32 Oral bacterial neuraminidase enhances influenza virus infections**
Noriaki Kamio
(Department of Microbiology, Nihon University School of Dentistry, Japan)
- P2-33 Blocking MMP-12-modulated epithelial-mesenchymal transition by repurposing penfluridol restrains lung adenocarcinoma metastasis via uPA/uPAR/TGF- β /Akt pathway**
Wen-Yueh Hung
(Taipei Medical University, Taiwan)
- P2-34 Differential Gene Expression in Airway Epithelial Cells after Preterm Birth**
Denby Evans
(Telethon Kids Institute; Curtin University; Wal-yan Respiratory Research Centre, Australia)
- P2-35 Identification of prognostic and therapeutic biomarker of tumor immune-micro-environment infiltrating lymphocytes INOF malignant pleural mesothelioma: A spatial analysis in Asian population**
Yuting Yin
(Tokyo Medical Dental University, Japan)
- P2-36 Activation of G protein-coupled estrogen receptor (GPER) regulates ILC2.**
Masamichi Itoga
(Hirosaki University Graduate School of Medicine, Japan)
- P2-37 The mechanism of cigarette smoke-induced mitochondrial DNA release in pulmonary epithelial cell**
Kenji Mizumura
(Division of Respiratory Medicine, Nihon University School of Medicine, Japan)
- P2-38 Examination of microRNAs in serum exosomes in interstitial pneumonia**
Motoko Sunakawa
(Department of Respiratory Medicine, Toho University Omori Medical Center, Japan)
- P2-39 Assessment of inter-lobe biological diversity in the lung by DNA methylation profiles in autopsy cases**
Hioaki Harada
(NHO Higashihiroshima Medical Center, Japan)

- P2-40 Expression of the SARS-CoV-2 Receptor ACE2 and Proinflammatory Cytokines Induced by the Periodontopathic Bacterium *Fusobacterium nucleatum* in Human Respiratory Epithelial Cells**
Sho Yokoe
(Department of Periodontology, Nihon University School of Dentistry, Japan)
- P2-41 *Porphyromonas gingivalis* gingipains potentially affects MUC5AC gene expression and protein levels in respiratory epithelial cells**
Noriyoshi Watanabe
(Department of Periodontology, Nihon University School of Dentistry, Japan)
- P2-42 Effects of protease-activated receptor antagonist on steroid insensitive airway inflammation induced by LPS in mice**
Genki Kimura
(Nihon University School of Pharmacy, Japan)
- P2-43 Effect of oxidative stress on the production of dsDNA-induced interferon in airway epithelial cells**
Akira Koarai
(Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Japan)
- P2-44 Exposure to *Porphyromonas gingivalis* Induces Production of Proinflammatory Cytokine via TLR2 from Human Respiratory Epithelial Cells**
Yuwa Takahashi
(Department of Complete Denture Prosthodontic, Nihon University School of Dentistry, Japan)
- P2-45 *Porphyromonas gingivalis* enhances pneumococcal adhesion to human alveolar epithelial cells by increasing expression of host platelet-activating factor receptor**
Kenichi Imai
(Department of Microbiology, Nihon University School of Dentistry, Japan)
- P2-46 Effect of high fat diet on the severity and repair of lung fibrosis in mice**
Ahmed E Hegab
(Keio University and International University of Health and Welfare, Japan)
- P2-47 Double stranded RNA induces vulnerability of airway epithelial barrier integrity by influencing airway basal cells.**
Shinichi Okamoto
(Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Japan)
- P2-48 Correlation between MGAT4a and MGAT5 expression and poorer outcome in advanced lung adenocarcinoma**
Yoko Nakanishi
(Division of Oncologic Pathology, Nihon University School of Medicine, Japan)
- P2-49 The Japanese herbal medicine Hochuekkito (TJ-41) reduces lung inflammation in COPD exacerbation mouse model.**
Masaaki Yuki
(Department of Respiratory Medicine, the University of Tokyo Hospital, Japan)
- P2-50 TLR3 signaling induces IFITM1 expression via IFN- β and ISG56 in cultured BEAS-2B bronchial epithelial cells.**
Masaki Dobashi
(Department of Respiratory Medicine, Hirosaki University, Japan)
- P2-51 Action of Panton-Valentine leukocidin on rabbit alveolar macrophages**
Shinya Harada
(Kitasato University Graduate School of Medical Sciences, Japan)
- P2-52 *Rosa roxburghii* triterpenoid compounds with anti-lung cancer potential**
Jiaying LUO
(State Key Laboratory of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, China (Mainland))
- P2-53 Quercetin attenuated the inflammatory response in LPS-induced ALI mouse model**
Shiho Kono
(Department of Respiratory Medicine, Graduate School of Medicine, the University of Tokyo, Japan)
- P2-54 Lack of TRPA1-mediated effect in cigarette smoke-induced inhibition of phagocytosis**
Denis Naumov
(Far Eastern Scientific Center of Physiology and Pathology of Respiration, Russia)
- P2-55 Cigarette smoke reduces CXCL10 production by macrophages via TRPA1-dependent mechanism**
Denis Naumov
(Far Eastern Scientific Center of Physiology and Pathology of Respiration, Russia)
- P2-56 Metal-dependent oxidative alveolar type II cell injury by fine indoor PM**
Yasuo Takano
(Kochi Professional University of Rehabilitation, Japan)

P2-57 The periodontopathic bacterium *Fusobacterium nucleatum* induced proinflammatory cytokine production by human respiratory epithelial cell lines and in the lower respiratory organs in mice

Yukihiro Karahashi

(Department of Periodontology, Nihon University School of Dentistry, Japan)

P2-58 Effects of food nutritional components on lung cancer cell lines

Sakiko Toyoshima

(Department of Food Science and Nutrition, Faculty of Home Economics, Kyoritsu Women's University, Japan)

Poster Session 3

On-demand

P3 Clinical Allergy and Immunology

P3-1 Differential model of the deep convolutional neural network between sarcoidosis and lymphoma in 18F-FDG-PET/CT

Hikaru Aoki

(Department of Respiratory Medicine, Tokyo Medical and Dental University, Japan)

P3-2 Impact of air pollutant of polycyclic aromatic hydrocarbons (PAHs) on the yearly decline of pulmonary function in asthmatics sensitized to house dust mite (HDM)

Cheng-Yi Chang

(Department of Respiratory Therapy, Chang Gung Memorial Hospital, Linkuo, Taiwan; Institute of Medical Science, National Defense Medical Center, Taipei, Taiwan, Taiwan)

P3-3 Tiotropium bromide attenuates ILC2-derived type-2 cytokine production by suppressing IL-4 production from basophils

Takahiro Matsuyama

(Department of Pulmonary Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Japan)

P3-4 The TL1A/DR3 axis in the presence of TSLP induces steroid resistance of ILC2

Kentaro Machida

(Kagoshima University, Japan)

P3-5 Serum periostin levels and periostin immunostaining were useful in the evaluation of eosinophilic granulomatosis with polyangiitis patients

Jun Ito

(Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Japan)

P3-6 A clinical analysis of PAP (Pulmonary Alveolar Proteinosis) s diagnosed with difficulty in the Covid-19 pandemic

Ichiro Tsujino

(Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Japan)

P3-7 Mepolizumab may not induce long term remission in patients with eosinophilic granulomatosis with polyangiitis with high relapse rates

Naomi Tsurikisawa

(Department of Allergy, Hiratsuka City Hospital, Japan, Department of Pulmonology, Yokohama City University Graduate School of Medicine, Japan)

P3-8 Clinical application of serum and sputum YKL-40 in Asthma, ACO and COPD

Yasuhito Suzuki

(Department of Pulmonary Medicine, Fukushima Medical University School of Medicine, Japan)

P3-9 Allergy in IgG4-related disease

Shoko Matsui

(University of Toyama, Japan)

P3-10 Metabolism profiling of allergic rhinitis in children and adult

Wenjun YE

(State Key Laboratory of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, China (Mainland))

P3-11 A novel mechanism for TWEAK induces the production of TSLP, RANTES, MIP-1 α and TARC in BEAS-2B human bronchial epithelial cells during epithelial-mesenchymal transition.

Kei Matsuno

(Department of Respiratory Medicine, Juntendo University School of Medicine, Tokyo, Japan, Japan)

P3-12 A case of unilateral eosinophilic pneumonia associated with primary biliary cholangitis (PBC)

Ryosuke Ozoe

(Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Japan)

- P3-13 IL-17A acutely modulates airway smooth muscle contractility by PKC-alpha-mediated RhoA activation**
Makoto Kudo
(Yokohama City Univ. Medical center Respiratory disease center, Japan)
- P3-14 Changing anti-nuclear antibody profile in a patient with eosinophilic granulomatosis with polyangiitis: a case report**
Yutaka Kozu
(Nihon University School of Medicine, Department of Internal Medicine, Division of Respiratory Medicine, Japan)
- P3-15 Oral mite anaphylaxis after ingestion of Korean pancake**
TAKAO TSUJI
(Department of Respiratory Medicine, Institute of Geriatrics, Tokyo Women's Medical University, Japan)
- P3-16 Effects of eosinophils on patients with allergic rhinitis**
Hui-an Chen
(Guangzhou Medical University, China (Mainland))
- P3-17 Cases of bronchial asthma with eosinophil sinusitis and atopic dermatitis for which dupilumab was effective**
Norihiko Hata
(Kawaguchi Municipal Medical Center, Japan)
- P3-18 IL-17A with TNF- α synergistically enhances mouse airway smooth muscle contraction**
Makoto Kudo
(Yokohama City Univ. Medical center Respiratory disease center, Japan)
- P4-3 What are the factors contributing to decreased physical activity in outpatients with respiratory diseases?**
Keita Takagawa
(Jobu Hospital for Respiratory Diseases, Japan)
- P4-4 Role of the thiol-disulphide system in the protection of alveolar macrophages against exposure to suspended particle matter of the atmospheric surface layer**
Tatyana Vitkina
(Vladivostok Branch of Far Eastern Scientific Centre of Physiology and Pathology of Respiration, Institute of Medical Climatology and Rehabilitative Treatment, Russia)
- P4-6 Pleural fluid cytokeratin 19 fragment and other factors well predict diffuse pleural thickening among patients with benign asbestos pleural effusions**
Satoko Kozawa
(Yokohama Rosai Hospital, Japan)
- P4-7 Associations between long-term exposure to PM10 and NO2 and serum metabolite concentration in CODA cohort**
Hea Young Shin
(Department of Internal Medicine, Kangwon National University, Korea)
- P4-8 Toxicity of two different biodiesel exhausts in primary human airway epithelial cells grown at air-liquid interface.**
Katherine Landwehr
(Telethon Kids Institute/Curtin University, Australia)
- P4-10 Burnout among Healthcare Workers during COVID-19 Pandemic in Aceh, Indonesia**
Ferry Dwi Kurniawan
(Department of Pulmonology, dr. Zainoel Abidin Hospital, Universitas Syiah Kuala, Indonesia)

Poster Session 4

On-demand

P4 Environmental and Occupational Health and Epidemiology

- P4-2 Mite allergen avoidance decreases allergic symptoms in children in Ishinomaki city after natural disasters**
Chiyako Oshikata
(Department of Allergy and Respiriology, Hiratsuka City Hospital & Department of Pulmonology, Yokohama City University Graduate School of Medicine, Japan)
- P4-11 Results of questionnaire survey on the use of new type tobacco (heated or electronic cigarettes) in households with minors**
Naoto Watanabe
(Seirei Yokohama Hospital, Japan)
- P4-12 Dynamics and regional gradients of respiratory diseases on the territory of the Far Eastern Federal District of Russia**
Victor P. Kolosov
(Far Eastern Scientific Center of Physiology and Pathology of Respiration, Russia)

- P4-13 Assessment of the impact of atmospheric air microsuspensions on the respiratory function of patients with chronic obstructive pulmonary disease**
Tatyana Vitkina
(Vladivostok Branch of Federal State Budgetary Science Institution "Far Eastern Scientific Center of Physiology and Pathology of Respiration"—Institute of Medical Climatology and Rehabilitative Treatment, Russia)
- P4-14 Hydrofluorocarbons pneumonitis as a complication of inhalation injury following air-conditioning repairs**
Afifah Aqilah Abdul Malik
(Respiratory Unit, Hospital Canselor Tuanku Muhriz, Malaysia)
- P4-15 A clinical research of heated tobacco products users in our smoking cessation clinic.**
Hitomi Yoshikawa
(Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Japan)
- P4-16 Swallowing dysfunction in patients with chronic respiratory disease**
Ayumu Akiyama
(School of Rehabilitation Sciences, Seirei Christopher University, Japan)
- P4-17 Don't Bring Home that Bacon: A Report of Two Simultaneous Cases of Streptococcus suis meningitis**
Gwen Marcellana
(Department of Medicine, St. Luke's Medical Center Global City, Philippines)
- P4-18 Comparative analysis of the incidence of respiratory diseases among urban and rural population**
Victor P. Kolosov
(Far Eastern Scientific Center of Physiology and Pathology of Respiration, Russia)
- P4-19 Comparison of expiratory carbon monoxide level in white and clove cigarette among college students smokers**
Karel Sumarsudi
(Faculty of Medicine, Universitas Indonesia, Indonesia)
- P4-20 Correlation between smoking behavior and level of nicotine dependence in actively smoking college students**
Dio Alief Supriyanto
(Faculty of Medicine, Universitas Indonesia, Indonesia)
- P4-21 Fitness Level Studies using 6-Minute Walking Test Method and its Relationship to the Type of Work on Non Staff Employees of Universitas Indonesia Depok**
Kemal Akbar Suryoadji
(Faculty of Medicine, Universitas Indonesia, Indonesia)
- P4-22 The effect and safety of ultraviolet germicidal irradiation on reusing N95 filtering facepiece respirators at weekly intervals**
Keitaro Nakamoto
(Department of Respiratory Medicine, Kyorin University School of Medicine, Japan)
- P4-23 A case report of bronchial anthracofibrosis - A Sri Lankan experience**
Niranjan Chandramal
(National hospital of Sri Lanka, Sri Lanka)
- P4-24 Respiratory symptoms and lung function among active smokers in Indonesian college students**
Nathaniel Jason Zacharia
(Faculty of Medicine, Universitas Indonesia, Indonesia)
- P4-25 The dynamics of the quality of life of healthy people amid the COVID-19 pandemic when soy and pumpkin products are included in the diet**
Natalia L. Perelman
(Far Eastern Scientific Center of Physiology and Pathology of Respiration, Russia)
- P4-27 Correlation between Smoking Habit and Factors that Determines Smoking Habit in Male College Students in Depok**
Irfan Tadjoeidin
(Faculty of Medicine, Universitas Indonesia, Indonesia)
- P4-28 CASE SERIES : HIGH FLOW NASAL CAN- NULA IN CARBON MONOXIDE INTOXICATION**
Irvan Medison
(Faculty of Medicine, Universitas Andalas, Indonesia)
- P4-29 Associaton between Physical Activity and Physical Fitness of the Janitors in the Universitas Indonesia, Depok**
Sakinasha Siva Utami
(Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, Indonesia)

P4-30 The Relationship of Nutritional Status of Non-Staff UI Depok Employees with Fitness Level Using the 6 Minute walking Test Method

Neny Zain
(Faculty of Medicine, Universitas Indonesia, Indonesia)

P5-8 Risk Factors for Mortality of COVID-19 Confirmed Cases Admitted at Lung Center of the Philippines

Genevie Ombao
(Philippine College of Chest Physicians, Philippines)

Poster Session 5

On-demand

P5 Respiratory Infections (non-tuberculous)

P5-1 Factors associated with the development of bacterial pneumonia related to seasonal influenza virus infection: A study using a large-scale health insurance claim database.

Masahiro Shirata
(Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Japan)

P5-2 Intrathoracic vacuum-assisted closure therapy for the management of acute lung abscess

Siarhei Yermashkevich
(Vitebsk State Order of Peoples' Friendship Medical University, Belarus)

P5-3 Efficacy and safety of first-line therapy for pulmonary nocardiosis; trimethoprim/sulfamethoxazole versus alternative antibiotics

Shohei Hamada
(Kumamoto University Hospital, Japan)

P5-5 Impaired functional activities related to prolonged hospitalization among the patients of community acquired pneumonia

Yu-Cheng Wu
(Taichung Veterans General Hospital, Taiwan)

P5-6 A convenient risk prediction score for COVID-19 in determining whether hospitalization should be recommended: Kanagawa admission priority assessment score (KAPAS).

Nobumasa Tamura
(Atsugi City Hospital, Japan)

P5-7 Phagocytotic analysis of alveolar macrophage phenotypes in patients with Mycobacterium avium complex lung disease

Hiroaki Ikegami
(Department of Respiratory Medicine, University of Occupational and Environmental Health, Japan, Japan)

P5-9 Microbiologic pattern and clinical outcome of hospital acquired pneumonia in a general ward: Korean HAP registry analysis

Jin Ho Jang
(Division of Allergy, Pulmonary and Critical care medicine, Department of Internal Medicine, Pusan National University Yangsan Hospital, Korea)

P5-10 The influence of rifampicin dosage in radiological outcomes of Mycobacterium kansasii lung disease

Takehiko Kobayashi
(Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, Japan)

P5-11 Vaccine-induced immune thrombotic thrombocytopenia (VITT) after ChAdOx1 nCoV-19 vaccination

Yen Shen Wong
(Faculty of Medicine, Universiti Teknologi MARA (UiTM), Sungai Buloh, Selangor, Malaysia, Malaysia)

P5-12 Clinical characteristics distinguish between acute cardiogenic pulmonary edema and community-associated pneumonia in the elderly patients

Genki Inui
(Department of Respiratory Medicine, National Hospital Organization Yonago Medical Centre, Japan)

P5-13 COVID-19 Mobile Test Unit (COMBAT): a novel pharyngeal sampling platform for COVID-19 testing in Malaysia

Aisya Natasya Musa
(Faculty of Medicine, Universiti Teknologi MARA, Malaysia)

P5-14 An age-matched comparison between COVID-19 pneumonia and pneumococcal pneumonia cases.

Kensuke Nishioka
(Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Japan)

P5-15 A case of recurred exacerbations and remissions of COVID-19 pneumonia in a patient with B-cell lymphoma undergoing chemotherapy

Hisanori Hirokawa
(Dokkyo Medical University, Saitama Medical Center, Japan)

- P5-16 Lung transplantation cases with nontuberculous mycobacteriosis**
Masaki Fujita
(Fukuoka University Hospital, Japan)
- P5-17 The First and Second Wave of COVID 19 In Rural India: A Comparison of Inflammatory Markers with Severity of Pneumonia**
Aniket Inamdar
(Samarpan Clinic, India)
- P5-18 Risk factors associated with methicillin-resistant *Staphylococcus aureus* pneumonia among adult patients at St. Luke's Medical Center, Philippines**
Carina Benitez
(St. Luke's Medical Center, Philippines)
- P5-19 Spontaneous Pneumothorax in Indonesian COVID-19 Patients: A Retrospective Case Series**
Maia Thalia Giani
(Pertamina Jaya Hospital, Indonesia)
- P5-20 The prevalence of comorbid respiratory disease among COVID-19 patients, and mortality during the first wave in Japan: A nationwide survey by the Japanese Respiratory Society.**
Hiroyuki Nagase
(Teikyo University School of Medicine, Japan)
- P5-21 Serum Ferritin levels : A Cost-Effective Marker for Severity of Pneumonia in Patients with COVID 19**
Aniket Inamdar
(Samarpan Clinic, India)
- P5-22 Epidemiology and outcomes of non-tuberculous mycobacterial pulmonary disease in Auckland, New Zealand**
Charlotte Chen
(University of Auckland, New Zealand)
- P5-23 Neurological complications of patients with COVID-19**
Paul Borodin
(Amur State Medical Academy, Russia)
- P5-24 Severity and clinical outcome of SARS-CoV-2 infected patients following CoVID vaccination - an observational study in Bangladesh**
Nirmal Kanti Sarkar
(Mugda Medical College, Bangladesh)
- P5-25 Spontaneous development of Pneumocystis pneumonia in mice lacking death ligand-induced apoptosis and necroptosis**
Shion Miyoshi
(Department of Respiratory medicine, Toho University School of Medicine, Japan)
- P5-26 Validity of PIRO-score as an assessment tool for mortality risk of COVID-19 Pneumonia in World Citi Medical Center. A Retrospective Observational Cohort Study**
Graciano III Natividad
(World Citi Medical Center, Philippines)
- P5-27 Evaluation of serum interferon lambda 3 in hospitalized COVID-19 patients as a biomarker to predict the severity**
Taichi Kaneko
(Department of Respiratory Medicine, Chigasaki Municipal Hospital, Japan)
- P5-28 CORRELATION OF SERUM INTERLEUKIN-6 LEVEL AND COVID-19 SEVERITY ON HOSPITAL ADMISSION AND SURVIVAL**
RUDY SATRIAWAN
(UNIVERSITAS INDONESIA, Indonesia)
- P5-29 Fungal hydro-pneumothoraces! A series of patients presenting with hydro-pneumothoraces secondary to invasive fungal infection and a review of literature regarding the same.**
Mihir Gangakhedkar
(All India Institute of Medical Sciences Rishikesh, India)
- P5-30 Risk factors for hospitalization in patients with mild SARS-CoV-2 infection (COVID-19) during residential or home care**
Yasuhiro Tanaka
(Department of Respiratory Medicine, Nagasaki University Hospital, Japan)
- P5-31 High prevalence of silent hypoxia among patients with COVID-19 warrants screening for oxyhemoglobin desaturation among patients with fever, cough or dyspnea**
De-En Lu
(Wan Fang Hospital, Taiwan)
- P5-32 Investigation of Exacerbation Factors in Patients with Coronavirus Disease 2019**
Toshiyuki Kita
(National Hospital Organization, Kanazawa Medical Center, The department of respiratory medicine, Japan)
- P5-33 Impacts of the Covid-19 pandemic on hospitalizations for pneumonia in Brazil**
Raissa Lima
(Bahia School of Medicine and Public Health, Brazil)
- P5-34 Long-haul COVID-19 among University of Santo Tomas Hospital-Health Care Workers Following Hospitalization for COVID-19 Pneumonia.**
Vehement Jay Ventic
(UST Hospital, Philippines)

- P5-35 Successful treatment of disseminated nontuberculous infection with Mycobacterium genavense mimicking malignancy in a patient with anti- Interferon-gamma (IFN- γ) autoantibodies**
Haruka Yamamoto
(Takatsuki Redcross hospital, Japan)
- P5-36 Association of C-reactive protein (CRP), serum ferritin, and patient outcome in COVID-19 patients in tertiary referral hospital**
Rantih Intani
(Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Indonesia, Persahabatan Hospital, Indonesia)
- P5-37 Community-acquired respiratory virus cases mimic COVID-19 on lung computed tomography**
Daijiro Nabeya
(University of the Ryukyus, Japan)
- P5-38 Effects of adjunctive corticosteroids on Pneumocystis pneumonia in non-HIV-infected patients at five facilities in Nagano Prefecture**
Jumpei Akahane
(First Department of Internal Medicine, Shinshu University School of Medicine, Japan)
- P5-39 Impact of chronic co-infection in pulmonary Mycobacterium avium complex disease after commencing treatment.**
Naohisa Urabe
(Department of Respiratory Medicine, Toho University Omori Medical Center, Japan)
- P5-40 An autopsy case of Covid-19 with disseminated mucormycosis**
Yoko Toyama
(Department of Respiratory Medicine, Fujita Health University School of Medicine, Japan)
- P5-41 Rapid and simultaneous identification of multiple mutations by the Novaplex™ SARS-CoV-2 Variants Assay kits**
Takeshi Kinjo
(University of the Ryukyus, Japan)
- P5-42 Assessment of outcome and risk categorization of COVID-19 exposed healthcare workers using a risk assessment tool in a Tertiary care Hospital, Sri Lanka**
Neranzan Dissanayake
(Consultant Respiratory Physician, Teaching Hospital Ratnapura, Sri Lanka, Sri Lanka)
- P5-43 A case of hyperpyrexia of hypothalamic origin associated with severe COVID-19 pneumonia in pregnancy**
Madushanka Rathnayake
(Senior Registrar in Respiratory Medicine, Sri Lanka)
- P5-44 Pulmonary nontuberculous mycobacterial infection in patients with rheumatoid arthritis on biological therapy**
Yurika Ishii
(Department of Respiratory Medicine, Nagoya Medical Center, Nagoya, Japan, Japan)
- P5-45 Osteoporosis in nontuberculous mycobacterial pulmonary disease**
Hiromu Tanaka
(Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Japan)
- P5-46 Myocardial injury association with severity of disease in hospitalized COVID-19 patients**
Mega Juliana
(Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Indonesia, Persahabatan Hospital, Jakarta, Indonesia, Indonesia)
- P5-47 Safety and Efficacy of Remdesivir, Baricitinib and High-dose Steroid Combination Therapy in Patients Hospitalized with COVID-19**
Takashi Niwa
(Kanagawa Cardiovascular and Respiratory Center, Japan)
- P5-48 Short versus long antibiotic course for pleural infection management: a randomised trial**
Maged Hassan
(Chest Diseases Department, Alexandria University, Egypt)
- P5-50 Withdrawn**
- P5-51 Organizing Pneumonia Post COVID-19: Outcomes of Treatment with Corticosteroids in the Outpatient Setting**
Alejandra Yu Lee-Mateus
(Department of Pulmonary, Allergy, and Sleep Medicine, Mayo Clinic Florida, United States of America)
- P5-52 Evaluation of the Luminex xTAG Respiratory Viral Panel FAST v2 assay for rapid diagnosis of respiratory viral infections**
Li-Min Xie
(The Third Affiliated Hospital of Guangzhou Medical University, China (Mainland))

- P5-53 Early initiation of steroid therapy is a risk factor of treatment failure in patients with COVID-19**
Toshiyuki Yonezawa
(Department of Internal Medicine, Aichi Prefectural Hospital, Japan)
- P5-54 Guillain-Barre Syndrome-Acute Motor Axonal Neuropathy as Neurologic Sequela in a COVID-19 Critically-Ill Patient: A Case Report**
Catherine Jordan
(St. Luke's Medical Center, Philippines)
- P5-55 What kind of disease has developed in a teenager against the background of a new coronavirus infection? Is it Kawasaki's or Reye's syndrome?**
Victoria Shamraeva
(Amur State Medical Academy, Russia)
- P5-56 Predictive model for the development of critical coronavirus disease 2019 in Japan**
Yutaka Muto
(Department of Respiratory Medicine, Japanese Red Cross Medical Center, Japan)
- P5-57 Comparison of chest HRCT findings between COVID-19 pneumonia and anti-MDA5 antibody-positive interstitial pneumonia by computer-based quantitative CT image analysis.**
Nobuyoshi Hamao
(Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan., Japan)
- P5-58 Efficacy of concurrent administration of tocilizumab with corticosteroids for patients with COVID-19**
Takaya Kawamata
(Fukushima Medical University, Japan)
- P5-59 Comparative analysis of the course of post-covid-19 syndrome in individuals of different age groups**
Tatiana Luchnikova
(Amur State Medical Academy, Russia)
- P5-60 Clinical and radiological features of COVID-19 in pregnant women: a case-control study**
Wakako Arakaki
(University of the Ryukyus, Japan)
- P5-61 Online team-based learning: A novel pedagogical approach for undergraduate MBBS students**
Saswati Das
(Ram Manohar Lohia Hospital, India)
- P5-62 Evaluation of lung cell populations in severe COVID-19 pneumonia**
Shuichi Abe
(Yamagata Prefectural Central Hospital, Japan)
- P5-63 Effect of Hyperbaric Oxygen Therapy among COVID19 patients: A Meta-Analysis**
Martin Kristoffer Ogbac
(Perpetual Help Medical Center - Las Piñas, Philippines)
- P5-64 Therapeutic Effectiveness & Safety of Favipiravir in COVID-19 patients with Risk Factors for Mortality: Clinical practice experience from India.**
Sagar Bhagat
(Global Medical Affairs, Glenmark pharmaceuticals Ltd, India)
- P5-65 Association between clinical, microbiologic profile, and outcomes of patients with Ventilator Associated Pneumonia admitted in the Critical Care Unit in San Juan de Dios Hospital**
Donnah Alvarado
(San Juan de Dios Hospital, Philippines)
- P5-67 Predictors of mortality in severe COVID-19 pneumonia: An interim analysis from a single tertiary care centre in Central Sri Lanka.**
Duminda Yasaratne
(Faculty of Medicine, University of Peradeniya, Sri Lanka)
- P5-68 The use of an institutionalized respiratory protocol as a decision-making tool improved outcomes among severe and critically-ill COVID-19 patients in Perpetual Succour Hospital**
Kris Ray Dumaguin
(Perpetual Succour Hospital - Cebu Lung Institute, Philippines)
- P5-69 Patterns of chronic pulmonary aspergillosis in Sri Lanka**
Harshana Bandara
(Senior Registrar in Respiratory Medicine, National Hospital for Respiratory Diseases, Sri Lanka)
- P5-70 Effectiveness of Favipiravir in COVID-19 patients with multiple (≥ 2) or less (< 2) comorbidities: A real word experience from India**
Sagar Bhagat
(Global Medical Affairs, Glenmark pharmaceuticals Ltd, India)

- P5-71 Rapidly Progressive Honeycombing in a Spontaneously Breathing Patient with COVID-19 Pneumonia**
Nai-Chien Huan
(Respiratory Department, Sultanah Aminah Hospital, Malaysia)
- P5-72 Lipid involvements on inflammatory changes and clinical outcomes in patients with COVID-19**
Satoshi Inoue
(Yamato Municipal Hospital, Pulmonary Medicine, Japan)
- P5-73 Clinical characteristics of pulmonary melioidosis diagnosed at respiratory department of the tertiary hospital in Southern Vietnam**
Lam Nguyen-Ho
(University Medical Center Ho Chi Minh City, Viet Nam)
- P5-74 Serial changes in clinical characteristics of COVID-19 infected patients**
Yui Shimanuki
(Division of Respiratory Medicine, Toho University Omori Medical Center, Ota-ku, Tokyo, Japan)
- P5-75 Risk factors for pneumonia in nursing home residents**
Yuichi Ohteru
(Hofu Rehabilitation Hospital, Japan)
- P5-76 Prolonged viral clearance in COVID-19 patients treated with tocilizumab**
Wataru Segawa
(Respiratory Disease Center, Yokohama City University Medical Center, Japan)
- P5-77 Prognostic factors associated with death and progressiveness of COVID-19 disease at Sanglah Hospital, Denpasar**
Ni Luh Putu Eka Arisanti
(DEPARTEMEN PULMONOLOGI DAN KEDOKTERAN RESPIRASI FK UNUD/RSUP SANGLAH, Indonesia)
- P5-78 Pulmonary nocardiosis with osteolytic lesions mimicking lung cancer**
Kumiko Yamatsuta
(Fujita Health University, Japan)
- P5-79 Clinical Comparison of the First Wave and the Later Waves in COVID-19 Patients with Pneumonia**
Yasuyuki Hayashi
(Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Japan)
- P5-80 A case report of pneumothorax associated with COVID-19 pneumoniae.**
Tomonori Uruma
(Tokyo medical university hachioji medical center, Japan)
- P5-81 Correlation of Serum Ferritin Level with Disease Severity of COVID-19 at Arifin Achmad General Hospital Riau Province**
Ananda Febriani Aulia
(Department of Pulmonology and Respiratory Medicine, Faculty of Medicine Riau University- Arifin Achmad General Hospital Riau Province, Indonesia)
- P5-82 The Correlation of Cycle Threshold Value with Severity of COVID-19 at The Isolation of New Emerging and Re-Emerging Infectious Diseases Room Arifin Achmad General Hospital Riau Province Indonesia**
Tantrie Desty Lianawati
(Department of Pulmonology and Respiratory Medicine, Faculty of Medicine Universitas Riau / Arifin Achmad General Hospital, Riau Province Indonesia, Indonesia)
- P5-83 The Correlation between Cycle Threshold Polymerase Chain Reaction Covid-19 with the Extent of Chest X-Ray Abnormalities and D-dimer in Covid-19 Patients at Arifin Achmad General Hospital Riau Province.**
Roni Ardian
(Department of Pulmonology and Respiratory Medicine Arifin Achmad General Hospital Riau Province Indonesia, Indonesia)
- P5-84 A case of organizing pneumonia caused by sclerosing agent used in endoscopic injection sclerotherapy.**
Takuya OHASHI
(Department of Thoracic and Cardiovascular Surgery, Wakayama Medical University, Japan)
- P5-85 Staged treatment of middle lobe lung gangrene using the vacuum-assisted closure therapy in a patient with severe COVID-19 pneumonia**
Siarhei Yermashkevich
(Vitebsk State Order of Peoples' Friendship Medical University, Belarus)
- P5-86 The effect of N-acetylcysteine inhalation on tumor necrosis factor- α and cough severity score in community acquired pneumonia**
Dhani Rahmanto
(Undergraduated student, Department of Pulmonology and Respiratory Medicine, Medical Faculty of Sebelas Maret University/ Dr. Moewardi General Hospital Surakarta, Indonesia)

- P5-87 Time course of oxygen demand in patients with COVID-19 pneumonia**
Tsuneyuki Oda
(Kanagawa Cardiovascular and Respiratory Center, Japan)
- P5-88 Study of C Reactive Protein (hs-CRP) in post COVID-19 geriatric patients**
Saswati Das
(Ram Manohar Lohia Hospital, India)
- P5-89 Effectiveness of a questionnaire to screen Covid-19**
Sakuo Hoshi
(Infection Control Team, Koto Hospital, Japan)
- P5-90 Association of persistent and delayed symptoms with pneumonia in COVID-19**
Takeshi Oshio
(Respiratory Medicine, Toho University Ohashi Medical Center, Tokyo, Japan, Japan)
- P5-91 Clinical characteristics and mortality risk in patients with severe COVID-19**
Masamichi Mineshita
(Internal Medicine, Division of Respiratory Medicine, St. Marianna University School of Medicine, Japan)
- P5-92 Respiratory viruses during COVID-19 pandemic in Okinawa, Japan**
Wakaki Kami
(Department of Infectious, Respiratory, and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus, Japan)
- P5-93 Therapeutic effectiveness and tolerability of Favipiravir in Mild Covid-19: Real World experience from India**
Sagar Bhagat
(Global Medical Affairs, Glenmark pharmaceuticals Ltd, India)
- P5-94 The usefulness of a combination of age, body mass index, and blood urea nitrogen as prognostic factors in predicting oxygen requirements in patients with coronavirus disease 2019**
Yosuke Wada
(First Department of Internal Medicine, Shinshu University School of Medicine, Japan)
- P5-95 Complete heart block and neutropenia due to SARS - Corona virus-2 in a patient with Chronic lymphocytic leukemia - Misery of an elderly gentleman**
Sugeesha Wickramasinghe
(Senior Clinical Fellow in Respiratory Medicine, Chorley and South Ribble Hospital, United Kingdom, United Kingdom)
- P5-96 Giant lung abscess following tooth extraction in an immunocompetent patient**
Hiroki Tashiro
(Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University Hospital, Saga, Japan, Japan)
- P5-97 High-dose methylprednisolone in combination with Tocilizumab in Hospitalized Patients with critical Covid-19 Pneumonia: a case series**
Yasuki Uchida
(Shiga University of Medical Science, Japan)
- P5-98 Vitamin D deficiency as a marker of severe COVID-19 course**
Tatiana Luchnikova
(Amur State Medical Academy, Russia)
- P5-99 The successful of intrapleural alteplase and pulmozyme in treating Rhodococcus empyema in an immunocompromised patient.**
Mas Fazlin Mohamad Jailaini
(Universiti Kebangsaan Malaysia Medical Centre, Malaysia)
- P5-100 A rare case of endobronchial actinomycosis responding to short course of antibiotics**
Nik Nuratiqah Nik Abeed
(Respiratory Unit, Department of Internal Medicine, Pusat Perubatan Universiti Kebangsaan Malaysia, Malaysia)
- P5-101 A case report of COVID-19 in an adult Filipino with HIV-associated Histoplasmosis**
Aldrin John Almario
(Lung Center of the Philippines, Philippines)
- P5-102 Chronic pulmonary melioidosis in a 9 year old child**
Sokchinda Kong
(Angkor Hospital for Children, Cambodia)
- P5-103 Post COVID Cavitory Lung Lesions: Individualised Approach**
Vishnu Gireesh
(CONSULTANT PULMONOLOGIST, RUBY HALL CLINIC, India)
- P5-104 Reinfection of COVID-19 Critical Condition in Miliary Tuberculosis Case with Multiple Comorbidities**
Mohamad Isa
(Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Lambung Mangkurat, Banjarmasin, Indonesia/Ulin Hospital, Banjarmasin, Indonesia, Indonesia)

- P5-105 RELATIONSHIP OF TOTAL THROMBOCYTE, LYMPHOCYTE ACCOUNT AND PLR (PLATELET LYMPHOCYTE RATIO) TO SEVERITY DEGREE OF COVID-19 PATIENTS IN WARD**
Indah Puji Lestari
(Brawijaya university, Indonesia)
- P5-106 Japanese, multicenter, phase II trial of combination therapy with favipiravir and methylprednisolone for COVID-19 patients with non-critical respiratory failure: The J-CRITICAL trial**
Yuichiro Shindo
(Nagoya University Graduate School of Medicine, Japan)
- P5-107 Disseminated non-tuberculous mycobacterium in an anti-IFN-gamma antibody positive patient**
Akinari Noda
(Kyorin univ., Japan)
- P5-108 The association between awake prone positioning and mortality in COVID-19 patients**
Tomoki Tanaka
(Rakuwakai Otowa Hospital, Department of Respiratory Medicine, Japan)
- P5-109 A fatal case of multiple mycotic pulmonary artery aneurysms due to Aspergillus Terreus in a post COVID-19 patient.**
Anez Aslan
(KKM, Malaysia)
- P5-110 Safety and efficacy confirmation study of PanbioTMCOVID19AgRapidTestDevice KIT operation by specimen self-collection**
Shu Hashimoto
(Hibiya Kokusai Clinic and Nihon University, Japan)
- P5-111 SARS-CoV-2 PCR and antigen positivity continued for 3 months after treatment for severe COVID-19: Case report**
Yutaka Kozu
(Nihon University School of Medicine Department of Internal Medicine Division of Respiratory Medicine, Japan)
- P5-112 The relationship of chest x-ray in COVID-19 patients towards disease severity at Arifin Achmad regional general hospital, Riau Province.**
Aulia Rahman
(Department of Pulmonology and Respiratory Medicine, Faculty of Medicine University of Riau / Arifin Achmad General Hospital, Riau Province Indonesia, Indonesia)
- P5-113 Baseline characteristics, clinical course and outcomes of COVID-19 confirmed healthcare workers in the University of Santo Tomas Hospital**
Maria Elizabeth Santos
(University of Santo Tomas Hospital, Philippines)
- P5-114 A young lady with bones in the lungs -A case of Diffuse Pulmonary Fibro Ossification complicated with fungal Infection**
Sasanka Wijayawardhana
(Senior Registrar in Respiratory Medicine, Sri Lanka)
- P5-115 A Case Report on Invasive Aspergillosis in an Immunocompetent Male**
Jamie Lynn Co
(St. Luke's Medical Center, Philippines, Philippines)
- P5-116 Challenges in diagnosis of melioidosis in a child presented with uncomplicated community acquired pneumonia**
Sokchinda Kong
(Angkor Hospital for Children, Cambodia)
- P5-117 A Case of Bronchiolitis Obliterans Post Influenza A Pneumonia in Adults**
Mohd Faizul Abu Samah
(Penang General Hospital, Malaysia)
- P5-118 Clinical outcomes of diffuse alveolar damage and organising pneumonia in severe COVID-19 infection**
Ka Kiat Chin
(Department of Medicine, Faculty of Medicine, University of Malaya, Malaysia)
- P5-119 Community Acquired Pneumonia secondary to Multidrug Resistant Pseudomonas luteola: A Case Report**
Martin Kristoffer Ogbac
(Perpetual Help Medical Center - Las Piñas, Philippines)
- P5-121 Inhaled beclomethasone in the treatment of early COVID-19: a placebo-controlled, randomized trial**
Channa Ranasinha
(University of Kelaniya, Sri Lanka)
- P5-122 A case of secondary organizing pneumonia caused by relapse of inflammation after COVID-19 treatment with systemic corticosteroid and tocilizumab**
Yasumitsu Ueki
(Shiga University of Medical Science, Japan)

- P5-123 The clinical features and outcomes of discharged SARS-CoV-2 patients: A prospective cohort study**
Daniel Smith
(The Sutherland Hospital, Caringbah NSW 2229, Australia)
- P5-124 Analysis of Chemotherapy History and Absolute Neutrophil Count to Antibodi Antiman-nan in Lung Cancer Patients with Candidiasis**
In Noor Chozin
(Brawijaya University, Indonesia)
- P5-125 Abrupt cessation of systemic corticosteroid in Coronavirus disease 19 (COVID-19) related secondary organizing pneumonia resulted in a rebound.**
Leng Cheng Sia
(Department of Medicine, Faculty of Medicine, University Malaya Medical Centre, Malaysia)
- P5-126 Absolute Lymphocyte Count and Neutrophil Lymphocyte Ratio As Biomarker for Candidiasis in Lung Cancer Patients**
Muhamad Yusuf Musthafa
(Pulmonology Brawijaya University-RSSA Malang, Indonesia)
- P5-127 Clinical characteristics of SARS-CoV-2 infected (COVID-19) patients and mutant viral strains in rural area of Japan**
Masafumi Seki
(Tohoku Medical and Pharmaceutical University, Japan)
- P5-128 Study on Lung abscess: A single Centre experience in National Hospital for Respiratory Diseases Sri Lanka**
Dawpadee Dharmasena
(Welisara, Sri Lanka, Senior Registrar in Respiratory, Sri Lanka)
- P5-129 Community-Acquired Methicillin-Resistant Staphylococcus aureus Pneumonia in a Previously Healthy 12-year-old Male**
Nikki Francheska Tubeo
(Chong Hua Hospital, Philippines)
- P5-130 Scrub Typhus complicated with pneumonitis and myocarditis; potentially a fatal complication**
Chandana Dahanayake
(Teaching Hospital Karapitiya Galle-Srilanka, Sri Lanka)
- P5-131 Melioidosis presenting as hoarseness of voice**
Justin Yu Kuan Tan
(Respiratory Unit, Hospital Sultanah Nur Zahirah, Malaysia)
- P5-132 Rehabilitation interventions and tasks for patients with COVID-19 in our hospital**
Soh Imamura
(Division of Rehabilitation, Tokyo Women's Medical University Yachiyo Medical Center, Japan)
- P5-133 Invasive Pulmonary Aspergillosis mimicking lung malignancy**
Arthihai Srirangan
(NHSL, Sri Lanka)
- P5-134 Persistent cough in a diabetic due to invasive aspergillosis - A case report**
Sugeesha Wickramasinghe
(Senior Registrar in Respiratory Medicine, Central Chest Clinic, Borella, Sri Lanka, Sri Lanka)
- P5-135 D-Dimer as A Predictor Severity and Mortality In Hospitalized COVID-19 Patients at Saiful Anwar General Hospital Malang**
Achmad Syamsufandi Rozi
(Brawijaya University, Indonesia)
- P5-136 The correlation between leucocyte, lymphocyte, thrombocyte, and SOFA score on the severity of COVID-19 patients hospitalized in the Pinere Ward of Saiful Anwar Hospital**
Harman Prayitno
(Universitas Brawijaya, Indonesia)
- P5-137 Corona Virus Disease (COVID 19) in Human Immunodeficiency Virus (HIV) patient**
R Ananda Nuriman
(Faculty of Medicine, Universitas Andalas, Indonesia)
- P5-138 Correlation between Brixia score and RTPCR-SARS-CoV-2 result of pediatric patients with suspected or confirmed Covid-19 infection seen at Chong Hua Hospital, Cebu city from March 2020 to February 2021**
Daphnie Zyra Khan
(Chong Hua Hospital, Philippines)
- P5-139 Melioidosis complicated with pyopneumothorax as a mycobacterium tuberculosis mimic**
Nirasha Jayathilaka
(National Hospital for Respiratory Diseases, Sri Lanka)
- P5-140 Solitary pulmonary cryptococcoma mimicking lung malignancy in an immunocompetent patient**
Boon Hau Ng
(RESPIRATORY UNIT, DEPARTMENT OF MEDICINE, PUSAT PERUBATAN UNIVERSITI KEBANGSAAN MALAYSIA, Malaysia)

- P5-141 Invasive Pulmonary Aspergillosis in a Case of Metastatic Lung Adenocarcinoma: Challenges in diagnosis and treatment**
Angelica Pearl Reyes
(University of Santo Tomas Hospital, Philippines)
- P5-142 A case series on corticosteroid use in COVID-19 patients who suffered from chronic lung disease**
Kosumi Kubo
(Shin-Yurigaoka General Hospital, Japan)
- P5-143 Post-Corona Virus Disease 2019 (COVID-19) Pneumothorax**
Anna Rossa Magda Cuerdo
(Perpetual Help Medical Center - Las Piñas, Philippines)
- P5-144 Infected pneumatoceles complicating the course of COVID-19 pneumonia**
Benjamin Gan
(Selayang Hospital, Ministry of Health, Malaysia)
- P5-145 COVID-19: Performance of oseltamivir and isoprinosine in neutrophil-to-lymphocyte ratio improvement from confirmed COVID-19 patients in Saiful Anwar General Hospital, Malang**
Adelin Kole
(Brawijaya University, Indonesia)
- P5-146 A case of Mycobacterium Szulgai with hypothyroidism and electrolyte abnormalities**
Ryosuke Ozoe
(Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Japan)
- P5-147 Pulmonary cryptococcosis in an immunocompromised patient diagnosed by cryobiopsy**
Haruka Odagiri
(Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine, Japan)
- P5-148 The correlation between RT-PCR and antibody rapid test in SARS CoV-2**
Diah Permata Kinanti
(Pulmonary Disease Study Program Faculty of Medicine Udayana University, Indonesia)
- P5-149 Investigation of antibody level by the presence or absence of side effects after the new coronavirus vaccine**
Hiromi Nagashima
(Division of Pulmonary Medicine, Department of Internal Medicine, Iwate Medical University, Japan)
- P5-150 COVID-19 patients with a late diagnosis of HIV**
Desdiani Desdiani
(Faculty of Medicine, Universitas Sultan Ageng Tirtayasa, Serang, Banten, Indonesia, Indonesia)
- P5-151 Changes over time in six-minute walk test and the SGRQ scores in patients with nontuberculous mycobacterial pulmonary disease.**
Atsuhiko Morita
(Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan, Japan)
- P5-152 Familial ciclesonide-responsive cases of COVID-19 pneumonia**
Yutaka Kozu
(Nihon University School of Medicine, Department of Internal Medicine, Division of Respiratory Medicine, Japan)
- P5-153 Diagnostic performance of computed tomography imaging for COVID-19 in a region with low disease prevalence**
Ho Lee
(Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Japan)
- P5-154 A case of bilateral recurrent exudative pyogenic pleural effusion**
Sm Abdullah al mamun
(Square Hospital, Bangladesh)
- P5-155 Legionella pneumophila Pneumonia with Rapid Clinical Course in a Lung Cancer Patient**
Masaharu Aga
(Department of Respiratory Medicine, Yokohama Municipal Citizen's Hospital, Japan)
- P5-156 Pneumomediastinum in Covid-19 Confirmed Case: A rare case**
Andrew Santosa
(Resident of Pulmonology Department, Medical Faculty, Brawijaya University, Saiful Anwar General Hospital, Indonesia)
- P5-157 ADVERSE EVENT FOLLOWING COVID-19 VACCINATION AND ANTIBODY TITERS IN PULMONOLOGISTS AND PULMONOLOGY RESIDENTS**
Berly Tawary
(Dept of Pulmonology and Respiratory Medicine, FKUI, Indonesia)

P5-158 Examination of correspondence to COVID-19 patients in our hospital

Taichi Mochizuki

(Department of Respiratory Medicine, School of Medicine, International Medical Welfare University, Japan)

P6-7 Is Nontuberculous Mycobacterial Lung Disease A Risk Factor of Latent Tuberculous Infection? - A Prospective Study in A Medical Center

Ho-Sheng Lee

(E-Da Hospital, Taiwan)

Poster Session 6

On-demand

P6 Tuberculosis**P6-1 Impact of COVID-19 on the epidemiology of TB among migrants in Japan**

Lisa Kawatsu

(Research Institute of Tuberculosis, Japan)

P6-2 To study the efficacy and safety of bedaquiline plus optimized background regimen and high dose moxifloxacin plus optimized background regimen in drug resistant pulmonary tuberculosis-a prospective observational study

Govind Desai

(Post Graduate Student, Department of Respiratory Medicine, Dr Sampurnanand Medical College, India)

P6-3 Efficacy and safety of levamisole as an immunomodulator in the treatment of Pulmonary drug-resistant tuberculosis

Nikhil Sarangdhar

(Asst. Professor, K. J. Somaiya medical college and hospital, India)

P6-4 Endobronchial mass occurred during treatment of tuberculosis: two cases

Yeongha Ryu

(Dong kang hospital, Korea)

P6-5 Impact of COVID-19 on tuberculosis in Japan; A national database analysis

Nobuaki Kobayashi

(Department of Pulmonology, Yokohama City University Graduate School of Medicine, Japan)

P6-6 Anti Tuberculosis treatment induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) mimicking Meningitis

Chandana Dahanayake

(National Hospital for Respiratory Disease -Sri Lanka, Sri Lanka)

P6-8 Abandonment of tuberculosis treatment in patients with mental health disorders in Brazil

Gustavo Vilas-Boas

(Bahiana School of Medicine and Public Health, Brazil)

P6-9 A post COVID activation of latent Tuberculosis.

Chandana Dahanayake

(National Hospital for Respiratory Diseases, Sri Lanka)

P6-10 Mysterious nodule in the spermatic cord in an immunosuppressed patient - An executive's agony

Sugeesha Wickramasinghe

(Senior Registrar in Respiratory Medicine, Central Chest Clinic, Borella, Sri Lanka, Sri Lanka)

P6-11 Higher Bacterial Load in Drug Resistant Tuberculosis Leads to Unfavourable Treatment Outcome

Faiza Hatim

(Departement of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Indonesia, Indonesia)

P6-12 The cruel dual; SARS-COV-2 and Tuberculosis co-infection, the Sri Lankan experience.

Harshana Bandara

(Senior Registrar in Respiratory Medicine, Sri Lanka)

P6-13 Clinical impact of low body mass index in patients with Mycobacterium avium complex pulmonary disease

Hironori Sadamatsu

(Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Japan)

P6-14 Impact of nationwide lockdown due to COVID 19 on incidence of sputum positive pulmonary tuberculosis in rural India.

Aniket Inamdar

(Samarpan Clinic, India)

P6-15 Cardiotoxicity in Drug-Resistant Tuberculosis Patients Treated with Short Term Regimen

Airin Aldiani

(University of Indonesia, Indonesia)

- P6-16 TB salpingitis in a background of endometriosis - A rare association**
Sugeesha Wickramasinghe
(Senior Registrar in Respiratory Medicine, National Hospital for Respiratory Diseases, Welisara, Sri Lanka, Sri Lanka)
- P6-17 Effectiveness of inhaled hypertonic saline application for sputum induction to improve Mycobacterium tuberculosis (MTB) identification in patients with pulmonary tuberculosis**
Tetiana Butova
(Merefa Central District Hospital, Ukraine)
- P6-18 Endobronchial Ultrasound Transbronchial Aspiration Biopsy (EBUS-TBNA) in the Diagnosis of Mediastinal Mass of Unknown Etiology: A Case Series**
Vehement Jay Ventic
(UST-Hospital, Philippines)
- P6-19 Clinical characteristics of pulmonary tuberculosis in the central and eastern part of Shizuoka**
Yutaro Kishimoto
(Shizuoka General Hospital, Japan)
- P6-20 The clinical characteristics of MAC-PD patients with negative serum anti-glycopeptidolipid-core IgA antibody results.**
Norio Kodaka
(Division of Respiratory Medicine, Department of Internal Medicine, Toho University Ohashi Medical Center, Japan)
- P6-21 A case of tuberculous pleurisy masquerading malignant lymphoma**
Takahiro Arano
(JCHO Tokyo Shinjuku Medical Center, Japan)
- P6-22 Characteristics of pulmonary tuberculosis with delayed diagnosis in our hospital**
Anna Tanaka
(Yokohama Minami Kyou Sai Hospital, Japan)
- P6-23 Diagnostic utility of adenosine deaminase (ADA) activity in pleural fluid and pleural fluid lactate dehydrogenase/ ADA ratio of tuberculous and non-tuberculous pleural disease**
Boon Hau Ng
(RESPIRATORY UNIT, DEPARTMENT OF MEDICINE, PUSAT PERUBATAN UNIVERSITI KEBANGSAAN MALAYSIA, Malaysia)
- P6-24 CO-EXISTENCE OF ACTIVE PULMONARY TUBERCULOSIS AND ASPERGILLOMA- A RARE ENTITY**
Sneha Leo
(Jawaharlal Institute of Postgraduate Medical Educational and Research, India, India)
- P6-25 Thrombophlebitis and deep vein thrombosis, a rare presentation of Tuberculosis**
Isuru Navodani Ganearachchi
(Colombo North Teaching Hospital, Ragama, Sri Lanka, Sri Lanka)
- P6-26 Screening for Tuberculosis among Persons with Diabetes Mellitus in Metro Manila, Philippines: A Multi-Center Study**
Chua Jamie
(University of the Philippines - Philippine General Hospital, Philippines)
- P6-27 Intrapleural Alteplase and DNase for complex tuberculous pleural effusion**
Hafiz Aizat Shuhaimi
(Respiratory Unit, Department of Medicine, Pusat Perubatan Universiti Kebangsaan Malaysia, Malaysia)
- P6-28 Clinical case of using intravenous forms of anti-tuberculosis drugs to improve the treatment efficiency of tuberculosis in patients with malabsorption syndrome (MS)**
Dmytro Butov
(Kharkiv National Medical University, Ukraine)
- P6-29 A Case of Elderly Female With Unresponsive Anti-Tuberculosis Therapy In Rural Area**
Eduward Thendiono
(Siloam Hospital Buton, Indonesia)
- P6-30 Pulmonary tuberculosis presents radiologically as kaposi sarcoma: A case report**
Niranjan Chandramal
(National hospital of Sri Lanka, Sri Lanka)
- P6-31 CD4+ MAIT cells in blood of patients may enhanced anti-tuberculosis function by increasing IFN- γ and granzyme B production**
Kunlong Xiong
(Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China, China (Mainland))
- P6-32 Clinical efficacy of Endobronchial Ultrasonography in the diagnosis of mycobacterial infections.**
Yuriko Terayama
(National Center for Global Health and Medicine, Japan)
- P6-33 Evaluation of sustained treatment success rate of tuberculosis patients in Japan**
Kazuhiro Uchimura
(Research Institute of Tuberculosis, Japan Anti-Tuberculosis association, Japan)

- P6-34 Prevalence of rifampicin resistance in patients with pulmonary tuberculosis in western India using automated TrueNAT assay**
Aniket Inamdar
(Samarpan Clinic, India)
- P6-35 The predicament in diagnosing Mycobacterium Tuberculosis in young patients**
Nur Husna Mohd Aminuddin
(Respiratory Unit, Department of Medicine, Selayang Hospital, Selangor, Malaysia, Malaysia)
- P6-36 Components system of Nitric oxide as markers of pulmonary multi-drug resistant tuberculosis process activity**
Dmytro Butov
(Kharkiv National Medical University, Ukraine)
- P6-37 The difficult diagnosis of a common disease**
Nirmal Kanti Sarkar
(Mugda Medical College, Dhaka, Bangladesh, Bangladesh)
- P6-38 Utility of thoracoscopy under local anesthesia in the diagnosis of tuberculous pleurisy and drug susceptibility testing for tuberculosis.**
Hiroya Manaka
(Kitasato University, Japan)
- P6-39 A case of consecutive pneumocystis pneumonia and varicella pneumonia during the treatment of miliary tuberculosis**
Yutaka Kozu
(Nihon University School of Medicine, Department of Internal Medicine, Division of Respiratory Medicine, Japan)
- P6-40 Tuberculosis involving the subcutaneous tissue adjacent to Achilles tendon - A rare presentation**
Sugeesha Wickramasinghe
(Senior Registrar in Respiratory Medicine, National Hospital for Respiratory Diseases, Welisara, Sri Lanka, Sri Lanka)
- P6-41 Rifampicin Resistant Pulmonary Tuberculosis with Concomitant Bacterial Pneumonia Showing Left Lower Lobe Consolidation in the Young and Immunocompetent Physician**
Charry Mae Solidum-Sta. Ana
(East Avenue Medical Center, Philippines)
- P6-42 A case of extensively drug-resistant tuberculosis (XDR TB) unresponsive to many drug regimes : a treatment dilemma**
Malika Udugama
(National Hospital for respiratory diseases, Sri Lanka)
- P6-43 Multicenter Prospective Study on Gouty Arthritis and Predictors of Outcomes among Filipino Patients on Anti-Tuberculosis Treatment**
Anna Krystel Chua
(Mariano Marcos Memorial Hospital & Medical Center, Philippines)
- P6-44 Case report of a newly diagnosed bacteriologically confirmed pulmonary tuberculosis in a patient with COVID-19 critical infection**
Marc Anthony Donguines
(Lung Center of the Philippines, Philippines)
- P6-45 A case of multi-drug resistant tuberculosis (MDR-TB), presenting an abscess of the left leg in a trainee of nursing care visiting in Japan from Myanmar**
Motofumi Tsubakihara
(Respiratory Medicine, National Hospital Organization Yokohama Medical Center, Japan)
- P6-46 Long-term pass holders with multidrug-resistant tuberculosis (MDR-TB) in Singapore: missed opportunities for earlier diagnosis**
Shera Tan
(TB Control Unit, Tan Tock Seng Hospital, Singapore)
- P6-47 Adverse drug reactions and their impact on the treatment of pulmonary tuberculosis in elderly patients**
Takahiro Kaki
(Department of Respiratory Medicine, National Hospital Organization Wakayama Hospital, Japan)
- P6-48 Unilateral hypoplastic lung complicated with pulmonary Tuberculosis - A rare association**
Sugeesha Wickramasinghe
(Senior Registrar in Respiratory Medicine, Central Chest Clinic, Borella, Sri Lanka, Sri Lanka)
- P6-49 Association of interleukins genes polymorphisms with MDR TB in Kharkiv region, Ukraine**
Tetiana Butova
(Merefa Central District Hospital, Ukraine)
- P6-50 Primary Multidrug-Resistant Tuberculosis in Coronavirus Disease 2019**
Ahmad Junaidi
(Faculty of Medicine, Universitas Andalas, Indonesia)
- P6-51 Primary Pulmonary Multi-drug Resistant Tuberculosis on Silicotic Lung**
Amanullah Chowdhury
(National Institute of Diseases of the Chest and Hospital, Dhaka, Bangladesh)

- P6-52 Pediatric tuberculosis presenting with chest wall abscess**
Aunya Kulbun
(Division of Pulmonology, Department of Pediatrics, Faculty of Medicine Siriraj Hospital Mahidol University, Thailand)
- P6-53 A study of liver dysfunction due to combined use of PZA in elderly pulmonary tuberculosis**
Katsushi Tanaka
(Yokohama city university hospital, Japan)
- P6-54 TUBERCULAR MASTITIS - THE GREAT MASQUERADER**
MUNIZA BAI
(DEPARTMENT OF PULMONARY MEDICINE, JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH, India)
- P6-55 Peritoneal deposits with a hilar lesion due to Tuberculosis - A great masquerader**
Sugeesha Wickramasinghe
(Senior Registrar in Respiratory Medicine, National Hospital for Respiratory Diseases, Welisara, Sri Lanka, Sri Lanka)
- P6-56 One case of a patient on maintenance dialysis who concurrently suffered from both COVID-19 and a relapse of pulmonary tuberculosis.**
Takashi Ohki
(JCHO Yokohama Chuo Hospital, Japan)
- P6-57 Case report Heimlich valve as an ambulation management of persistent pneumothorax in patient with pulmonary tuberculosis**
Bagus Wicaksono
(Lambung Mangkurat, University / Ulin General Hospital, Indonesia)
- P6-58 Pneumothorax as A Clinical Manifestation of Lung Tuberculosis with Co-Infection COVID-19 and Bacterial Pneumonia**
Merry Dhama Yanti
(Faculty of Medicine, Universitas Andalas, Indonesia)
- P6-59 The age and outcomes of patients with tuberculosis in our hospital: A 30-year single-institution experience**
Kohei Somekawa
(Yokohama city university hospital, Japan)
- P6-60 Characteristics of tuberculous and malignant pleural effusion patients in Sanglah Hospital Denpasar, Indonesia**
Venny Singgih
(Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Udayana University, Indonesia)
- P6-61 Association of serum antibodies against the Mycobacterium avium complex with hemoptysis**
Hiroaki Ogata
(National Hospital Organization Fukuoka National Hospital, Japan)
- P6-62 Squamous cell carcinoma of the palate in a patient with pulmonary Tuberculosis getting complicated with exfoliative dermatitis - A case report**
Sugeesha Wickramasinghe
(Senior Registrar in Respiratory Medicine, National Hospital for Respiratory Diseases, Welisara, Sri Lanka, Sri Lanka)
- P6-63 Disseminated TB? Disseminated malignancy? or Both? A diagnostic trilemma.**
Sanjeeva Malinda Hettiarachchi
(National Hospital for Respiratory Diseases, Welisara, Sri Lanka, Sri Lanka)
- P6-64 The great masquerader: A case of tuberculous effusion and coexisting lung adenocarcinoma diagnosed through pleural biopsy**
Karen Anne Claridad
(Philippine General Hospital, Philippines)
- P6-65 A case of tuberculosis infection with a particular clinical course and difficulty in treatment**
Tsukasa Nishizawa
(Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Japan)
- P6-66 The effect of Miana Leaves on HIF-1 α protein expression in Balb/c mice infected with Mycobacterium Tuberculosis**
Rosamarlina Syahrir
(Prof. Dr. Sulianti Saroso Infectious Disease Hospital, Jakarta Indonesia, Indonesia)
- P6-67 Study on sputum non-conversion at the end of intensive phase in smear positive pulmonary tuberculosis patients**
Dawpadee Dharmasena
(Welisara, Sri Lanka, Senior Registrar in Respiratory, Sri Lanka)

Poster Session 7

On-demand

- P7 COPD**
- P7-1 Spontaneous pulmonary emphysema in mice lacking all three nitric oxide synthase isoforms**
Kaori Kato
(Department of Respiratory Medicine, University of Occupational and Environmental Health, Japan, Japan)
- P7-2 Diaphragmatic excursion is correlated with the improvement in exercise tolerance after pulmonary rehabilitation in COPD patients**
Masashi Shiraishi
(Department of Rehabilitation Medicine, Kindai University School of Medicine, Japan)
- P7-3 Exposure to the heated tobacco product IQOS generates apoptosis-mediated pulmonary emphysema in murine lungs**
Naoko Nitta
(Juntendo University Graduate School of Medicine, Japan)
- P7-4 The level of TLR2 expression on circulating CD4+ cells as a diagnostic biomarker of chronic obstructive pulmonary disease**
Tatyana Vitkina
(Vladivostok Branch of Federal State Budgetary Science Institution "Far Eastern Scientific Center of Physiology and Pathology of Respiration"—Institute of Medical Climatology and Rehabilitative Treatment, Russia)
- P7-5 Sex-specific differences of prevalence and risk factors for chronic obstructive pulmonary disease in subjects with preserved ratio impaired spirometry**
Kazufumi Takamatsu
(Department of Respiratory Medicine and Allergology, Kochi Medical School, Kochi University, Japan)
- P7-6 The association between alkaline phosphatase and COPD symptoms, severity, and exacerbation**
Kieun Hwang
(Division of Pulmonary, Department of Internal Medicine, Wonkwang university school of medicine, Iksan, Korea, Korea)
- P7-7 Effect of periodontal pathogen *Fusobacterium nucleatum* on a COPD mouse model**
Ryuta Suzuki
(Department of Oral Surgery, Nihon University School of Dentistry, Japan)
- P7-8 Effect of surgical mask on exercise capacity in patients with chronic obstructive pulmonary disease: A Randomized Controlled Trial**
Kuniaki Hirai
(Department of Medicine, Division of Respiratory Medicine and Allergology, Showa University School of Medicine, Japan)
- P7-9 Involvement of Parkin-mediated mitophagy in COPD-related sarcopenia pathogenesis**
Akihiko Ito
(Division of Respiratory medicine, Jikei University school of medicine, Japan)
- P7-10 Relationship of Quantitative Chest Computed Tomography with Clinical Characteristics and Functional Exercise Capacity in Chronic Obstructive Pulmonary Disease**
Ling-Kai Chang
(National Taiwan University Hospital, National Taiwan University College of Medicine, Taiwan)
- P7-11 Influence of chronic obstructive pulmonary disease in promoting arteriosclerosis in smokers**
Shohei Kawachi
(Department of Physical Therapy, Health Science University, Japan)
- P7-12 Sirtuin3 suppresses lung inflammation of COPD exacerbation mouse model**
Taro Ishimori
(Department of Respiratory Medicine, The University of Tokyo Hospital, Japan)
- P7-13 Identification of exacerbation phenotypes across asthma and COPD**
Kentaro Hyodo
(Department of Pulmonary Medicine, University of Tsukuba, National Hospital Organization Ibaraki Higashi National Hospital, Japan)
- P7-14 Longitudinal changes of Disease Probability Measure parameters in COPD**
Yumiko Matsuo
(Shiga University of Medical Science, Japan)
- P7-15 Biochemical markers of endothelial dysfunction in patients with chronic obstructive diseases of the lungs of different categories of risk of exacerbations**
Valentina Pavlenko
(Amur State Medical Academy, Russia)
- P7-16 Clinical utility of the electrocardiographic P-wave axis in patients with chronic obstructive pulmonary disease.**
Shiro Otake
(Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Japan)

- P7-17 One-year clinically important deterioration and long-term clinical course in Japanese patients with COPD**
Yuki Abe
(Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Japan)
- P7-18 Latent classes of cough phenotypes in middle-aged adults: Tasmanian Longitudinal Health Study**
Jingwen Zhang
(University of Melbourne, Australia)
- P7-19 Associations of body compositions with air-flow limitation and exercise-induced dynamic hyperinflation in patients with chronic obstructive pulmonary disease**
Yusuke Shiraishi
(Department of Respiratory Medicine, Kyoto University, Graduate School of Medicine, Japan)
- P7-20 Small airway dysfunction predict decline in FEV1: Results from a cross-sectional study in Shanghai, China**
Tingting Wei
(Zhongshan Hospital, Fudan University, China (Mainland))
- P7-21 Chronic obstructive pulmonary disease, cataract and oxidative stress**
Marya Petrenko
(Amur State Medical Academy, Russia)
- P7-22 Characteristics of nocturnal desaturation waveform pattern of SpO₂ in COPD patients**
Asuka Yoshizaki
(Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Japan)
- P7-23 Effectiveness of Combination Therapy with Selective Beta-1 Blockers and Pulmonary Rehabilitation for COPD**
Masashi Zenta
(Division of Rehabilitation, International University of Health and Welfare (IUHW) Ichikawa Hospital, Japan)
- P7-24 Up-regulation of LIM/homeobox protein Lhx9 in alveolar epithelial type 2 cells of COPD lungs**
Koji Okutomo
(Tohoku university, Japan)
- P7-25 The mortality difference in chronic obstructive pulmonary disease: ever-smoker versus never-smoker**
Hye-Ring Kang
(Division of pulmonary medicine, Department of Internal Medicine, Veterans Health service Medical Center, Seoul, Korea, Korea)
- P7-26 Cognitive functions in stable patients with chronic obstructive pulmonary disease compared to healthy volunteers assessed using PGI Memory Scale**
Saumya Gupta
(Kasturba Medical College, Manipal, India)
- P7-27 Biologics for the treatment of COPD with increased peripheral blood eosinophils: A systematic review and meta-analysis**
Hiroshi Ohnishi
(Department of Respiratory Medicine and Allergology, Kochi Medical School, Kochi University, Japan)
- P7-28 Changes of forced vital capacity are associated with poor outcome in Asthma-COPD overlap**
Tai Joon An
(Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Yeouido St. Mary's Hospital, The Catholic University of Korea, Korea)
- P7-29 Muscle mass evaluation using body composition analysis for COPD patients**
Naotaka Noda
(Department of Respiratory Medicine, National Hospital Organization Omuta National Hospital, Japan)
- P7-30 Expression profile of microRNAs in serum extracellular vesicles of COPD frequent exacerbators.**
Mitsuhiro Yamada
(Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Japan)
- P7-31 The role of KIAA1462 in chronic obstructive pulmonary disease (COPD).**
Masako Yumura
(Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Japan)
- P7-32 The frailty and the physical activity in COPD patients: Cross-sectional study**
Takahiro Kawai
(Department of Respiratory Medicine, Graduate School of Medicine, Osaka City University, Japan)
- P7-33 The different significance between sedentary time and high-intensity physical activities in patients with stable COPD**
Atsushi Miyamoto
(Department of Respiratory Medicine, Graduate School of Medicine, Osaka City University, Japan)

- P7-34 Impact of pulmonary rehabilitation on pulmonary function measures, exercise capacity, quality of life and psychosocial parameters in patients with chronic obstructive pulmonary disease**
Ramakant Dixit
(J L N Medical College, Ajmer, India, India)
- P7-35 Quantitative CT-based evaluation of skeletal muscle and presence of sarcopenia in patients with chronic obstructive pulmonary disease.**
Susumu Sato
(Respiratory Care and Sleep Control Medicine, Graduate School of Medicine, Kyoto University, Japan)
- P7-36 The effect of nutritional status on exacerbation in COPD patients : a retrospective and prospective cohort study**
Chang Youl Lee
(Chuncheon Sacred Heart Hospital, Hallym University, Korea)
- P7-37 The characteristics of responders to treatment with Tiotropium/Olodaterol: a large cohort Post-Marketing Surveillance post-hoc analysis in Japan**
Atsuyasu Sato
(Department of Respiratory Medicine, Kyoto University, Graduate School of Medicine, Japan)
- P7-38 Interleukin-6 and interleukin-8 in patients with chronic obstructive lung disease with different risk of exacerbations**
Anastasiia Bakina
(Amur State Medical Academy, Russia)
- P7-39 Evaluation of the effect of ICS containing triple therapy with LAMA/LABA in comparison with LAMA/LABA in COPD patients**
Mizuki Yuasa
(Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan, Japan)
- P7-40 Assessment of the screening strategy of early detection of COPD**
Ching-Hsiung Lin
(Division of Chest Medicine, Changhua Christian Hospital, Taiwan)
- P7-41 Risk factors for mortality and readmission in patients hospitalized with congestive heart failure and chronic obstructive pulmonary disease**
Chiung-Hung Lin
(Chang Gung Memorial Hospital, Taiwan)
- P7-42 Significance of Monitoring Patients with Chronic Obstructive Pulmonary Disease during Walking Rehabilitation by Transcutaneous Blood Gas Analysis**
Akira Umeda
(Department of General Medicine, School of Medicine, International University of Health and Welfare (IUHW), IUHW Shioya Hospital, Japan)
- P7-43 The impact of fungal sensitization on clinical features in asthma and chronic pulmonary obstructive disease**
Yuta Kono
(The department of respiratory medicine, Tokyo medical university hospital, Japan)
- P7-44 Involvement of airway hyperresponsiveness in the therapy for COPD**
Hiroaki Kume
(Fukushima Medical University Aizu Medical Center, Japan)
- P7-45 Non-pulmonary medicine specialists' knowledge, attitude and practice in the diagnosis of chronic obstructive pulmonary disease (COPD) in a tertiary hospital in Manila, Philippines**
Shane Villamonte
(University of Santo Tomas Hospital, Philippines)
- P7-46 Airflow obstruction on spirometry in patients undergoing surgery using general anesthesia**
Yasuhiro Goto
(Fujita health university, Japan)
- P7-47 Blood eosinophil count as a predictive biomarker of COPD exacerbation in a real-world setting**
Yohei Suzuki
(Department of Respiratory Medicine, Juntendo University Urayasu Hospital, Japan)
- P7-48 Usefulness of non-exercise activity thermogenesis (NEAT) score to estimate physical activity level in patients with COPD**
Hideaki Sato
(Saitama Medical University, Japan)
- P7-49 Clinical experience of Budesonide/Glycopyrrolate/Formoterol in patients with Chronic Obstructive Pulmonary Disease.**
Suguru Ueda
(Department of Respiratory Medicine, Fujisawa City Hospital, Japan)
- P7-50 Air pollution and mortality in chronic obstructive pulmonary disease (COPD) patients**
Suna Kang
(Division for Environmental Economy, Korea Environment Institute, Korea)

- P7-51 The effect of increased frequency of home-based upper-extremity strength and endurance training, and additional egg-white diet on COPD patients' fat-free muscle mass**
Yessi Andriani Zainal
(Universitas Sumatera Utara, Indonesia)
- P7-52 The Effectiveness of Home-Based Upper Arm Endurance and Strength Exercises with Eggwhite Supplementation on Functional Capacity and Quality of Life in Stable COPD Patients**
Pandu Putra
(Medical Departement, Indonesia)
- P7-53 Association between vitamin D level and respiratory symptom in patients with stable chronic obstructive pulmonary disease**
Lee Chaikyung
(Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea)
- P7-54 Association of CAT score with PFT and 6 minute walk test in assessing the severity of COPD**
Tisa Paul
(Amrita institute of medical sciences, India)
- P7-55 One-year follow-up of instruction in inhalation technique for chronic obstructive pulmonary disease patients.**
Naotaka Noda
(Department of Respiratory Medicine, National Hospital Organization Omuta National Hospital, Japan)
- P7-56 Evaluation of useful guide to which cases ICS should be added in combination with a long-acting bronchodilator in the patients with chronic obstructive pulmonary disease**
Ken Okamura
(Department of Respiratory Medicine, Nippon Medical School Hospital, Japan)
- P7-57 The effectiveness of home-based upper-body strength and endurance training pulmonary rehabilitation program on the muscle mass of stable COPD patients**
Agi Hidjri Tarigan
(Universitas Sumatera Utara, Indonesia)
- P7-58 INHALER ADHERENCE AND TECHNIQUE IN PATIENTS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE AT PHAM NGOC THACH HOSPITAL, HO CHI MINH CITY**
Dinh Phuong Nguyen
(University of Medicine and Pharmacy at Ho Chi Minh city, Viet Nam)
- P7-59 Relationship between Stable Chronic Obstructive Pulmonary Disease with the Incidence of Heart Failure and its Influencing Factors in the Lung Polyclinic at Arifin Achmad General Hospital, Riau Province**
Andry Wahyudi Agus
(Department of Pulmonology and Respiratory Medicine, Faculty of Medicine Riau University / Arifin Achmad General Hospital, Pekanbaru - Indonesia, Indonesia)
- P7-60 The effectiveness of strength and resistance exercise of the upper extremity on muscle mass in chronic obstructive pulmonary diseases patients**
Fifi Maylida S
(Universitas Sumatera Utara, Indonesia)
- P7-61 Management & Caring for patients of COPD with COVID-19: A current perspective**
Sm Abdullah al mamun
(Square Hospital, Bangladesh)
- P7-62 Face mask protective or trigger for exacerbation in COPD patients**
Sarang Patil
(Assistant Professor, Department of Respiratory, Sleep and Critical Care Medicine, Maharashtra University of Health Sciences, India)
- P7-63 Real world comparative effectiveness and tolerability of Glycopyrronium/Formoterol (G/F - 25µg/12µg) versus Glycopyrronium/Formoterol (G/F - 25µg/6µg) dry powder inhaler in COPD patients - Retrospective study**
Sagar Bhagat
(Global Medical Affairs, Glenmark pharmaceuticals Ltd, India)
- P7-64 Comparative effectiveness of Glycopyrronium monotherapy vs ICS/LABA in drug-Naïve mild-moderate COPD patients: A real world Experience from India**
Sagar Bhagat
(Global Medical Affairs, Glenmark pharmaceuticals Ltd, India)
- P7-65 Correlation between Body Mass Index (BMI) and Chronic Obstructive Pulmonary Disease (COPD)**
Dwi Robbiardy Eksa
(University of Lampung, Indonesia)
- P7-66 Clinical inertia in the management of COPD: A Review of the Literature**
Shinji Teramoto
(Tokyo Medical University Hachioji Medical Center, Japan)

P7-67 The Association between history of respiratory infection in childhood and the incidence of COPD

David Tongon Silaen
(University of Lampung, Indonesia)

P7-68 The Association of History Respiratory Infection in Childhood and Level Epidermal Growth Factor in COPD

Adhi Nugroho Latief
(University of Lampung, Indonesia)

Poster Session 8

On-demand

P8 Lung Cancer**P8-1 Differential expression of miR-375 and miR-455-3p is related to molecular subtyping of small cell lung cancer**

Naoya Miyashita
(Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Japan)

P8-2 The new scoring system for predicting in-hospital death after lung cancer surgery (The SABCIIP Score) using a Japanese nationwide administrative database

Masahiro Tahara
(Department of Respiratory Medicine, University of Occupational and Environmental Health, Japan, Japan)

P8-3 Gene amplification of ACTN4 is a predictive biomarker for the adjuvant chemotherapy with Uracil-Tegafur in stage-I patients with adenocarcinoma of the lung.

Rintaro Noro
(Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan., Japan)

P8-4 An integrated analysis of the competing endogenous RNA network associated of prognosis of stage I lung adenocarcinoma

Hai Lin
(Department of Respiratory Pulmonary and Critical Care Medicine, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian province, 362000, China, China (Mainland))

P8-5 Quantification of visible HER family dimers by proximity ligation assay and its clinical evaluation in non-small cell lung cancer patients treated with EGFR-TKI

Keiichi Ota
(Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Japan)

P8-6 Cross-talk between erasers and readers of N6-methyladenosine regulates cell proliferation in non-small cell lung cancer

Kazuo Tsuchiya
(Hamamatsu University School of Medicine, Japan)

P8-7 Antigen-presenting capacity of fibrocytes and its regulation by anti-PD-1/PD-L1 antibodies

Hirokazu Ogino
(Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Japan)

P8-8 Construction of lncRNA Prognostic Risk Model for Lung Adenocarcinoma

Zhimin Zeng
(The First Affiliated Hospital of Sun Yat-sen University, China (Mainland))

P8-9 Genomics on circulating tumor DNA predicts survival under afatinib treatment for EGFR-mutated non-small cell lung cancer

Tomomi Nakamura
(Saga University, Japan)

P8-10 Minichromosome maintenance complex component (MCM) genes in lung adenocarcinoma: MCM-family acts as a potential therapeutic target

Kengo Tanigawa
(Department of Pulmonary Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Japan)

P8-11 Inhibition of the Bax and Bak apoptotic function by paclitaxel prevents genotoxic cell death in gefitinib-resistant non-small-cell lung cancer

Md Mohiuddin
(Department of Respiratory Medicine, Kanazawa University, Japan)

P8-12 The relationship between lung microbiota and pathologic subtype with prognosis

Hye Jin Jang
(Division of Pulmonology, Department of Internal Medicine, Severance hospital, Yonsei University College of Medicine, Korea)

- P8-13 The gut microbiome as a new marker of tumor progression among female never-smokers with lung adenocarcinoma**
Takehiro Otoshi
(Kobe University Graduate School of Medicine, Japan)
- P8-14 Development of an optimal protocol for molecular profiling of tumor cells in malignant pleural effusions at single-cell level**
Ikuko Nakamura
(Division of Respiratory Medicine, Juntendo University, Japan)
- P8-15 Usefulness of liquid biopsy for patients with non-small cell lung cancer harboring an EGFR mutation treated with afatinib**
Hiroaki Fujii
(Department of pulmonology, Graduate school of medicine, Yokohama city university, Japan)
- P8-16 An exploratory study of biomarkers in blood of osimertinib for EGFR-T790M mutation-positive NSCLC**
Norimitsu Kasahara
(Gunma University Hospital, Japan)
- P8-17 Efficacy of first line pembrolizumab in recurrent non-small cell lung cancer after curative intent treatment**
Keita Miura
(Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Japan)
- P8-18 Analysis of Trace Element Concentrations and Relationship between Trace Element and Prognosis in Lung Cancer Patients**
Hirotaka Saikawa
(Division of Pulmonary Medicine, Department of Internal Medicine, Iwate Medical University, Japan)
- P8-19 The Association Between the Incidence Risk of Pneumonitis and PD-1/PD-L1 Inhibitors in Advanced NSCLC: A Meta-analysis of Randomized Controlled Trials**
Yingxuan Xu
(Department of Respiratory Pulmonary and Critical Care Medicine, The Second Affiliated Hospital of Fujian Medical University, China, Respiratory Medicine Center of Fujian Province, China (Mainland))
- P8-20 Postoperative Radiotherapy prolongs survival of Completely Resected Masaoka/Masaoka-Koga Stage II/III Thymoma.**
Nobuyuki Horita
(Yokohama City University, Japan)
- P8-21 Heterogeneity among tumors with acquired resistance to EGFR-TKIs harboring EGFR-T790M mutation in non-small cell lung cancer cells**
Yuki Katayama
(Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Japan)
- P8-22 Solo surgery style. Benefits and technical points of robot-assisted respiratory surgery.**
Hiromitsu Domen
(Department of Surgery, NTT Medical Center Sapporo, Japan)
- P8-23 Clinical importance of LINC00460 expression in EGFR mutation-positive lung cancer treated with osimertinib**
Kazutoshi Isobe
(Department of Respiratory Medicine, Toho University School of Medicine, Japan)
- P8-24 The miR-124-3p/ZFP36L1 axis is suppressed by ASCL1 in lung adenocarcinoma.**
Takayoshi Enokido
(Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Japan)
- P8-25 Type A CpG oligodeoxynucleotide competitively Inhibits IFN- γ receptors in human lung cancer cells**
Shuhei Teranishi
(Respiratory Disease Center, Yokohama City University Medical Center, Japan)
- P8-26 Study of the number of courses required for the first response to immune checkpoint inhibitor (+chemo) therapy for lung cancer**
Takanobu Sasaki
(Thoracic Surgery, Tohoku Medical and Pharmaceutical University hospital, Japan)
- P8-27 A comprehensive retrospective analysis to assess the clinical impact of cerebral infarction in patients with non-small cell lung cancer**
Moriyasu Anai
(Kumamoto University Hospitals, Japan)
- P8-28 A Case of Malignant Pleural Mesothelioma Achieved Improvement by Specific Substance of Maruyama**
Manami Haba
(Koto hospital, Japan)

- P8-29 Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in EGFR-mutant NSCLC with T790M mutation**
Daisuke Hayakawa
(Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Japan)
- P8-30 Usefulness of Pulmonary Rehabilitation in Non-small Cell Lung Cancer Patients Based on Pulmonary Function Tests and Muscle Index Analysis Using Computed Tomography Images**
Juwhan Choi
(Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea, Korea)
- P8-31 Prospective observational study of sequential afatinib and osimertinib in NSCLC patients with EGFR mutation: Gio-Tag Japan**
Takashi Fukushima
(Department of Respiratory Medicine, Hirosaki University, Graduate School of Medicine, Japan)
- P8-32 Significance of positive blood culture in chemotherapy induced febrile neutropenia patients with lung cancer**
Toshikazu Watanabe
(Department of Respiratory Medicine, Fujita Health University School of Medicine, Japan)
- P8-33 A case of enterocolitis with bleeding caused by osimertinib**
Saori Nishizawa
(Iizuka hospital, Japan)
- P8-34 The relation between immune-related adverse events and therapeutic effects of nivolumab or pembrolizumab monotherapy for patients with non-small cell lung cancer**
Yusuke Hamakawa
(Department of Respiratory Medicine, Yokohama Municipal Citizen's Hospital, Japan)
- P8-35 Metronomic irinotecan and irinotecan plus everolimus induce angiogenesis inhibitory effect in human small cell lung cancer xenografts**
Yoshihiro Amano
(Department of Internal Medicine, Division of Medical Oncology & Respiratory Medicine, Shimane University Faculty of Medicine, Japan)
- P8-37 Delayed visit and treatment of lung cancer during the coronavirus disease 2019 pandemic in Japan**
Takeshi Terashima
(Department of Respiratory Medicine, Tokyo Dental College Ichikawa General Hospital, Japan)
- P8-38 Analysis of OncomineDx target test multi CDx system cases in Juntendo hospital**
Naohisa Matsumoto
(Department of Respiratory Medicine, Juntendo University, Graduate school of Medicine and Faculty of Medicine, Japan)
- P8-39 Current status and future challenges of lung cancer genomic medicine at Hiroshima University Hospital**
Masashi Namba
(Department of Clinical Oncology, Hiroshima University Hospital, Japan)
- P8-40 Efficacy of unscheduled discontinuation of Durvalumab monotherapy after concurrent chemoradiotherapy in locally advanced unresectable non-small cell lung carcinoma: A single-center retrospective analysis.**
Nobuyuki Hirama
(Respartory Disease Center, Yokohama City University Medical Center, Japan)
- P8-41 A herbal medicine Ninjin-yoei-to ameliorates lung cancer cachexia in mice.**
Takafumi Shigekusa
(University of Miyazaki, Japan)
- P8-42 Expression of anti-Müllerian hormone type II receptor and antiproliferative effects of anti-Müllerian hormone on human lung adenocarcinoma**
Yoshika Koinuma
(Juntendo University, Graduate School of Medicine, Department of Respiratory Medicine, Japan)
- P8-43 Retrospective study on timing of PET/CT scanning in pulmonary nodule management**
Mahmoud Alkhatir
(Gold Coast University Hospital, Australia)
- P8-44 Predictive biomarker for the therapeutic effect of PD-L1 inhibitor maintenance therapy in patients with extensive-stage small-cell lung cancer**
Ryota Ushio
(Department of Thoracic Oncology, Kanagawa Cancer Center., Japan)
- P8-45 ONO-7475, a novel AXL inhibitor, suppresses the emergence and maintenance of tolerant cells to initial EGFR-TKI treatment in EGFR-mutated non-small lung cancer**
Tadaaki Yamada
(Kyoto Prefectural University of Medicine, Kyoto, Japan)

- P8-46 Clinical impact of chemotherapy combined with pembrolizumab in elderly patients with advanced non-small-cell lung cancer**
Kenji Morimoto
(Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Japan)
- P8-47 Autoantibody positivity is a risk factor for chemotherapy-induced exacerbation of interstitial pneumonia in lung cancer**
Noriaki Ito
(Hiroshima City Funairi Citizens Hospital, Department of Respiratory Medicine, Hiroshima University, Japan)
- P8-48 Analyses of association between characteristics of patients with EGFR mutations and antitumor effect of ICIs after EGFR-TKIs**
Takashi Ito
(Division of Pulmonary Medicine, Department of Internal Medicine, Iwate Medical University School of Medicine, Japan)
- P8-49 Clinical characteristics of adrenal insufficiency induced by pembrolizumab in non-small cell lung cancer**
Kana Kurokawa
(Department of Respiratory Medicine, Juntendo University, Graduate School of Medicine, Japan)
- P8-50 Lung cancer, as a risk factor for Abdominal Aortic Aneurysm (AAA)**
Hyeran Gwon
(Yonsei university college of medicine, Korea)
- P8-51 AIM2 overexpression and its relationship to KRAS mutations in non-small cell lung cancer**
Noriaki Sunaga
(Department of Respiratory Medicine, Gunma University Graduate School of Medicine, Japan)
- P8-52 Non-inferior Clinical Outcomes of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer Patients with Interstitial Lung Disease**
Yuri Tasaka
(Department of Respiratory Medicine, Tokyo Medical and Dental University, Japan)
- P8-53 The effects of anticancer drugs on lymphocyte immune checkpoints**
Chisato Kamimaki
(Department of Pulmonology, Yokohama City University Graduate School of Medicine, Japan)
- P8-54 Is combination chemotherapy with ICI and cytotoxic agents always better than monotherapy with ICI in patients with advanced NSCLC?**
Hiromi Matsumoto
(Department of Pulmonology, Yokohama City University Graduate School of Medicine, Japan)
- P8-55 A review of cases of gene panel testing using next-generation sequencers at our hospital**
Atsushi Miyasaka
(Respiratory Disease Center, Yokohama City University Medical Center, Japan)
- P8-56 Systemic anticancer therapy increases plasma levels of calreticulin and HMGB1 in patients with advanced lung cancer**
Hiroyuki Inoue
(Fukuoka University Kyushu University, Japan)
- P8-57 Current status of cancer genome profiling tests for thoracic malignancies.**
Takashi Yokoi
(Department of Respiratory Medicine and Hematology, Department of Thoracic Oncology, Hyogo College of Medicine, Japan)
- P8-58 Association between proton-pump inhibitors and the ABCG2 C421A polymorphism and plasma concentration of gefitinib**
Sho Sakamoto
(Department of Respiratory Medicine, Akita University Graduate School of Medicine, Japan)
- P8-59 Drebrin-positive tumor-infiltrating lymphocytes as a prognostic biomarker for lung squamous cell carcinoma**
Kosuke Imamura
(Department of Respiratory Medicine, Graduate School of Medical Sciences, Kumamoto University, Japan)
- P8-60 Evaluation of the inter-tumor heterogeneity of PD-L1 expression in primary and metastatic lesions of autopsy cases with untreated lung adenocarcinoma**
Hiroaki Harada
(NHO Higashihiroshima Medical Center, Japan)
- P8-61 Real world setting of malignant pleural mesothelioma post drug-approval of pemetrexed**
Ryuichi Nishihira
(Japan Organization of Occupational Health and Safety Kanto Rosai Hospital, Division of Respiratory Disease, Japan)

- P8-62 A phase II trial of osimertinib for elderly patients with epidermal growth factor receptor T790M-positive non-small cell lung cancer that progressed during previous treatment**
Akira Nakao
(Department of Respiratory Medicine, Faculty of Medicine, Fukuoka University, Japan)
- P8-63 Impact of the lung immune prognostic index (LIPI) in limited disease small cell lung cancer patients treated with chemoradiotherapy**
Hideki Ikeda
(Department of Respiriology, Chiba University Graduate School of Medicine, Department of Respiratory Medicine, Kimitsu Chuo Hospital, Japan)
- P8-64 Optimal dose of amrubicin for previously treated small-cell lung cancer: A retrospective study**
Anna Hayashi
(Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Japan)
- P8-65 Integrin alpha 2 in non-small cell lung cancer is associated with tumor progression and postoperative recurrence**
Yoko Matsumoto
(Department of Respiratory Medicine, The University of Tokyo, Japan)
- P8-66 Evaluation of atezolizumab monotherapy for chemotherapy-refractory patients with non-small cell lung cancer in clinical practice**
Masashi Kasajima
(Department of Respiratory Medicine, Kitasato University School of Medicine, Japan)
- P8-67 A retrospective study of recurrence patterns in chemoradiotherapy using volumetric modulated arc therapy for locally advanced non-small cell lung cancer**
Seigo Katakura
(Department of Thoracic Oncology, Kanagawa Cancer Center, Japan)
- P8-68 Development of a potential biomarker for PD-L1 expression in lung carcinoma**
Seigo Katakura
(Yokohama City University Graduate School of Medicine, Respiratory Disease, Japan)
- P8-69 Clinical Study of Chemotherapy with an Immune Checkpoint Inhibitor Combination Chemotherapy in Advanced Small Cell Lung Cancer**
Tadaharu Nakamoto
(Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Japan)
- P8-70 Correlation of tumour marker (CEA, Cyfra 21-1) with serial miRNA (miR-34, miR-222, miR-148 and miR-155) in advanced stage non-small cell lung cancer (NSCLC) in Indonesia**
Arif Riswahyudi Hanafi
(Department of Pulmonology, Dharmais Cancer Hospital, National Cancer Center, Jakarta, Indonesia, Indonesia)
- P8-71 Correlation of serum electrolyte with serial miRNA in advanced stage non-small cell lung cancer (NSCLC) in Indonesia**
Arif Riswahyudi Hanafi
(Department of Pulmonology, Dharmais Cancer Hospital, National Cancer Center, Jakarta, Indonesia, Indonesia)
- P8-72 A case of hemophagocytic lymphohistiocytosis during atezolizumab treatment for lung adenocarcinoma**
Hiroaki Ota
(Department of Respiratory medicine, Iizuka Hospital, Japan)
- P8-73 Diagnostic Test of Cancer Ratio and Pleural Fluid Red Blood Cell/ Adenosine Deaminase Ratio to Identify Malignant Pleural Effusion**
Mohammad Afien Mukti
(Undergraduted student, Department of Pulmonology and Respiratory Medicine Medical Faculty of Sebelas Maret University/ Dr. Moewardi General Hospital Surakarta, Indonesia)
- P8-74 Eosinophilic pleural effusion due to lung cancer has a better prognosis than non-eosinophilic malignant pleural effusion**
Eiji Takeuchi
(Department of Clinical Investigation, National Hospital Organization Kochi Hospital, Japan)
- P8-75 First- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large real-world cohort of non-small cell lung cancer patients**
Allen Chung-Cheng Huang
(Chang Gung Memorial Hospital, Taiwan)
- P8-76 Loss of glutathione S-transferase omega 2 caused by DNA hypermethylation is associated with progression of non-small cell lung cancer.**
Ryusuke Sumiya
(Department of Thoracic Surgery, National Center for Global Health and Medicine, Tokyo, Japan., Japan)

- P8-77 The Relationship between Incidence of Acquired Resistance (Exon 20 T790M Mutation) and RECIST 1.1 Results in EGFR-TKI treatment of Adenocarcinoma Lung Patients**
Muhammad Harbi Praditya
(Department of Pulmonology and Respiratory Medicine, Adam Malik General Hospital -- Faculty of Medicine Universitas Sumatera Utara, Indonesia)
- P8-78 Different response for crizocinib treatment for lung adenocarcinoma patients with the rare variants of SDC4-ROS1 rearrangement**
Yuta Ohishi
(Nihon University School of Medicine, Japan)
- P8-79 A comparison study on validity of the risk of malignancy using three mathematical prediction models in patients with solitary pulmonary nodules- A single center retrospective cross-sectional study**
Felli Claire Clavel
(St. Luke's Medical Center, Quezon City, Philippines)
- P8-80 Bevacizumab suppresses epithelial-to-mesenchymal transition in EGFR-mutant lung cancer**
Nobuhiko Fukuda
(Yokohama City University, Japan)
- P8-81 Concurrent chemoradiotherapy with cisplatin + S-1 versus cisplatin + other third-generation agents for locally advanced non-small-cell lung cancer: A meta-analysis of individual patient data**
Yuri Taniguchi
(Yokohama Municipal Citizen's Hospital, Japan)
- P8-82 CD8-positive peripheral T cell lymphoma in a patient following long-term nivolumab for advanced lung adenocarcinoma: A case report**
Keigo Koda
(Department of Respiratory Medicine, Hamamatsu Rosai Hospital, Japan)
- P8-83 Giant Pleuro parenchymal metastases from a rare primary tumor**
Ramya Priya Anbalagan
(Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India)
- P8-84 S-1 reduces myeloid-derived suppressor cells in murine mesothelioma model and enhances the anti-tumor activity of anti-PD-1 antibody**
Thi Na Nguyen
(Department of Respiratory Medicine and Rheumatology, Graduate School of Medicine, Tokushima University, Japan)
- P8-85 Analyses of lung sounds altered by cancers or surgical complications**
Shinichi Ohashi
(Showa University Fujigaoka Hospital, Respiration Disease Center, Japan)
- P8-86 Puncture Frequency is the Determinants of Iatrogenic Pneumothorax in Preoperative Pulmonary Nodule Localization: A Propensity Matched Study.**
Frank C. Lin
(Department of Thoracic Surgery, Chung Shan Medical University Hospital, Taiwan)
- P8-87 Clinical study of amrubicin-induced interstitial lung disease in lung cancer patients with interstitial lung abnormality**
Hiroki Ishikawa
(Division of Respiratory Medicine and Rheumatology, Department of Multidisciplinary Internal Medicine, Faculty of Medicine, Tottori University, Japan)
- P8-88 The risk of drug-induced interstitial lung disease induced by chemotherapy plus immune checkpoint inhibitors in advanced non-small cell lung cancer with interstitial lung abnormality.**
Takafumi Fukui
(Kobe University Graduate School of Medicine, Division of Respiratory Medicine/Department of Internal Medicine, Japan)
- P8-89 Carcinoid tumors of Lung - Diagnosis, Treatment and Outcomes in a tertiary care centre, India**
Sneha Leo
(Jawaharlal Institute of Postgraduate Medical Educational and Research, India, India)
- P8-90 An approach to improve the success rate of the Oncomine Dx Target Test on lobectomy samples**
Tadashi Sakaguchi
(Matsusaka Municipal Hospital, Respiratory Center, Japan)
- P8-91 Anti-PD-1/PD-L1 antibody plus chemotherapy after platinum-based chemotherapy in patients with advanced non-small cell lung cancer**
Takehiro Tozuka
(Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Japan)
- P8-92 Association of PD-L1 expression and density of CT imaging of non-small cell lung cancer: possible roles of tissue stiffness as a tumor microenvironment**
Toshio Kato
(Aichi medical university, Japan)

- P8-93 Relationship between efficacy of afatinib and plasma EGFR mutation in osimertinib-resistant patients with EGFR mutated lung cancer; NJLCG1801B study**
Takashi Ito
(Division of Pulmonary Medicine, Department of Internal Medicine, Iwate Medical University School of Medicine, Japan)
- P8-94 Cross resistance to nab-paclitaxel and other taxanes in non-small cell lung cancer**
Satoru Matsuki
(Graduate School of Medicine, Nippon Medical School, Japan)
- P8-95 Corellation of Neutrophil Lymphocyte Ratio (NLR), Platelet Lymphocyte Ratio (PLR) and Carcinoembryonic Antigen (CEA) with Overall Survival. Review of patients with Non-Small Cell Carcinoma (NSCLC) at Ulin General Hospital on Period 2017-2019**
Ayudiah Puspita
(Lambung Mangkurat University, Indonesia)
- P8-96 The effectiveness of Pericardium 6 (PC6) And Stomach 36 (ST36) PointAcupressure In The Management Of Acute Type Nausea And Vomiting, AnxietyAnd Quality Of Life Of Patients Undergoing Chemotherapy**
Dyan Tony Cahya Tony
(Indonesia)
- P8-97 Retrospective study of the carcinogenic preventive effect of nintedanib in patients with interstitial pneumonia**
Toshio Kubo
(Okayama University Hospital, Japan)
- P8-98 Withdrawn**
- P8-99 Efficacy of repeat re-biopsy and osimertinib in patients with EGFR mutation positive advanced NSCLC**
Takashi Hirose
(Nippon Medical School of Medicine Tamanagayama Hospital, Japan)
- P8-100 A Case of Lung Cancer Without Recurrence for One Year Despite the Absence of Treatment After irAE**
Noriko Hayama
(Department of Respiratory Medicine, Koto Hospital, Japan)
- P8-101 EGFR-TKI treatment for squamous cell lung carcinoma with EGFR mutations.**
Tomoyuki Ogisu
(Division of Respiratory Medicine and Allergology, Aichi Medical University, Japan)
- P8-102 Prognostic significance of cachexia in advanced non-small cell lung cancer patients treated with pembrolizumab.**
Hitomi Jo
(Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Department of Thoracic Oncology, National Cancer Center Hospital, Japan)
- P8-103 Real world Long-term survival in patients with non-small cell lung cancer treated with immune checkpoint inhibitor monotherapy.**
Taro Yoneda
(Respiratory Medicine, Komatsu Municipal Hospital, Japan)
- P8-104 The clinical outcomes of nivolumab plus ipilimumab combined with platinum-based chemotherapy, single-center, retrospective analysis**
Natsuko Komiya
(Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan, Japan)
- P8-105 Clinical impact of the modified Glasgow prognostic score in patients diagnosed with advanced non-small cell lung cancer following emergency admission**
Hironari Matsuda
(Department of Respiratory Medicine, Juntendo University Shizuoka Hospital, Japan)
- P8-106 Efficacy and safety of atezolizumab plus bevacizumab plus chemotherapy in patients with advanced nonsquamous non-small-cell lung cancer**
Fumiyasu Igata
(Fukuoka University Hospital, Japan)
- P8-107 Successful treatment with durvalumab, etoposide, and cisplatin in relapsed small cell lung cancer: a case report**
Yosuke Miura
(Division of Allergy and Respiratory Medicine, Integrative Center of Internal Medicine, Gunma University Hospital, Japan)
- P8-108 The Analysis of Genomic Profiles of Lung Cancer with Idiopathic Pulmonary Fibrosis (IPF)**
Aya Fukuizumi
(Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Japan)

- P8-109 Prognostic impact and efficacy of neutrophil-to-lymphocyte ratio (NLR) in patients with malignant mesothelioma**
Masashi Ishihara
(Teikyo University Hospital, Division of Medical Oncology, Department of Internal Medicine, Japan)
- P8-110 One year survival of advanced lung cancer patients at Sanglah Hospital Denpasar Bali**
Pande Made Andikayasa
(Departemen of pulmonology and respiratory medicine Udayana, Indonesia)
- P8-111 Retrospective Study of Immune Checkpoint Inhibitors in Patients with EGFR Mutation-Positive Lung Cancer**
Daishi Fujiwara
(Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Japan)
- P8-112 Clinical laboratory result as prognosis marker in advanced stage non-small cell lung cancer (NSCLC) in Indonesia**
Arif Riswahyudi Hanafi
(Department of Pulmonology, Dharmais Cancer Hospital, National Cancer Center, Jakarta, Indonesia, Indonesia)
- P8-113 Soluble ULBP2 in the sera of patients with EGFR-mutated non-small cell lung cancer**
Naoki Kinoshita
(Tottori University Hospital, Japan)
- P8-114 Impact of clinical features on two-year survival in T790M mutant NSCLC treated with osimertinib**
Po-Lan Su
(Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Taiwan)
- P8-115 An extremely rare case of atypical pulmonary carcinoid with possible ectopic insulin production in a 36-year old Filipino**
Kris Ray Dumaguin
(Perpetual Succour Hospital - Cebu Lung Institute, Philippines)
- P8-116 The clinical efficacy and safety of the second-line chemotherapy in extensive-disease small cell lung cancer patients with interstitial lung disease**
Ryohiko Ozaki
(Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Japan)
- P8-117 Safety and efficacy of immune checkpoint inhibitors rechallenge in patients with advanced non-small cell lung cancer**
Shiting Xu
(Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Japan)
- P8-118 Adenoid cystic carcinoma of the trachea in a patient managed as pulmonary tuberculosis: a case report.**
Paolo Hilado
(Chinese General Hospital and Medical Center, Philippines)
- P8-119 An autopsy case of immune-related severe colitis consequent to long-term treatment with nivolumab in a patient with non-small cell lung cancer**
Masashi Fujikawa
(Department of Respiratory Medicine, Graduate School of Medical Sciences, Nagoya City University, Japan)
- P8-120 Therapeutic efficacy of osimertinib following afatinib for the rare EGFR mutation exon19 delL747_P753insS: A case report**
Taku Noumi
(Department of Respiratory Medicine, Okayama University Hospital, Japan)
- P8-121 Prognostic Effect of Cachexia in Non-Small Lung Cancer Patients Receiving Immune Checkpoint inhibitors**
Norikazu Matsuo
(Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Japan)
- P8-122 Comparison of the Oncomine Dx Target Test and the Cobas EGFR mutation detection kit v 2 for detecting gene mutations of epidermal growth factor receptor among patients with non-small cell lung cancer: the experience of a single institution**
Chihiro Yamada
(Yokohama city university hospital, Japan)
- P8-123 Case Series of Bronchial Adenomas Treated with Cryoablation Therapy**
Noel Gomez
(LCP, Philippines)
- P8-124 Pierre-Marie-Bamberger Syndrome in a Patient with a Malignant Pleural Solitary Fibrous Tumor: a Rare Case with Review of Literature**
Arriane Evangelista
(Convention Attendee, Philippines)

- P8-125 Proposing clinical prognostic model for 1st line immunotherapy in advanced non-small-cell lung cancer**
Taichi Miyawaki
(Division of Thoracic Oncology, Shizuoka Cancer Center, Japan)
- P8-126 High level of C-reactive protein as a predictive and prognostic factor in pre-immunotreated non-small cell lung cancer patients**
Ren Onodera
(Department of Internal Medicine, Division of Pulmonary Medicine, Iwate Medical University, Department of Pharmacy, Iwate Medical University Hospital, Japan)
- P8-127 A case of stage IV lung adenocarcinoma with long-term survival for over 18 years, finally found to be positive for EGFR gene mutations**
Ichiro Tsujino
(Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Japan)
- P8-128 Phase II trial of pembrolizumab in poor performance status NSCLC patients with PD-L1 \geq 50%: OLCSG 1801**
Shoichi Kuyama
(NHO Iwakuni Clinical Center, Japan)
- P8-129 Withdrawn**
- P8-130 Diffuse mediastinal edema caused by thoracic lymphoma; A rare cause for Superior Vena Cava narrowing**
Sugeesha Wickramasinghe
(Senior Registrar in Respiratory Medicine, National Hospital for Respiratory Diseases, Welisara, Sri Lanka, Sri Lanka)
- P8-131 Lung cancer that recurred as carcinoma en cuirasse**
Shohei Nozu
(Ehime Prefectural Central Hospital, Japan)
- P8-132 The Role of Caspase-4 in the Progression of Lung Cancer.**
Yosuke Chiba
(Department of Respiratory Medicine, University of Occupational and Environmental Health, Japan)
- P8-133 Clinical course of the patients who survived more than five-years in patients with EGFR mutated or ALK rearranged advanced non-small cell lung cancer (NSCLC)**
Shoko Shimamura
(Department of Respiratory Medicine, Juntendo University, Graduate School of Medicine, Japan)
- P8-134 Bone Metastases in Malignant Pleural Mesothelioma**
Taichiro Otsuki
(Department of Respiratory Medicine and Hematology Hyogo College of Medicine, Japan)
- P8-135 Typical bronchial carcinoid tumor: A case report**
Krizelle Acibal
(Lung Center of the Philippines, Philippines)
- P8-136 Nivolumab for malignant mesothelioma: a real-world experience**
Maiko Niki
(Department of Thoracic Oncology, Department of Respiratory Medicine and Hematology, Hyogo College of Medicine, Japan)
- P8-137 Association of immune-related adverse events with therapeutic response to Nivolumab in patients with malignant pleural mesothelioma**
Hiroto Yoneda
(Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Japan)
- P8-138 A case of successful treatment with dabrafenib and trametinib combination therapy in a patient with recurrent BRAFV600E- mutant non-small-cell lung cancer coexisting radiation pneumonitis**
Eriko Hamada
(Department of Respiratory Medicine, Nara Medical University, Japan)
- P8-139 A case of pulmonary mucoepidermoid carcinoma treated with carboplatin, nab-paclitaxel, and pembrolizumab.**
Chie Mori
(Respiratory Center, Asahikawa Medical University, Japan)
- P8-140 Relationship Between Response and Survival Time with Immune Checkpoint Inhibitor Combination Chemotherapy in Advanced Non-small Cell Lung Cancer**
Masayuki Nomoto
(Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Japan)
- P8-141 Whole-brain Radiation Therapy for Intracranial Metastases as Initial or Late Treatment**
Hisato Hiranuma
(Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Japan)

- P8-142 A case of pleural mesothelioma with ascites which was well-controlled by GEM plus CPT-11 after the failure of nivolumab treatment.**
Akio Tada
(Hyogo College of Medicine, Department of Respiratory Medicine and Hematology, Japan)
- P8-143 Clinical impact of post-progression survival on overall survival in NSCLC patients with pre-existing interstitial lung disease**
Satoshi Igawa
(Department of Respiratory Medicine, Kitasato University School of Medicine, Japan)
- P8-144 Prognostic value of neutrophil-to-lymphocyte ratio in patients of malignant pleural mesothelioma treated with nivolumab.**
Mayuko Tokuda
(Department of Respiratory Medicine and Hematology, Hyogo College of Medicine, Japan)
- P8-145 Successful immune checkpoint inhibition in an EGFR-TKI-refractory lung cancer with EGFR mutation and transformation**
Takayuki Suetsugu
(Department of Pulmonary Medicine, Kagoshima University, Japan)
- P8-146 Comparison of Progression Free Survival and Overall Survival Between 1st and 2nd Generation Tyrosine Kinase Inhibitors as First Line Therapy for Non Small Cell Lung Cancer**
Suryanti Dwi Pratiwi
(Brawijaya University, Indonesia)
- P8-147 Incidence of thromboembolism in lung cancer patients treated with immune checkpoint inhibitors and chemotherapy**
Satoshi Endo
(Department of Respiratory Medicine, Tokyo Medical and Dental University, Japan)
- P8-148 A case of recurrent respiratory papillomatosis with malignant transformation in a young Filipino female presenting as multiple pulmonary nodules**
Jamie Lynn Co
(St. Luke's Medical Center, Philippines)
- P8-149 Lung volume reduction surgery with opportunistic bilateral upper lobe resections for primary synchronous lung cancers: a case report**
Yang Jian Ong
(Department of Respiratory Medicine, Sir Charles Gairdner Hospital, WA, Australia)
- P8-150 REAL WORLD STUDY OF AFATINIB AND ERLOTINIB AS FIRSTLINE THERAPY OF POSITIVE EGFR MUTATION JAVANESE LUNG ADENOCARCINOMA**
Brigitta Devi Anindita Hapsari
(Undergraduated student, Department of Pulmonology and Respiratory Medicine Medical Faculty of Sebelas Maret University/ Dr. Moewardi General Hospital Surakarta, Indonesia)
- P8-151 Impact of maintenance therapy following induction immunochemotherapy for untreated advanced non-small cell lung cancer patients**
Ryota Nakamura
(Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Japan)
- P8-152 EBUS and EUS-B in resource-limited settings: A single center experience from Nepal.**
Deebya Raj Mishra
(Department of Pulmonary, Critical Care and Sleep Medicine BP Koirala Institute of Health Sciences, Dharan, Nepal., Nepal)
- P8-153 Real-data analysis of the combination of an immune checkpoint inhibitor to platinum doublet chemotherapy for small cell lung cancer patients**
Sousuke Kubo
(Department of Pulmonology, Yokohama City University Graduate School of Medicine, Japan)
- P8-154 Pulmonary Epithelioid Hemangioendothelioma In Adult Young Man**
Artini Dewi Ida Ayu
(Pulmonology Dept of Udayana, Indonesia)
- P8-155 Budd-Chiari syndrome caused by a latent hepatic metastasis from a thymoma**
Tomoya Horiguchi
(Department of Respiratory Medicine, Fujita Health University School of Medicine, Japan)
- P8-156 A case of thymic cancer treated with chemotherapy of S-1**
Reiko Sakurai
(Division of Allergy and Respiratory Medicine, Integrative Center of Internal Medicine, Gunma University Hospital, Oncology Center, Gunma University Hospital, Japan)
- P8-157 Extraskkeletal Ewing sarcoma: a rare cause of primary mediastinal tumour in an elderly**
Haly Rozie Ahmad
(Hospital Tengku Ampuan Afzan, Malaysia)

- P8-158 A case of pulmonary sarcomatoid carcinoma successfully treated with carboplatin + paclitaxel + bevacizumab + atezolizumab**
Yuki Hirayama
(Division of Respiratory Medicine and Rheumatology, Department of Multidisciplinary Internal Medicine, Faculty of Medicine, Tottori University, Japan)
- P8-159 A rare presentation of respiratory failure with skin involvement in renal transplant recipient**
Muhammad Jawwad Nazmi
(SIUT hospital, Pakistan)
- P8-160 The steroids worked well on the Steven-Johnson syndrome caused by Osimertinib in a patient with EGFR mutation-positive (Exon 19 deletion) non-small cell lung cancer.**
Hiromi Murakami
(Yokohama Sakae Kyosai Hospital, Japan)
- P8-161 CURATIVE LOBECTOMY WITHOUT A PRE-OPERATIVE TISSUE DIAGNOSIS IN A TUBERCULOSIS ENDEMIC COUNTRY: A CASE REPORT AND DISCUSSION**
Aimie Razali
(National Heart Institute, Malaysia)
- P8-162 The Different in serum calcium levels between bone metastases and no bone metastases lung cancer patients at Dr. Mohammad Hoesin General Hospital in Palembang**
Natalie Duyen
(Pulmonology Division Departement of Internal Medicine Dr. Mohammad Hoesin General Hospital, Indonesia)
- P8-163 A case report of spontaneous regression of malignant pleural mesothelioma**
Jotaro Kiyota
(Department of Respiratory medicine and Hematology, Hyogo College of Medicine, Japan)
- P8-164 Paclitaxel inhibits EGFR-mutated PC9 cell proliferation via the induction of necroptosis and G1 phase arrest**
Md Mohiuddin
(Department of Respiratory Medicine, Kanazawa University, Japan)
- P8-165 Paclitaxel induced apoptosis in EGFR-mutated PC9 cells by inhibiting the c-Myc signaling pathway**
Md Mohiuddin
(Department of Respiratory Medicine, Kanazawa University, Japan)
- P8-166 A case of meningeal carcinomatosis due to small cell lung cancer triggered by cauda equina syndrome**
Ryosuke Ozoe
(Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Japan)
- P8-167 Sclerosing Thymoma: A rare subtype**
Anna Rossa Magda Cuerdo
(Perpetual Help Medical Center - Las Piñas, Philippines)
- P8-168 A case of MET mutation-positive lung adenocarcinoma in which immune checkpoint inhibitors appear to contribute to long-term survival**
Masahiko Okada
(Division of Pulmonary Medicine, Department of Medicine, Keio University, School of Medicine, Japan)
- P8-169 Comparison of the Efficacy of Gefitinib and Afatinib in Pulmonary Adenocarcinoma Therapy with Positive EGFR Mutations in Javanese Race.**
Harimurti Swastika Dewayani
(Undergraduated student, Departement of Pulmonology and Respiratory Medicine Medical Faculty of Sebelas Maret University/ Dr. Moewardi General Hospital Surakarta, Indonesia)
- P8-170 A patient with ALK translocation-positive lung adenocarcinoma in whom an EGFR mutation developed during the treatment with ALK inhibitors.**
Misaki Morishita
(Department of Respiratory Medicine and Hematology, and Department of Thoracic Oncology, Hyogo College of Medicine, Japan)
- P8-171 Misdiagnosis of Lung Cancer and Tuberculosis Exudative Pleurisy**
Diana Nur Asrini
(Faculty of Medicine, Universitas Andalas, Indonesia)
- P8-172 A retrospective study of the efficacy and safety of nivolumab plus ipilimumab combination therapy for advanced stage non-small cell lung cancer**
Naoki Terashi
(Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Japan, Japan)

- P8-173 The evaluation of the relationship between the plasma concentration and toxicities and effects using divided erlotinib for EGFR-Mutant NSCLC.**
Yasuhiro Umeyama
(Second Department of Internal Medicine, Nagasaki University Hospital, Japan)
- P8-174 Highly elevated serum levels of CA 19-9 in metastatic adenocarcinoma of the lung**
Boon Hau Ng
(RESPIRATORY UNIT, DEPARTMENT OF MEDICINE, PUSAT PERUBATAN UNIVERSITI KEBANGSAAN MALAYSIA, Malaysia)
- P8-175 A retrospective analysis on the lung cancer specimens for Oncomine Dx Target Test in Keio University Hospital**
Ayaka Saito
(Division of Pulmonary Medicine, Department of Medicine, Keio University, School of Medicine, Japan)
- P8-176 Synchronous double primary malignancies of the lung and colon presenting with superior vena cava syndrome and colonic obstruction**
Charlie Clarion
(Philippine College of Chest Physicians, Philippines)
- P8-177 CHEST WALL EWING'S SARCOMA - A DIAGNOSTIC AND THERAPEUTIC ADVENTURE**
MUNIZA BAI
(DEPARTMENT OF PULMONARY MEDICINE, JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH, India)
- P8-178 Immune-mediated thrombocytopenia induced with durvalumab after chemoradiotherapy in a non-small cell lung cancer patient: a case report**
Tomonori Makiguchi
(Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine, Japan)
- P8-179 The inhibitory effect of cisplatin on the growth of A549 cells, and its underlying mechanism**
Md Mohiuddin
(Department of Respiratory Medicine, Kanazawa University, Japan)
- P8-180 Growth inhibitory effects of chemotherapeutic drugs in EGFR-mutated PC9 cells during the COVID-19 pandemic**
Md Mohiuddin
(Department of Respiratory Medicine, Kanazawa University, Japan)
- P8-181 Comparison between Intrathoracic and Extra thoracic Malignant Pleural Effusion in Clinical Features**
Sabrina Ermayanti
(Faculty of Medicine, Universitas Andalas, Indonesia)
- P8-182 Response Evaluation Criteria In Solid Tumors (RECIST) in Adenocarcinoma Lung Patients who received EGFR-TKI and Chemotherapy in Adam Malik General Hospital Medan**
Muhammad Redha
(Department of Pulmonology and Respiratory Medicine, Adam Malik General Hospital -- Faculty of Medicine Universitas Sumatera Utara, Indonesia)
- P8-183 Giant cell lung carcinoma: a case report**
Kadek Sri Adi Putri
(Udayana University-Sanglah Hospital, Indonesia)
- P8-184 Clinical analysis of the course of two cases of small cell lung cancer that were difficult to perform bronchoscopy**
Ichiro Tsujino
(Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Japan)
- P8-185 Rare case of a Posterior Mediastinal Mass in a 43 year old, male from the PHILIPPINES**
Fel Angelie Colon
(West Visayas state university medical center, Philippines)
- P8-186 Squamous Cell Carcinoma Of Lung In Non-Smoker Women**
Bobby Hasibuan
(Faculty of Medicine, Universitas Andalas, Indonesia)
- P8-187 A case of lung adenocarcinoma with 4.5 years of sustained erlotinib response and reversion of EGFR mutation positiveness**
Yasuhito Nagata
(Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Japan)
- P8-188 The inhibitory effect of pemetrexed disodium heptahydrate on the growth of KRAS-dependent A549 cells**
Md Mohiuddin
(Department of Respiratory Medicine, Kanazawa University, Japan)

Poster Session 9

On-demand

- P9 Asthma**
- P9-1 Supersulfides are involved in the allergen-induced type2 airway inflammation through T cell receptor signaling**
Tadahisa Numakura
(Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Japan)
- P9-2 Potential mechanisms underlying association between depressive status and asthma**
Noriyuki Tashima
(Kyoto University, Japan)
- P9-3 A RAS inhibitor reduces allergic airway remodeling via regulating IL-33-derived type 2 innate lymphoid cells.**
Masahiko Azuma
(Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Japan)
- P9-4 Interim report of a multicenter prospective cohort study of patients with asthma (TNH-Azma) in Japan**
Maho Suzukawa
(National Hospital Organization Tokyo National Hospital, Japan)
- P9-5 Mepolizumab decreased the levels of serum galectin-10 and eosinophil cationic protein in asthma**
Konomi Kobayashi
(Division of Respiratory Medicine and Allergology, Department of Medicine, Teikyo University School of Medicine, Japan)
- P9-6 Establishment of a human severe asthma model using humanized mice**
Shiho Yamada
(Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Japan)
- P9-7 Angiotensin-converting enzyme 2 (ACE2) activator attenuates house dust mite-induced allergic inflammation in mice.**
Asami Fukuda
(Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Japan)
- P9-8 Association between non-contrast chest computed tomography attenuation of lower airway mucus plugs and clinical features in asthmatic patients**
Yusuke Hayashi
(Respiratory Disease Center, Japan)
- P9-9 Functional activation of human eosinophils by acetylcholine**
Yuri Takeshita
(Department of Medicine, Division of Respiratory Medicine and Allergology, Teikyo University School of Medicine, Japan)
- P9-10 A Clinical study of Bronchial Thermoplasty in the treatment of refractory asthma**
Yang Liu
(Shanghai Tenth People's Hospital, Tongji University, China (Mainland))
- P9-11 Japanese cedar pollen sublingual immunotherapy for asthma patients with Japanese cedar pollinosis provided stability of symptoms of asthma in the off-season**
Shoko Ueda
(Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Japan)
- P9-12 TLR7 agonist suppresses type 2 airway inflammation via IL-27-producing interstitial macrophages**
Shinichi Okuzumi
(Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Japan)
- P9-13 Steroid-resistant airway inflammation in mice induced by chitin.**
Tomohito Takeshige
(Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Japan)
- P9-14 Genetic liability for insomnia and asthma risk**
Fan Ge
(Guangzhou Medical University, China (Mainland))
- P9-15 Examination of the inflammatory pattern of the bronchi in asthma patients with cold airway hyperresponsiveness with controller anti-inflammatory therapy**
Juliya M. Perelman
(Far Eastern Scientific Center of Physiology and Pathology of Respiration, Russia)

- P9-16 High serum EDN levels may be a predictive biomarker for the responsiveness of benralizumab treatment**
Sekiko Uehara
(Department of Clinical Pharmacology & Genetics, School of Pharmaceutical Sciences, University of Shizuoka, Japan)
- P9-17 Patterns and determinants for longitudinal changes in spirometric parameters among Chinese schoolchildren with asthma**
Ting Fan Leung
(Department of Paediatrics, The Chinese University of Hong Kong, Hong Kong)
- P9-18 Effects of one-year of dupilumab treatment in patients with severe asthma**
Sumiko Abe
(Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Japan)
- P9-19 The usefulness of CT images in evaluating the effects of bronchial thermoplasty in patients with severe asthma**
Sumiko Abe
(Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Japan)
- P9-20 Respiratory rehabilitation protocol for post-COVID-19 patients with asthma**
Rostyslav Bubnov
(Clinical Hospital “Pheophania”, Kyiv, Ukraine, Ukraine)
- P9-21 Inhaled Corticosteroids for All Asthma**
Pee Hwee Pang
(Tan Tock Seng Hospital, Singapore)
- P9-22 Dynamics of asthma control and lung function in patients with stable persistent cold airway hyperresponsiveness**
Anna G. Prikhodko
(Far Eastern Scientific Center of Physiology and Pathology of Respiration, Russia)
- P9-23 Prevalence of SABA over-prescription and association with clinical outcomes for asthma management in primary care in the Asian cohort of SABINA III**
Hao-Chien Wang
(National Taiwan University Hospital, Taiwan, Taiwan)
- P9-24 Hydrogen sulfide in serum or sputum supernatant as a biomarker for cough reflex sensitivity in patients with asthma**
Kensuke Fukumitsu
(Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Japan)
- P9-25 Usefulness of comprehensive evaluation of spirometry and impulse oscillometry with airway reversibility in the diagnosis of cough variant asthma, bronchial asthma, and asthma-COPD Overlap**
Namiko Taniuchi
(Respiratory Care Clinic, Nippon Medical School, Japan)
- P9-26 Induction of asthma by sensitization to substances derived from periodontal disease bacteria**
Yusuke Kurosawa
(Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Japan)
- P9-27 Clinical feature and effectiveness of benralizumab therapy for severe asthma**
Tomoya Harada
(Division of Respiratory Medicine and Rheumatology, Faculty of Medicine, Tottori University, Japan)
- P9-28 A comparison of clinical characteristics, between severe asthmatics who continued omalizumab administration and those underwent switch to other biologic agents**
Hironobu Sunadome
(Kyoto University, Japan)
- P9-29 Bone mineral density can be one of the predictors of response to biologics in severe asthma**
Kazuyuki Chibana
(Department of Pulmonary Medicine and Clinical Immunology, Dokkyo University School of Medicine, Japan)
- P9-30 Increase in FEV1 after dupilumab treatment for refractory asthma is associated with post-treatment eosinophilia**
Toru Hamada
(Ehime Prefectural Central Hospital, Japan)
- P9-31 Dietary habits of adult asthmatics—Internet survey—**
Katsunori Masaki
(Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan, Japan)

- P9-32 Exertional hypoxemia, a potential contributor to activity limitation in patients with asthma**
Keita Murakawa
(Department of Respiratory Medicine and Infectious Disease, Graduate School of Medicine, Japan)
- P9-33 A study of severe asthma patients who continued omalizumab treatment for more than 3 years**
Ai Goto
(Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Japan)
- P9-34 Seasonal dynamics of cold airway hyperresponsiveness in asthma patients**
Juliy M. Perelman
(Far Eastern Scientific Center of Physiology and Pathology of Respiration, Russia)
- P9-35 Clinical features of patients with bronchial asthma refractory to multiple biological therapies.**
Ayami Kaneko
(Department of Pulmonology, Yokohama City University Graduate School of Medicine, Japan)
- P9-36 Aspergillus sensitization in Bronchial Asthma; A single centre study in Sri Lanka**
Kamani Jayasinghe
(Central Chest Clinic Colombo and National Hospital of Sri Lanka, Sri Lanka)
- P9-37 Baseline features and control status of Asian patients with mild asthma in the SYGMA 1 and 2 trials**
Lan Le Thi Tuyet
(University Medical Centre of Ho Chi Minh City, Viet Nam)
- P9-38 The time course of type 2 biomarkers in asthmatics treated with dupilumab**
Mami Rikimaru
(Department of Pulmonary Medicine, Fukushima Medical University School of Medicine, Japan)
- P9-39 Efficacy of Vitamin D Supplementation in Children with Asthma and Vitamin D Deficiency: a Systematic Review**
Ana Carolina Pachêco de Menezes Rios
(Bahiana School of Medicine and Public Health, Brazil)
- P9-40 Study of Dysfunctional Breathing in Patients with Bronchial Asthma in Japan**
Yusuke Kurosawa
(Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Japan)
- P9-41 Analysis of Benralizumab on humanized IL-33-mediated asthma model**
Shota Toyoshima
(Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Japan)
- P9-42 Impact of an asthma shared care service on hospital attendances and admissions**
Mamta Ruparel
(Department of Respiratory and Critical Care Medicine, Tan Tock Seng Hospital, Singapore)
- P9-43 Real-world Experience of Treatment for Severe Asthma with Biologics in Single Center**
Takashi Kumagai
(Tokyo Medical and Dental University, Japan)
- P9-44 One-year treatment with benralizumab in patients with severe asthma**
Yuuki Sandhu
(Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Japan)
- P9-45 Use of Smartphone Applications in Identification of Risk Factors of Asthma Attack: A Systematic Review**
Sohail Ahmad
(Faculty of Pharmacy, MAHSA University, Malaysia)
- P9-46 One-year follow-up of instruction in inhalation technique for well-controlled asthma patients**
Naotaka Noda
(Department of Respiratory Medicine, National Hospital Organization Omuta National Hospital, Japan)
- P9-47 Increased levels of MMP12 and its clinical significance in induced sputum in asthma patients**
Fengjia Chen
(The First Affiliated Hospital of Sun Yat-Sen University, China (Mainland))
- P9-48 Clinical Investigation of Serum IL-36 subfamily in Patients with Asthma**
Yuki Hoshino
(Department of Respiratory Medicine, Saitama Medical University, Japan)
- P9-49 Involvements of endotoxin in airway inflammation of asthma**
Kazuki Katayama
(Saitama Medical University, Japan)

- P9-50 Effect of TRPV2 rs7217735 polymorphism in the development of hypoosmotic airway hyperresponsiveness in asthma patients**
Olesya Kotova
(Far Eastern Scientific Center of Physiology and Pathology of Respiration, Russia)
- P9-51 Differences in viral etiology and impact of human rhinovirus C in exacerbations of adult asthma and chronic obstructive pulmonary disease**
Keiko Kan-o
(Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Japan)
- P9-52 Mouthpiece for pressurized metered-dose inhaler (pMDI) to assist in correct inhalation technique.**
Reiko Ito
(Department of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Japan)
- P9-53 Establishment of humanized IgE-mediated asthma model**
Shota Toyoshima
(Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Japan)
- P9-54 Association of longitudinal changes in quality of life with comorbidities and exacerbations in patients with severe asthma**
Machiko Mastsumoto-Sasaki
(Hokkaido University, Japan)
- P9-55 Inhaler techniques and confidence of use of inhalers**
Sarang Patil
(Assistant Professor, Maharashtra University of Health Sciences, India)
- P9-56 Frequency of biologics use for the treatment of severe asthma in six hospitals in Kanagawa, Japan: A retrospective multi-center retrospective analysis**
Masaki Yamamoto
(Respiratory Disease Centre, Yokohama City University Medical Centre, Japan)
- P9-57 A study of severe asthma patients who continued mepolizumab treatment for more than 3 years**
Takayasu Nishimaki
(Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Japan)
- P9-58 The effect of asthma education program of asthmatic patients**
Tumen-Ulzii Gankhuyag
(Department of Pulmonology and Allergology, Mongolian National University Medical Science, Mongolia)
- P9-59 A forced oscillation technique examination at the start of asthma treatment can be helpful in considering whether DPIs or pMDIs should be selected.**
Susumu Fukahori
(Nagasaki University Hospital, Japan)
- P9-60 Successful treatment with benralizumab for asthma with eosinophilic myocarditis**
Takatomo Hirouchi
(Division of Respiratory Medicine, Department of Internal Medicine, Toho University Ohashi Medical Center, Japan)
- P9-61 Resolvin E3 dampens asthmatic inflammation in a murine model**
Makiko Sato
(Department of Allergy and Respiratory Medicine, Gunma University, Japan)
- P9-62 Effectiveness of Benralizumab for severe eosinophilic asthma**
Muneyuki Sekiya
(Division of Respiratory Medicine, Department of Internal Medicine, Toho University Graduate School of Medicine, Japan)
- P9-63 Prevalence and clinical relevance of pertussis infection in adult patients with asthma**
Hirono Nishiyama
(Nagoya City University, Japan)
- P9-64 The Positioning of Measurements of Serum YKL-40 in patients with ACO.**
Chihiro Nakano
(Division of Respiratory Medicine, Department of Internal medicine Toho university Ohashi medical center, Japan)
- P9-65 Analysis of anti-inflammatory effects of Resolvin E3 and its deoxy derivatives**
Haruka Aoki-Saito
(Department of Respiratory Medicine, Gunma University Graduate School of Medicine, Japan)
- P9-66 Retrospective study on the current status and short-term effectiveness of single Inhaler triple therapy (SITT) for asthma or asthma and COPD overlap (ACO)**
Keima Ito
(Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Japan)

- P9-67 Adherence to Inhaled Corticosteroids in Working-age Patients with Asthma: A Non-Interventional Study with Secondary Use of Data**
Hajime Yoshisue
(Novartis Pharma K.K., Japan)
- P9-68 A trend in use of asthma medications and healthcare resource utilization in moderate-to-severe asthma patients in Japan: A non-interventional study with secondary use of data**
Hajime Yoshisue
(Novartis Pharma K.K., Japan)
- P9-69 Persistent airway inflammation and airflow limitation in patients with not well-controlled asthma even on ICS/LABA therapy**
Shuichiro Ohata
(The University of Yamaguchi, Japan)
- P9-70 The effect of inhalation instruction with wearing masks on therapeutic effect**
Mayu Aizawa
(Faculty of life science, Ritsumeikan university, Japan)
- P9-71 Reactivation of Asthma into Severe Uncontrolled Symptoms after COVID 19 Pneumonia: A Case Report**
Mary Bianca Doreen Ditching
(Philippine General Hospital, Philippines)
- P9-72 Development and Pilot Testing of Asma-Boleh: A Mobile Application to Identify the Risk Factors of Asthma Attack among Malaysian Adults**
Sohail Ahmad
(Faculty of Pharmacy, MAHSA University, Malaysia)
- P9-73 Effects of dupilumab for severe eosinophilic Asthma COPD overlap**
Hirotsugu Morita
(Division of Respiratory Medicine, Department of Internal Medicine, Toho University Ohashi Medical Center, Japan)
- P9-74 Analysis of blood plasma 1,2-diacyl phosphatidylcholine molecular species from obese-asthma patients**
Yulia Denisenko
(Vladivostok Branch of Far Eastern Scientific Center of Physiology and Pathology of Respiration—Institute of Medical Climatology and Rehabilitative Treatment, Russia)
- P9-75 Comparative Study Of The Effect Of Fine-Particle Size And Extrafine Particle Size Inhaled Corticosteroid In Reducing Airway Resistance In Asthmatic Patients**
Asyraf Ahmad
(Respiratory Unit, Department of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Malaysia, Malaysia)
- P9-76 FP/Salm maintenance plus SABA reliever versus Bud/Form MART regimen in the treatment of uncontrolled asthma in a Philippine government hospital setting: direct cost comparison**
Melvin Pasay
(GSK Philippines, Philippines)
- P9-77 The correlation of Childhood asthma and family history of atopy in Harum Melati Clinic, Pringsewu, Lampung, Indonesia.**
Retno Ariza Soeprihatini Soemarwoto
(Universitas Lampung, Indonesia)
- P9-78 Vitamin D binding protein (DBP) in Japanese patients with bronchial asthma.**
Kazuhiro Tada
(Department of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University Saitama Medical Center, Japan)
- P9-79 The relationship between the severity of obstructive sleep apnea and airway hyperreactivity in patients with asthma**
Akiko Sano
(Department of Respiratory medicine and Allergology, Kindai University, Japan)
- P9-80 Exposures to Cigarette Smoke and House Dust in relation to Child Asthma at Harum Melati Clinic, Pringsewu Regency, Lampung, Indonesia.**
Retno Ariza Soeprihatini Soemarwoto
(Universitas Lampung, Indonesia)
- P9-81 A case of mepolizumab-tolerant allergic bronchopulmonary aspergillosis successfully switching to benralizumab**
Chiyako Oshikata
(Department of Allergy and Respiriology, Hiratsuka City Hospital, Department of Pulmonology, Yokohama City University Graduate School of Medicine, Japan)
- P9-82 Combination biologic therapy for refractory asthma: A report of two cases.**
Masafumi Yamaguchi
(Division of Respiratory Medicine, Department of Medicine, Shiga University of Medical Science, Japan)

- P9-83 Assessing Peak Inspiratory Flow Rate of patients on Dry Powdered Inhalers using training kits and the In-Check Dial G16 inspiratory flow meter**
Amy KJ Teoh
(Tan Tock Seng Hospital, Singapore)
- P9-84 The prevalence of Obstructive Sleep Apnea in Japanese patients with asthma.**
Mina Yasuda
(Department of Respiratory Medicine, Iizuka Hospital, Japan)
- P9-85 The reaction of the pituitary-adrenal system to cold bronchoprovocation in asthma patients with subclinical hypothyroidism**
Anna G. Prikhodko
(Far Eastern Scientific Center of Physiology and Pathology of Respiration, Russia)
- P10-5 Euclidean and geodesic measurements of facial profiles in obstructive sleep apnea**
Shih-Wei Lin
(Chang Gung Memorial Hospital, Linkou, Taiwan, Taiwan)
- P10-6 Determinants of excessive daytime sleepiness in adults with Obstructive Sleep Apnea in Taiwan**
Yi-an Hsieh
(Center of Sleep Medicine, Taipei Veterans General Hospital, Taiwan)
- P10-7 A case of Platypnea-Orthodeoxia Syndrome with sleep apnea syndrome which improved following surgery for her atrial septal defect**
Mamiko Hoshi
(Nihon University School of Medicine Department of Internal Medicine Division of Respiratory Medicine, Japan)

Poster Session 10

On-demand

- P10 Respiratory Neurobiology and Sleep**
- P10-1 Chronic intermittent hypoxia can induce expression of senescence markers in the liver of C57BL / 6J mice**
Yina Wang
(Department of Geriatrics, The Second Xiangya Hospital of Central South University, China (Mainland))
- P10-2 Intermittent hypoxia resulted in defective phagocytosis of phagocytes and poorer sepsis outcomes in murine and in vitro study**
Yi-an Hsieh
(Center of Sleep Medicine, Taipei Veterans General Hospital, Taiwan)
- P10-3 Differences between subjective and objective sleep duration according to actual sleep duration and sleep disordered breathing: The Nagahama Study**
Naomi Takahashi
(Department of Respiratory Care and Sleep Control Medicine, Graduate School of Medicine, Kyoto University, Japan)
- P10-4 Clinical study about the safety of Orexin receptor antagonist Suvorexant for severe sleep apnea syndrome.**
Yuki Mieno
(Department of Respiratory Medicine, Fujita Health University, Japan)
- P10-8 Association between sleep disordered breathing and hemoglobin A1c across antidiabetic treatment; the Nagahama Study**
Takeshi Matsumoto
(Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Japan)
- P10-9 The role of long-term Continuous Positive Airway Pressure in the progression of Obstructive Sleep Apnea: A longitudinal cohort study**
Ai Sugiyama
(Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Japan)
- P10-10 Association between sleep-disordered breathing and chronic spontaneous urticaria**
Kisako Nagayama
(Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, Japan)
- P10-11 The effect of body mass index on polysomnographic parameters in adults with obstructive sleep apnea**
Yang Ji
(Division of Respiratory Medicine, University of Hong Kong-Shenzhen Hospital, China (Mainland))
- P10-12 Risk factors for poor sleep quality and excessive daytime sleepiness in late pregnancy: A preliminary analysis of a cross-sectional survey.**
Duminda Yasaratne
(Faculty of Medicine, University of Peradeniya, Sri Lanka)

- P10-13 CIH can induce liver macrophage M2 polarization**
Yina Wang
(Department of Geriatric, The Second Xiangya Hospital, CSU, China (Mainland))
- P10-14 Long term follow-up in pediatric OHS/OSA treated conservatively: survival tips beyond home ventilation**
Affida Ahmad
(Universiti Teknologi MARA, Malaysia)
- P10-15 The Importance of Polysomnography screening in Bariatric Surgery. Sheikh Khaliah Medical City experience.**
Yasser Alkassar
(Sheikh Khalifa Medical City, United Arab Emirates)
- P10-16 A novel mutation in SEPN 1 gene causing Rigid Spinal Muscular Dystrophy presenting as diaphragmatic dysfunction and respiratory failure in adulthood.**
Sasanka Wijayawardhana
(Senior Registrar in Respiratory Medicine, Sri Lanka)
- P10-17 Idiopathic central alveolar hypoventilation without respiratory failure that required differentiation from obstructive sleep apnea**
Atsushi Sasaki
(Department of Respiriology, Graduate School of Medicine, Chiba University, Japan)
- P10-18 Cohort study comparing adherence of fixed and auto-adjusting continuous positive airway pressure (CPAP) in obstructive sleep apnea (OSA) children**
Prakarn Tovichien
(Division of Pulmonology, Department of Pediatrics, Siriraj Hospital Mahidol University, Thailand)
- P10-19 OBSTRUCTIVE SLEEP APNOEA AND QUALITY OF SLEEP AMONG GENERAL PUBLIC IN KLANG, MALAYSIA**
Muhammad Qamar
(Department of Clinical Pharmacy, Faculty of Pharmacy, MAHSA University, Bandar Saujana Putra, Malaysia)
- P10-20 Sleep and the usage of smart devices among Sri Lankan doctors**
Harshana Bandara
(Senior Registrar in Respiratory Medicine, Welisara, Sri Lanka)
- P10-21 Factors associated with moderate to severe sleep disordered breathing among filipino school children**
Crestita Gorme
(Philippine Heart Center, Philippines)
- P10-22 The diagnostic role of portable respiratory monitor in heart failure patient with cheyne stoke respiration**
Pi-Hung Tung
(Department of Thoracic Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ROC, Taiwan)
- P10-23 Magnitude of sleep quality and factor associated among undergraduate medical students in Nepal; cross-sectional study**
Kiran Paudel
(Institute Of Medicine, Nepal)
- P10-24 Successful extubation in a phenobarbital overdose attempted suicide in a non-ideal set-up at the time of COVID 19 pandemic**
April Calleja
(East Avenue Medical Center, Philippines)

Poster Session 11

On-demand

P11 Critical Care Medicine

- P11-1 The therapeutic effects of lactoferrin on thioacetamide-induced liver fibrosis in rats**
Chih-Ching Yen
(China Medical University Hospital, Taiwan)
- P11-2 Clinical Profiles and Respiratory System Mechanics of Mechanically Ventilated Patients with COVID-19 versus Non-COVID-19-Associated ARDS**
Giselle Dianne Uy
(UST Hospital, Philippines)
- P11-3 The risk of suicide in critical illness patients-The Known, the Unknown, and the Unknowable**
Weisyun Hu
(China Medical University Hospital, Taiwan)
- P11-4 Delayed cardiovascular events and one-year mortality among intensive care unit (ICU) sepsis survivors**
Sharlene Ho
(Tan Tock Seng Hospital, Singapore)
- P11-5 Clinical Outcomes of Hypoxemic, COVID-19 Confirmed Patients on High-Flow Nasal Cannula (HFNC) Therapy in a Tertiary Government Hospital in Metro Manila, Philippines: A Retrospective Study**
Charry Mae Sta. Ana
(East Avenue Medical Center, Philippines)

- P11-6 Indices of endogenous intoxication in patients with COVID-19 associated pneumonia**
Alexey Kucher
(Amur State Medical Academy, Russia)
- P11-7 Issues related to ECMO management in critically ill patients with COVID-19: a Systematic Review and Meta-analysis**
Gustavo Vilas-Boas
(Bahiana School of Medicine and Public Health, Brazil)
- P11-8 Surviving covid: a case report on the first covid survivor after extracorporeal membrane oxygenation (ECMO) in the Philippines**
Marra Monique Cantela
(LCP, Philippines)
- P11-9 Vanishing lung syndrome mimicking spontaneous pneumothorax: A case report and literature review**
Luong Dinh Van
(Vietnam National Lung Hospital, Viet Nam)
- P11-10 Application of High-flow nasal oxygen (HFNC) for acute exacerbations of interstitial lung diseases. Experiences from National Lung Hospital, Vietnam.**
Luong Dinh Van
(Vietnam National Lung Hospital, Viet Nam)
- P11-11 Bilateral iliopsoas hematomas in a severe COVID-19 patient treated with unfractionated heparin: a case report and review of literature**
Yu Ito
(Department of Respiratory Medicine, Japanese Red Cross Medical Center, Japan)
- P11-12 A Tale of Ice and Fire: Dexmedetomidine-Induced Hyperthermia After Complex Coronary Artery Revascularization for Cardiogenic Shock**
Gwen Marcellana
(St. Luke's Medical Center Global City, Philippines)
- P11-13 Diffuse Pulmonary Hemorrhage, a Catastrophic Outcome of a 57-year-old Venezuelan, with COVID-19 Pneumonia, who developed multiple thrombosis and AMAN-Variant GBS**
Fidela Anne Salvador-Badilles
(St. Lukes Medical Center Global City, Philippines)
- P11-14 Blood Gas Analysis and Alveolar-Arterial Gradient as Predictor of Mortality Confirmed COVID-19 Patients Outcome in Tertiary Referral Hospital**
Bobby Anggara
(Departement of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Indonesia, Persahabatan Hospital, Indonesia)
- P11-15 Use of Intravenous immunoglobulin in Streptococcus Dysgalactiae associated Toxic Shock Syndrome**
Glenn Yong
(Tan Tock Seng Hospital, Singapore)
- P11-16 Intubation and artificial ventilation treatment for elderly patients with respiratory failure**
Kazuhisa Nakashima
(Department of Internal Medicine, Division of Medical Oncology & Respiratory Medicine, Shimane University Faculty of Medicine, Japan)
- P11-17 Outcomes of COVID19 Critical Care Patients in Indonesia Periphery**
Ferry Dwi Kurniawan
(Department of Pulmonology, dr. Zainoel Abidin Hospital, Universitas Syiah Kuala, Indonesia)

Poster Session 12

On-demand

P12 Bronchoscopy and Interventional Techniques

- P12-1 Fixation rate of gold markers placed for stereotactic body radiotherapy in each bronchus**
Keisuke Imasaka
(Division of Respiratory Medicine, Toho University Graduate School of Medicine, Japan)
- P12-2 A comparison of radial endobronchial ultrasound (r-EBUS) guided cryobiopsy and forceps biopsies for lung nodules: An Australian perspective.**
Sarika Sundar
(BE (Hons 1), BMath, MBBS, Concord Repatriation General Hospital and St Vincent's Hospital, Australia)
- P12-3 Diagnostic efficacy of cryobiopsy for peripheral pulmonary lesions with ground-glass opacity: a propensity score-matched analysis**
Hideaki Furuse
(Department of Endoscopy, Respiratory Endoscopy Division, National Cancer Center Hospital, Japan)
- P12-4 Interventional pulmonology for elderly patients with malignant central airway obstruction**
Chia-Hung Chen
(China Medical University Hospital, Taiwan)

- P12-5 Correlation between bispectral index (BIS) and modified observer's assessment of alertness/sedation (MOAA/S) score in flexible bronchoscopy.**
Jun Yamada
(Kobe University graduate school of medicine, Japan)
- P12-6 Endobronchial and pleural cryobiopsy for pulmonary malignancy**
Kazuyoshi Imaizumi
(Department of Respiratory Medicine, Fujita Health University, Japan)
- P12-7 Preoperative chest CT localization under different positions with appropriate amount of air in the pleural space for the evaluation of bullae related to spontaneous pneumothorax**
Hua Zhang
(Rizhao Hospital of Traditional Chinese Medicine, China (Mainland))
- P12-8 New style for bronchoscopy to prevent infection under COVID-19 pandemic**
Kazuhide Sato
(IAR, Nagoya Univ, Japan)
- P12-9 Predictive risk factors for pneumothorax after transbronchial biopsy using endobronchial ultrasonography with a guide sheath**
Yusuke Gotoh
(Department of Respiratory Medicine, Fujita Health University School of Medicine, Japan)
- P12-10 Additional use of propofol during flexible bronchoscopy in difficult-to-sedate cases with transcutaneous blood gas monitoring, anesthetized with midazolam and fentanyl: A retrospective study**
Nana Yazawa
(Department of Pulmonary Medicine and Clinical Immunology, Dokkyo University School of Medicine, Japan)
- P12-11 Routine gargling before bronchoscopy for prevention of post-bronchoscopic infection**
Tomohide Souma
(Department of Respiratory Medicine, Fujita Health University School of Medicine, Japan)
- P12-12 Bronchoscopy with N-acetylcysteine lavage in a COVID-19 patient with massive grade IV inhalation injury**
Karen Anne Claridad
(Philippine General Hospital, Philippines)
- P12-13 Characteristics of visible leak under medical thoracoscopy in persistent pneumothorax**
Hua Zhang
(Rizhao Hospital of Traditional Chinese Medicine, China (Mainland))
- P12-14 The accuracy of rapid on-site cytologic evaluation (ROSE) in bronchoscopy**
Yuki Ko
(Iizuka Hospital, Japan)
- P12-15 Comparison of EBUS/TBNA Specimen Adequacy of Tissue-Clot-Coagulum Cell Block versus Normal Saline Rinse Cytology**
Sze Shyang Kho
(Division of Respiratory Medicine, Department of Internal Medicine, Sarawak General Hospital, Malaysia)
- P12-16 The feasibility and safety of transbronchial cryobiopsy using a 2-scope technique in peripheral pulmonary lesions.**
Toshiyuki Nakai
(Department of Respiratory Medicine, Graduate school of Medicine, Osaka City University, Japan)
- P12-17 Clinical significance of bronchoscopy in elderly patients with lung cancer**
Shingo Maeda
(FUJITA HEALTH UNIVERSITY HOSPITAL, Japan)
- P12-18 Comparison between Manual vs Other Techniques of Pleural Fluid Evacuation during Thoracentesis: A Meta-Analysis**
Martin Kristoffer Ogbac
(Perpetual Help Medical Center - Las Piñas, Philippines)
- P12-19 Cryptogenic hemoptysis in smokers: clinical characteristics, CT, angiography and prognosis after bronchial artery embolization using coils in 60 patients.**
Takashi Nishihara
(Hemoptysis and Pulmonary-Circulation Center, Eishinkai Kishiwada Rehabilitation Hospital, Japan)
- P12-20 A prospective observational study on the tolerability of nasal bronchoscopy with surgical mask for aerosol control**
Yusuke Usui
(Division of Respiratory Medicine, Department of Internal Medicine, Toho University Graduate School of Medicine, Japan)
- P12-21 The recommended image features of peripheral lung parenchymal targets for diagnosis by CT-guided needle biopsy**
Manabu Tajima
(Division of Respiratory Medicine, Juntendo University Faculty of Medicine & Graduate School of Medicine, Japan)

- P12-22 Three-Dimensional Printing of Reconstructed Airway Model for Complex Post Tuberculous Tracheobronchial Stenosis**
Sze Shyang Kho
(Pulmonology Unit, Serdang Hospital, Ministry of Health Malaysia, Selangor, Malaysia, Malaysia)
- P12-23 Bronchial artery embolization in patients with hemoptysis: self-assessed patients satisfaction with treatment, efficacy, safety, and quality of life**
Naoki Omachi
(Eishinkai Kishiwada Rehabilitation Hospital Hemoptysis and Pulmonary-Circulation Center, Japan)
- P12-24 Tracheo- bronchial stenosis- Different clinical presentations and individualised treatment approach.**
Kaumudi Devi
(3rd year DNB resident, Department of pulmonology, Ruby hall clinic, India)
- P12-25 Optimal midazolam dose for bronchoscopy in elderly patients based on changes in respiratory parameters**
Naotaka Noda
(Department of Respiratory Medicine, National Hospital Organization Omuta National Hospital, Japan)
- P12-26 Isolated mediastinal lymphadenopathy - a great deception**
Kaumudi Devi
(3rd Year DNB resident, Department of Pulmonary medicine, Ruby hall clinic, India)
- P12-27 Bronchoscopy under non-invasive ventilation therapy**
Nobuki Nanki
(Department of Respiratory Medicine, Sanuki Municipal Hospital, Japan)
- P12-28 Bronchiolitis obliterans after bone marrow transplantation diagnosed by ultrathin bronchoscopy: A case report**
Masayuki Sato
(Third Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Japan)
- P12-29 Diagnostic value and correlation between findings on pleuroscopy and histopathological diagnosis in patients with pleural effusion: a 3 years retrospective study**
Boon Hau Ng
(Respiratory Unit, Department of Medicine, Pusat Perubatan Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia., Malaysia)
- P12-30 Double Stenting in Bronchoesophageal Fistula: A Case Report**
Rocio Castillo-Larios
(Mayo Clinic Florida, Department of Pulmonary, Allergy, and Sleep Medicine, United States of America)
- P12-31 Macroscopical and pathological findings by thoracoscopy under local anesthesia in malignant pleural mesothelioma**
Hiroki Nakazawa
(Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Japan)
- P12-32 Cryo-Recanalization in a case of Recurrent Endobronchial Diffuse Large B-Cell Lymphoma**
John Edward Bucayan Cervales
(Lung Center of Philippines, Philippines)
- P12-33 Endobronchial carcinoid mimicking bronchial asthma**
Boon Hau Ng
(Respiratory Unit, Department of Medicine, Pusat Perubatan Universiti Kebangsaan Malaysia, Malaysia)
- P12-34 Broncholithiasis successfully removed using a cryo-probe under rigid bronchoscopy: a case report**
Moe Kato
(Department of Respiratory Medicine, Matsunami General Hospital, Japan)
- P12-35 Role Of Bronchoscopy In Centrally-Located Lung Tumor**
Candrawati Ni Wayan
(Faculty of medicine Universitas Udayana/Sanglah Hospital, Indonesia)
- P12-36 Bronchoscopic cryo-excision of a large chondroid hemartoma presented as right middle lobe collapse in a 63 yrs gentleman**
Rashid Md. Mamunur
(National Institute of Diseases of the Chest and Hospital, Bangladesh)
- P12-37 Tracheobronchopathia Osteochondroplastica associated with Lung adenocarcinoma: a rare in rare presentation**
Sneha Leo
(Jawaharlal Institute of Postgraduate Medical Educational and Research, India, India)
- P12-38 A Young Woman with Bilateral Primary Spontaneous Pneumothorax**
Made Nian Anggara Anggara
(Udayana University, Indonesia)

Poster Session 13

On-demand

P13 Paediatric Lung Disease

P13-1 Chest X-ray Findings of Coronavirus-19 Disease in Patients Age 0 to 18 Years Old Admitted at Chong Hua Hospital from March 2020 to February 2021

Neil Jose Montecillo
(Chong Hua Hospital, Philippines)

P13-2 The effect of vitamin D on the course of COVID-19 in children

Tatiana Luchnikova
(Amur State Medical Academy, Russia)

P13-4 Congenital cystic adenomatoid malformation (CCAM) of the lung in a teenager: a case report

Punchalee Kaenmuang
(Division of Respiratory and Respiratory Critical Care Medicine, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Thailand)

P13-5 PRIMARY SPONTANEOUS PNEUMOTHORAX IN CHILDREN: CAUSES OR NOT ?

Anh Tuan Tran
(Children's Hospital No1, HCMC, Viet Nam)

Poster Session 14

On-demand

P14 Respiratory Structure and Function

P14-1 Long-acting muscarinic antagonists enhance ciliary function in airway epithelium

Mineo Katsumata
(Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Japan)

P14-2 Sex differences in airway and lung sizes on CT in healthy non-smokers with normal spirometry

Satoru Terada
(Department of respiratory medicine, Graduate school of medicine, Kyoto university, Japan)

P14-3 Relationship between gait asymmetry and respiratory muscle strength in the stroke patients.

Yoshino Terui
(Akita University Graduate School of Health Sciences, Japan)

P14-4 Thoracic Kidney: A rare form of Renal Ectopia

Everly Joy Balino
(East Avenue Medical Center, Philippines)

P14-5 A method of analysis of pulmonary function by movement of the left and right lungs using a three dimensional depth sensor

Junko Izawa
(Komatsu University, Japan)

P14-6 Associations between extrapulmonary airway to lung size ratio and forced expiratory airflow in smokers with and without chronic obstructive pulmonary disease and healthy non-smokers.

Tomoki Maetani
(Department of Respiratory Medicine, Kyoto University, Graduate School of Medicine, Japan)

P14-7 Restrictive spirometry pattern and the risk of rapid kidney function decline: Analysis from the community-based prospective Ansan-Ansung cohort in Korea

Sang Hyuk Kim
(Samsung Medical Center, Korea)

P14-8 Intralobar pulmonary sequestration with significantly elevated CA 19-9 level: a case report

Kuan-Ming Su
(Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan, Taiwan)

P14-9 Lung Function Analysis of COVID-19 Survivors in dr. Zainoel Abidin Hospital Banda Aceh, Indonesia

Ferry Dwi Kurniawan
(Respiratory High Care Unit, dr. Zainoel Abidin Hospital, Syiah Kuala University, Indonesia)

P14-10 Sniff nasal inspiratory pressure in healthy laboratory staff

Nur Diyaningsih Amrun
(Respiratory Function Laboratory, Tan Tock Seng Hospital, Singapore)

P14-11 Impulse Oscillometry Test Quality in a Clinical Laboratory

Chu Ying Gan
(Respiratory Function Laboratory, Tan Tock Seng Hospital, Singapore)

P14-12 A Case Report of Tracheal Bronchus associated with Koch's Disease in a 7 month old female with Down Syndrome

Vivien Lorraine Duyongco
(Chong Hua Hospital Mandaue, Philippines)

P14-13 Correlation of airway hyperresponsiveness with peripheral blood eosinophilia by histamine challenge in young adult patients with chronic cough

Nikhil Sarangdhar

(Asst. Professor, K. J. Somaiya medical college and hospital, India)

P14-14 Preoperative Examination as Predictor of Postoperative Pulmonary Complication in Abdominal Surgery

Muhamad Wawan Kurniawan

(Undergraduated student, Departement of Pulmonology and Respiratory Medicine, Medical Faculty of Sebelas Maret University/ Dr. Moewardi General Hospital Surakarta, Indonesia)

P14-15 Pleural effusion secondary to Left Atrial Myxoma in a 36 year old Chinese Male

Alexander Joaquin Alcantara

(St. Lukes Medical Center Global City, Philippines)

Poster Session 15

On-demand

P15 Pulmonary Circulation

P15-1 Risk assessment in pulmonary hypertension due to interstitial lung disease

Kazuya Yoshikawa

(Department of Respiratory Medicine and Allergology, Kindai University Faculty of Medicine, Osaka-sayama, Japan)

P15-2 Activation of Cleaved Caspase-3 in Young Rats of Emphysema with Pulmonary Hypertension Induced by SU5416

Norihiko Goto

(First Department of Internal Medicine, Shinshu University School of Medicine, Japan)

P15-3 Potential amelioration of Pulmonary Hypertension in COPD by budesonide/glycopyrronium/formoterol via central NF κ B inflammatory signaling deactivation: in vivo mouse model

Ratoe Suraya

(Division of Respiratory Medicine, Kobe University Graduate School of Medicine, Japan)

P15-4 Pulmonary vasculopathy in pulmonary hypertension with interstitial lung disease: a morphometric study of autopsy cases.

Ayako Sugimoto

(Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Japan)

P15-5 Diagnosis of platypnea-orthodeoxia syndrome secondary to an intracardiac shunt following the development of organizing pneumonia: A case report

Hitomi Hirano

(National Hospital Organization Ibaraki Higashi National Hospital, Japan)

P15-6 Analysis of %FVC/%DLco ratio for pulmonary hypertension associated with interstitial lung disease

Kenichiro Atsumi

(Department of Pulmonary Medicine and Medical Oncology, Nippon Medical School Tama Nagayama Hospital, Japan)

P15-7 Bosentan has potential benefits in patients with exercise or mild-to-moderate pulmonary hypertension associated with COPD

Takeru Kashiwada

(Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Japan)

P15-8 Withdrawn

P15-9 A case report on pulmonary hypertension in pregnancy.

Kaumudi Devi

(3rd year DNB resident, Department of Pulmonology, Ruby Hall Clinic, India)

P15-10 A rare case of May-Thurner Syndrome presenting as venous thromboembolism: a Case Report

Celene Marie Rey

(Chinese General Hospital, Philippines)

P15-11 Prognostic analysis of pulmonary hypertension with parenchymal lung lesion—Comparison of connective tissue disease and chronic lung disease—

Yoshifumi Suzuki

(Juntendo University, Japan)

P15-12 Pulmonary artery pseudoaneurysms: 3 cases examined and treated at the National Lung Hospital, Hanoi, Vietnam

Luong Hoang

(Radiology department of National Lung Hospital, Hanoi, Viet Nam)

P15-13 Pulmonary arteriovenous malformations presenting as a fatal hemorrhage: a case report

Punchalee Kaenmuang

(Division of Respiratory and Respiratory Critical Care Medicine, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Thailand)

P15-14 Management of Pulmonary Embolism in an Australian Tertiary Centre.

Johnny Hong Chun Siu
(Department of Respiratory and Sleep Medicine St. George Hospital, Sydney, Australia, South Eastern Sydney Clinical School, University of New South Wales, Australia)

P15-15 A rare case of Bilateral Chylothorax and Chylous Ascites in Diffuse Large Beta Cell Non-Hodgkin's Lymphoma

Everly Joy Balino
(East Avenue Medical Center, Philippines)

P15-16 Modified dose thrombolysis in a covid-19 related massive acute pulmonary embolism: A case report

Maria Yña Eluisia Pereyra-Borlongan
(East Avenue Medical Center, Philippines)

P15-17 Proportion of pulmonary hypertension in drug resistant tuberculosis patient

Adityo Wibowo
(Departement of Pulmonology and Respiratory Medicine, Medical Faculty of Universitas Indonesia, Per Sahabatan National Respiratory Referral Hospital, Jakarta, Indonesia, Indonesia)

P16-4 Therapeutic effect of oligonucleotide therapeutics PK-7010 in mouse model of bleomycin-induced lung fibrosis.

Kojin Murakami
(Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Japan)

P16-5 Evaluation of pulmonary artery vasculopathy in patients with IPF

Osamu Nishiyama
(Department of Respiratory Medicine and Allergology, Kindai University Faculty of Medicine, Japan)

P16-6 Analysis of anti-fibrotic potential of JAK inhibitors in bleomycin-induced pulmonary fibrosis model

Hiroshi Kawano
(Department of Respiratory Medicine & Rheumatology, Department of Community Medicine for Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Japan)

P16-7 Radiological unilateral pleuroparenchymal fibroelastosis as a notable late complication after lung cancer surgery

Akimasa Sekine
(Kanagawa Cardiovascular and Respiratory Center, Japan)

P16-8 Cut-off points for step count to predict all-cause mortality in patients with idiopathic pulmonary fibrosis

Kazuya Shingai
(Department of Rehabilitation, Inoue Hospital, Department of Physical Therapy Science, Nagasaki University Graduate School of Biomedical Sciences, Japan)

P16-9 Gremlin-1 for the differential diagnosis of idiopathic pulmonary fibrosis versus other interstitial lung diseases

Yoichiro Aoshima
(Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Japan)

P16-10 Usefulness of plasma and urine lysophospholipids-producing enzymes as a prognostic marker for sarcoidosis

Koji Murakami
(Department of respiratory medicine, Tohoku University Graduate School of medicine, Japan)

P16-11 Atypical radiologic computed tomography appearances of the chest in patients with lymphangiomyomatosis

Yasuhito Sekimoto
(Divisions of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Japan)

Poster Session 16

On-demand

P16 Interstitial Lung Disease**P16-1 Verifying performance of the deep learning algorism to detect chronic fibrosing interstitial lung diseases on chest radiograph: assessment of detectability in each disease type**

Hiroataka Nishikiori
(Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, Japan)

P16-2 Development and assessment of the efficacy and safety of human lung-targeting liposomal methylprednisolone crosslinked with nanobody

Xian He
(Department of Respiratory Medicine, Shanghai Pulmonary Hospital, Tongji University, School of Medicine, China (Mainland))

P16-3 The roles of Angiopoietin-like 4 in lung fibrosis

Minako Saito
(Department of Respiratory Medicine, The University of Tokyo, Japan)

- P16-12 Key Findings of the Fukuoka Tobacco-Related Lung Disease (FOLD) Registry Study in Japan**
Daisuke Eto
(Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, Japan)
- P16-13 Bronchial epithelial cell-derived extracellular vesicles attenuate pulmonary fibrosis targeting TGF- β -WNT crosstalk**
Tsukasa Kadota
(Division of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Japan)
- P16-14 Iron-dependent mitochondrial dysfunction contributes to the pathogenesis of pulmonary fibrosis**
Kenji Mizumura
(Division of Respiratory Medicine, Nihon University School of Medicine, Japan)
- P16-15 Predictive factors for relapse in corticosteroid-treated patients with chronic eosinophilic pneumonia**
Naoko Takeuchi
(Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, Japan)
- P16-16 The role of statins on the risk of the cancer among the interstitial lung diseases and pulmonary fibrosis: A time-dependent in propensity-matched general population study focus on the immunologic cancer**
Jun-Jun Yeh
(Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi, Taiwan, Taiwan)
- P16-17 Clinical characteristics of drug-induced interstitial pneumonia in Japan**
Atsuhito Ushiki
(First Department of Internal Medicine, Shinshu University School of Medicine, Japan)
- P16-18 Role of IGF-1 in idiopathic pulmonary fibrosis: Analysis of patient lung specimens**
Tomoko Nishimura
(Department of Immunology, Nara Medical University, Japan)
- P16-19 Efficacy and safety of tacrolimus for fibrotic hypersensitivity pneumonitis.**
Kazuaki Sato
(Tokyo Medical Dental University, Japan)
- P16-20 Database Analysis of Hypersensitivity Pneumonitis in Japan**
Shohei Yamashita
(Tokyo medical and dental university, Japan)
- P16-21 Clinical course and outcomes of acute exacerbation of fibrosing interstitial lung disease; A multicenter retrospective cohort study**
Katsuyuki Furuta
(Wakayama Medical University, Japan)
- P16-22 Clinical characteristics in patients with asymmetric fibrotic hypersensitivity pneumonitis**
Tsukasa Okamoto
(Tokyo Medical and Dental University, Japan)
- P16-23 Polo-like kinase inhibitors identified by computational repositioning attenuates bleomycin-induced pulmonary fibrosis in mice**
Takeshi Imakura
(Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan, Japan)
- P16-24 Clinical Impact of Sarcopenia on Chemotherapy-triggered Exacerbation of Interstitial Lung Disease in Patients with Non-small Cell Lung Cancer**
Ryota Kikuchi
(Department of Respiratory Medicine, Tokyo Medical University Hospital, Japan)
- P16-25 Effects of Statins and steroids on stroke and coronary artery disease among patients with interstitial lung disease and pulmonary fibrosis: A general population study**
Jun-Jun Yeh
(Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi, Taiwan, Taiwan)
- P16-26 Assessment of diagnostic accuracy of serum hemoxygenase-1 measurement for acute exacerbation of interstitial lung disease**
Yu Hara
(Department of Pulmonology, Yokohama City University Graduate School of Medicine, Japan)
- P16-27 A Deep Learning Approach using Chest X-ray Data for Screening Drug-induced Interstitial Lung Disease.**
Kentaro Ito
(Matsusaka Municipal Hospital, Japan)
- P16-28 CD38+ HLA-DR- helper T lymphocytes are associated with immune checkpoint inhibitors-related interstitial pneumonia**
Tsukie Tsukuda
(Department of Respiratory Medicine and Allergology, Kochi Medical School, Kochi University, Japan)

- P16-29 The attempt to establish the disease prognosis prediction model using Charlson Comorbidity Index score in interstitial lung disease**
Kenichi Seki
(Department of Pulmonology, Yokohama City University Graduate School of Medicine, Japan)
- P16-30 Serum hemoxygenase-1 as the potential biomarker for acute exacerbation of fibrosing interstitial lung disease**
Yoichi Tagami
(Department of Pulmonology, Yokohama City University Graduate School of Medicine, Japan)
- P16-31 Pulmonary manifestation of anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder**
Atsuki Furube
(Department of Respiratory Medicine, The Jikei University Kashiwa Hospital, Chiba 277-8567, Japan., Japan)
- P16-32 Charlson Comorbidity Index score could not influence the duration and efficacy of antifibrotic treatment for idiopathic pulmonary fibrosis (real world cohort data in 131 patients)**
Ayako Aoki
(Department of Pulmonology, Yokohama City University Graduate School of Medicine, Japan)
- P16-33 Real world experience of the antifibrotic treatment for idiopathic pulmonary fibrosis (166 patients)**
Yu Hara
(Yokohama City University Graduate School of Medicine, Japan)
- P16-34 Clinical investigation of the relationship between interstitial lung disease and obstructive sleep apnea**
Yuki Iijima
(Tokyo Medical and Dental University, Japan)
- P16-35 Lung infiltration of immunoglobulin G1- and G4-positive cells is a prognostic marker for idiopathic interstitial pneumonias**
Masamichi Komatsu
(First Department of Internal Medicine, Shinshu University School of Medicine, Japan)
- P16-36 A Lck-specific inhibitor, A-770041, attenuates pulmonary fibrosis via the suppression of TGF- β production in regulatory T cells**
Kozo Kagawa
(Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Japan)
- P16-37 Effect of autophagy in human alveolar epithelial cells on pulmonary fibrosis**
Saki Nagoshi
(The University of Tokyo, Japan)
- P16-38 The phosphate binder attenuates microlith formation and cox-2 induction in pulmonary alveolar microlithiasis.**
Atsushi Saito
(Sapporo Medical University, Japan)
- P16-39 Identification of targetable kinases in idiopathic pulmonary fibrosis**
Hisao Higo
(Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan)
- P16-40 Survey of Nursing practice by Nurses Specializing in Respiratory Care for Japanese Idiopathic Pulmonary Fibrosis Patients—Comparison by Background—**
Yasuko Igai
(St. Luke's International University Graduate School of Nursing Science, Japan)
- P16-41 Post-marketing surveillance (all-case surveillance) of nintedanib in Japanese patients with idiopathic pulmonary fibrosis (4th interim report)**
Sakae Homma
(Toho University, Japan)
- P16-42 Clinical characteristics of obstructive sleep apnea in Japanese idiopathic pulmonary fibrosis patients**
Mari Hikichi
(Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Japan)
- P16-43 Development of ILD-GAP scoring system using Charlson Comorbidity Index score in patients with interstitial lung diseases**
Hiroaki Fujii
(Department of Pulmonology, Yokohama City University Graduate School of Medicine, Japan)
- P16-44 Unbiased retrospective survey of 'Real-World Data' generated a 1,000-case new cohort of interstitial lung diseases**
Koji Sakamoto
(Nagoya University Graduate School of Medicine, Japan)
- P16-45 Efficacy of multidisciplinary discussion (MDD) with transbronchial lung cryobiopsy**
Shota Kitagawa
(Tokyo medical and dental university, Japan)

- P16-46 Sarcoid-like reaction in patients with malignant solid-tumor: long term clinical course and outcome**
Jin-Young Huh
(Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, Korea)
- P16-47 A Study of lymphocyte fraction in bronchoalveolar lavage fluid in interstitial lung disease**
Sonoko Harada
(Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Atopy (Allergy) Research Center, Juntendo University Graduate School of Medicine, Japan)
- P16-48 The Prognostic Marker of Polymyxin B-Immobilized Fiber Column-Direct Hemoperfusion in Patients who Developed Acute Exacerbation of Chronic Fibrosing Idiopathic Interstitial Pneumonia**
Shun Nakazawa
(Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Japan)
- P16-49 Analysis of lymphocyte fractions in bronchoalveolar lavage fluid in chronic eosinophilic pneumonia**
Sonoko Harada
(Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Atopy (Allergy) Research Center, Juntendo University Graduate School of Medicine, Japan)
- P16-50 Clinical features of pleuroparenchymal fibroelastosis: idiopathic versus secondary phenotype**
Kazuhiko Iwasaki
(Kanazawa University Hospital, Japan)
- P16-51 Lung sound analysis for Idiopathic Pulmonary Fibrosis patients using an electronic stethoscope**
Yasuomi Satake
(Department of Respiratory Medicine, Shizuoka City Shizuoka Hospital, Japan)
- P16-52 Clinical significance of Charlson comorbidity index as a prognostic parameter for patients with acute exacerbation of interstitial pneumonia**
Kota Murohashi
(Yokohama City University, Japan)
- P16-53 Effectiveness of antifibrotic treatment for acute exacerbation of idiopathic pulmonary fibrosis.**
Hiroshige Shimizu
(Department of Respiratory Medicine, Toho University School of Medicine (Omori), Tokyo, Japan, Japan)
- P16-54 Association between Efficacy of Antifibrotic Agents and Immunohistochemical Localization of Fibrotic Factors in Progressive Fibrosing Interstitial Lung Disease**
Yasuhiko Nakamura
(Department of Respiratory Medicine, Toho University Omori Medical Center, Japan)
- P16-55 Additional effects of macrolides on steroid pulse therapy in patients with acute exacerbation of interstitial lung disease**
Ryo Nagasawa
(Department of Pulmonology, Yokohama City University Graduate School of Medicine, Japan)
- P16-56 The effect of pulmonary macrophage transplantation on mice with bleomycin-induced pulmonary fibrosis**
Eiko Suzuki
(Department of Respirology, Graduate School of Medicine, Chiba University, Japan)
- P16-57 RANKL-dependent pulmonary fibrosis in the silicosis model mouse**
Yoshihiro Hasegawa
(Departments of Biochemistry and Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, Japan)
- P16-58 Low BMI is associated with poor prognosis in patients with IPF who were incidentally diagnosed**
Ryo Yamazaki
(Department of Respiratory Medicine and Allergology, Kindai University Faculty of Medicine, Japan)
- P16-59 Clinical significance of serum heart-type fatty acid-binding protein (H-FABP) in acute exacerbation of idiopathic interstitial pneumonias**
Takefumi Nikaido
(Fukushima medical University, Japan)
- P16-60 Post Covid-19 Organizing Pneumonia treated with Mycophenolate Mofetil**
Hui Xin Tan
(Ministry Of Health, Malaysia)

- P16-61 Development of improved method to identify and analyze lung fibrocytes with flow cytometry in a reporter mouse strain**
Nobuhito Naito
(Department of Respiratory Medicine & Rheumatology, Department of Community Medicine for Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Japan)
- P16-62 The prognostic factor of idiopathic interstitial pneumonias patients complicated with pneumothorax: a multicenter retrospective study**
Hangchen Ge
(Department of Respiratory Medicine, Juntendo University Hospital, Japan)
- P16-63 Efficacy of high- versus low-dose corticosteroid therapy in patients with acute exacerbation of idiopathic interstitial pneumonia: A nationwide observational study**
Nobuyasu Awano
(Department of Respiratory Medicine, Japanese Red Cross Medical Center, Japan)
- P16-64 Safety of immune checkpoint inhibitors in advanced non-small cell lung cancer patients with interstitial lung abnormalities or interstitial lung disease**
Haruka Namba
(Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Japan)
- P16-65 Relationship between size and morphology of alveolar macrophages in bronchoalveolar lavage fluid in sarcoidosis.**
Manabu Ishida
(Kyorin University of Medicine, Japan)
- P16-66 Differences in prognosis by etiology among patients with chronic fibrosing idiopathic interstitial pneumonias with acute exacerbation**
Naho Sakamoto
(Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Japan)
- P16-67 Kinetic changes of serum KL-6 levels predict disease progression in systemic sclerosis-associated interstitial lung disease**
Satoshi Watanabe
(Kanazawa University Hospital, Japan)
- P16-68 Clinical, radiological and pathological differences between humidifier lung and summer-type hypersensitivity pneumonitis**
Susumu Sakamoto
(Toho University Omori Medical Center, Japan)
- P16-69 Assessment of the effect of endothelin receptor antagonist in patients with less severe or severe pulmonary hypertension associated with Interstitial lung disease.**
Yoza Sato
(Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Japan)
- P16-70 Clinical value of 18F-FDG PET/CT for acute exacerbation of interstitial lung disease in patients with lung cancer and interstitial lung disease after lung resection**
Kimitaka Akaike
(Department of Respiratory Medicine, Kumamoto University Hospital, Faculty of Life Sciences, Kumamoto University, Japan)
- P16-71 Factors associated with pulmonary function decline in patients with rheumatoid arthritis-associated interstitial lung disease**
Takako Kawaguchi
(Department of Respiratory medicine, University of Occupational and Environmental Health, Japan, Japan)
- P16-72 Effects of nintedanib on forced vital capacity categorical changes and disease progression in Japanese patients with progressive fibrosing interstitial lung diseases: Subanalysis of INBUILD study**
Yasuhiko Nishioka
(Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Japan)
- P16-73 Prognostic significance of serum serological and radiological findings in idiopathic chronic fibrosing interstitial pneumonia**
Keigo Koda
(Department of Respiratory Medicine, Hamamatsu Rosai Hospital, Japan)
- P16-74 A retrospective study to evaluate the prevalence, aetiologies and types of interstitial lung disease (ILD) at University Malaya Medical Centre from 2010 to 2020**
Leng Cheng Sia
(Department of Medicine, Faculty of Medicine, University Malaya Medical Centre, Malaysia)
- P16-75 Traction bronchiectasis on conventional chest computed tomography is a prognostic factor for rheumatoid arthritis-related interstitial lung disease.**
Takuto Sueyasu
(Department of Respiratory Medicine, Iizuka Hospital, Japan)

- P16-76 Evaluation of exercise capacity in patients with interstitial lung disease by dynamic-ventilatory digital radiography**
Noriyuki Ohkura
(Kanazawa University, Japan)
- P16-77 Factors associated with Interstitial Lung Disease in patients with Rheumatoid Arthritis (RA-ILD): experience from a Rheumatology-Respiratory centre in Malaysia.**
Aisya Natasya Musa
(Faculty of Medicine, Universiti Teknologi MARA (UiTM), Malaysia)
- P16-78 Early tapering of corticosteroid in patients with acute exacerbation of idiopathic pulmonary fibrosis: retrospective analyses of multicenter cohort and administrative data.**
Keisuke Anan
(Department of Healthcare Epidemiology, Kyoto University, Graduate School of Medicine, Japan)
- P16-79 The tolerability and efficacy of long-term nintedanib treatment for idiopathic pulmonary fibrosis in the real-world**
Yumi Kuroda
(Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Japan)
- P16-80 Differential source of early phase discontinuation between pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis**
Yasuhiko Koga
(Department of Respiratory Medicine, Gunma University Graduate School of Medicine, Japan)
- P16-81 The Effects of Fluoroquinolones on the Risk of Cancer in Patients with Interstitial Disease and Pulmonary Fibrosis**
Jun-Jun Yeh
(Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi, Taiwan, Taiwan)
- P16-82 Health-related quality of life in patients with idiopathic pulmonary fibrosis treated with nintedanib**
Hiromi Tomioka
(Kobe City Medical Center West Hospital, Japan)
- P16-83 HRCT scoring focused on ground-glass opacity, perilobular opacity, airspace consolidation, and interlobular septal thickening is useful for interstitial lung disease accompanied by anti-MDA5 antibody-positive dermatomyositis**
Yoshihiro Funaki
(Division of Respiratory Medicine and Rheumatology, Department of Multidisciplinary Internal Medicine, Faculty of Medicine, Tottori University, Japan)
- P16-84 The Relationship between the Treatment Dose and Survival of Patients with Interstitial Pneumonia Treated with Pirfenidone**
Yuri Takeshita
(Division of Respiratory Medicine and Allergology, Department of Medicine, Teikyo University School of Medicine, Japan)
- P16-85 Differences in the therapeutic effects of corticosteroid and immunosuppressants between the two subtypes of systemic sclerosis-associated interstitial lung disease**
Yuta Arai
(Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Japan)
- P16-86 Tolerability and safety of nintedanib for idiopathic pulmonary fibrosis and progressive fibrosing interstitial lung diseases**
Soichi Maruyama
(Tokyo Medical and Dental University, Japan)
- P16-87 Cryptogenic Organizing Pneumonia: Real-world Experience of Treatment with Corticosteroid**
Kouki Hata
(Tokyo Medical and Dental University, Japan)
- P16-88 Real world multicenter prospective study of combination therapy of anti-fibrotic agents in idiopathic pulmonary fibrosis (J-AVENGERS): an interim analysis**
Minoru Inomata
(Department of Respiratory Medicine, Japanese Red Cross Medical Center, Japan)
- P16-89 Comparison of clinical features between the high and low serum KL-6 patients with acute exacerbation of interstitial lung diseases**
Yoichi Tagami
(Department of Pulmonology, Yokohama City University Graduate School of Medicine, Japan)
- P16-90 Clinical comparison of patients with acute exacerbation of idiopathic interstitial pneumonias and secondary interstitial pneumonias**
Yuki Kata
(Yamato Municipal Hospital, Japan)
- P16-91 Idiopathic pulmonary fibrosis patients having refractory cough have bronchiectasis and airway architectural distortion: A single center retrospective study**
Kenta Yamamura
(Keiju Medical Center, Japan)

- P16-92 The CT extent of honeycomb cannot predict the treatment outcome of the patients with acute exacerbation of interstitial lung disease.**
Yurika Nishikawa
(Yokohama City University, Japan)
- P16-93 Preliminary analysis of serum risk factors during an acute exacerbation of chronic fibrosing interstitial pneumonia: A multi-institutional prospective study**
Takashi Akimoto
(Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Japan)
- P16-94 Characteristics of Connective Tissue Diseases Associated Interstitial Lung Diseases - A Single Centre Study in Sri Lanka**
Prasranjanie Jayasinghe
(National Hospital of Sri Lanka and Central Chest Clinic Colombo, Sri Lanka)
- P16-95 High incidence of MPO-ANCA positive interstitial pneumonia during the COVID-19 pandemic**
Yuki Sato
(Department of Pulmonary Medicine, Fukushima Medical University School of Medicine, Japan)
- P16-96 Efficacy and safety of combination therapy of antifibrotic agents in patients with idiopathic pulmonary fibrosis**
Kazushi Fujimoto
(Department of Respiratory Medicine, Japanese Red Cross Medical Center, Japan)
- P16-97 Secondary organizing pneumonia following COVID-19 infection**
Nik Nuratiqah Nik Abeed
(Respiratory Unit, Department of Medicine, Pusat Perubatan Universiti Kebangsaan Malaysia, Malaysia)
- P16-98 Investigation of predictive biomarker in patients with idiopathic pulmonary fibrosis treated with nintedanib**
Yasuhiko Koga
(Department of Respiratory Medicine, Gunma University Graduate School of Medicine, Japan)
- P16-99 Diffuse pulmonary ossification diagnosed pathologically: a four case series**
Yuichi Nagata
(Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Japan)
- P16-100 A rare case of Vertebral Sarcoidosis**
Lakmini Dassanayake
(Senior Registrar in Respiratory Medicine, Sri Lanka)
- P16-101 Pulmonary Actinomycosis: An Opportunistic Infection In Pulmonary Alveolar Proteinosis**
Sze Shyang Kho
(Department of Pulmonology, Serdang Hospital, Malaysia)
- P16-102 Five Cases of Interstitial Lung Disease with Organizing Pneumonia Pattern That Appeared during Treatment of Ulcerative Colitis**
Tadahiro Kuribayashi
(Department of Allergy and Respiratory Medicine, Okayama University Hospital, Japan)
- P16-103 Case Series Of Cryptogenic Organising Pneumonia Masquerading as Tuberculosis (TB) in a TB Endemic Area**
Sai Banu Selvarajah
(National University of Malaysia, Malaysia)
- P16-104 A case of IgG4-related lung disease diagnosed during a routine medical checkup**
Taisuke Kazuyori
(Department of Respiratory Medicine, Machida Municipal Hospital, Tokyo, Japan, Japan)
- P16-105 A case of pulmonary amyloidosis associated with systemic lupus erythematosus**
Satoshi Furuya
(Yamanashi university, Japan)
- P16-106 A rare case of Dapsone induced eosinophilic pneumonia**
Lakmini Dassanayake
(Senior Registrar in Respiratory Medicine, Sri Lanka)
- P16-107 A case report of rare disease: Pulmonary alveolar microlithiasis**
Huy Le Ngoc
(Vietnam National Lung Hospital, Viet Nam)
- P16-108 When you lose the way, history leads It!**
Ramya Priya Anbalagan
(Jawaharlal Institute of Postgraduate Medical Education and Research, India)
- P16-109 Vaping induced non-specific interstitial pneumonia - A rarely described entity**
Sugeesha Wickramasinghe
(Senior Clinical Fellow in Respiratory Medicine, Chorley and South Ribble Hospital, United Kingdom, United Kingdom)
- P16-110 The co-relation between exercise capacity and pulmonary hypertension in different types of interstitial lung diseases in a tertiary care center in India.**
Kaumudi Devi
(3RD YEAR DNB RESIDENT, RUBY HALL CLINIC, India)

- P16-111 Pneumothorax with rapid progression of respiratory failure secondary to pulmonary fibrosis in Hermansky-Pudlak syndrome: A case report**
Eri Hayakawa
(Division of Respiratory Medicine, Juntendo University Faculty of Medicine & Graduate School of Medicine, Japan)
- P16-112 A case of Pulmonary Langerhans Cell Histiocytosis (PLCH) presenting as massive hemoptysis.**
Chandana Dahanayake
(National Hospital For Respiratory Disease - Welisara, Srilanka, Sri Lanka)
- P16-113 ORGANIZING PNEUMONIA IN A POST PARTUM MOTHER; A RARE PRESENTATION OF SLE**
Menaka Thilakarathna
(National Hospital of Sri Lanka, Colombo, Sri Lanka)
- P16-114 Unexplained cachexia due to pleuropulmonary fibroelastosis of the lung - An old lady's agony**
Sugeesha Wickramasinghe
(Senior Registrar in Respiratory Medicine, Central Chest Clinic, Borella, Sri Lanka, Sri Lanka)
- P16-115 Sarcoidosis causing obliterative bronchiolitis -An unexplained entity**
Sugeesha Wickramasinghe
(Senior Clinical Fellow in Respiratory Medicine, Chorley and South Ribble Hospital, United Kingdom, United Kingdom)
- P16-116 Elusive Lung Adenocarcinoma in Systemic Sclerosis with Non Specific Interstitial Pneumonia**
Rokiah Fatmawati Abdul Kadir
(Universiti Teknologi MARA (UiTM), Malaysia)
- P16-117 A breathless man with a "Sandstorm" appearance on lung computed tomography.**
Vijayan Munusamy
(University Malaya Medical Center, Malaysia)
- P16-118 Vonoprazan-induced interstitial pneumonitis: A case report**
Yutaka Kozu
(Nihon University School of Medicine, Department of Internal Medicine, Division of Respiratory Medicine, Japan)
- P16-119 A case of interstitial pneumonia with lung lesion-preceding ANCA-related vasculitis improved after 7 years without treatment**
Yoshitaka Shintani
(Department of Respiratory Internal Medicine, Akabane Central General Hospital, Japan)
- P16-120 Pleuroparenchymal fibroelastosis, a rare idiopathic interstitial pneumonia with distinct clinical, radiological and pathological features**
Sanjeewa Malinda Hettiarachchi
(National Hospital for Respiratory Diseases, Welisara, Sri Lanka, Sri Lanka)
- P16-121 Chronic eosinophilic pneumonia as a cause for progressive fibrotic lung diseases - A rare entity**
Sugeesha Wickramasinghe
(Senior Clinical Fellow in Respiratory Medicine, Chorley and South Ribble Hospital, United Kingdom, United Kingdom)

Company Overview

■ Company Overview

Company Name Nippon Boehringer Ingelheim Co., Ltd.

Headquarters ThinkPark Tower 2-1-1 Shinagawa-ku,
Tokyo 141-6017 Japan
TEL : 03-6417-2200
FAX : 03-5435-2920

U R L <http://www.boehringer-ingelheim.jp>

Founded 30 June 1961

Capital JPY 7,200 million (as of January 2020)

Sales JPY 189,300 million (2019 - NHI base)(*)

Employees 1,618 (as of January 2020)

Line of business Research, development, import,
manufacturing and marketing of medicines

Representative Director, Chairman and President Yoshiaki Aono

Representative Director, President of Human Pharma Business Unit

Shashank Deshpande

(as of September 2020)

(*)Copyright © 2020 IQVIA. Created based on JPM MAT 2019 Reprinted with permission

Company Name Boehringer Ingelheim Seiyaku Co., Ltd.

Headquarters 5353-1 Oaza Higashine-Koh
Higashine, Yamagata 999-3701 Japan
TEL : 0237-42-1193
FAX : 0237-41-1013

U R L <http://www.boehringer-ingelheim.jp>

Founded February 1947

Capital JPY 2,127 million (as of January 2020)

Employees 159 (as of January 2020)

Line of business Manufacturing of pharmaceuticals

Representative Director, Chairman Yoshiaki Aono

Representative Director, President Seiji Yamasaki

(as of September 2020)

Company Name Boehringer Ingelheim Animal Health Japan Co., Ltd.

Headquarters ThinkPark Tower 2-1-1 Shinagawa-ku,
Tokyo 141-6017 Japan
TEL : 03-6417-2800
FAX : 03-5435-2950

U R L <http://www.boehringer-ingelheim.jp>

Founded 2 September 1997

Capital JPY 101 million (as of January 2020)

Sales JPY 21,800 million (2019 - wholesale shipments basis)(*)

Employees 120 (as of January 2020)

Line of business Manufacturing, marketing, research, import and
export of veterinary drugs, quasi-drugs for animals,
medical devices for animals, biological products etc

Representative Director, Chairman Yoshiaki Aono

Representative Director, President Michel Korenian

(as of September 2020)

(*)Fuji Keizai 2019, actual performance data

Company history

1885		Foundation of Boehringer Ingelheim
1905		Entry into the pharmaceutical business
1955		Entry into the Japanese market
1961	Jun	Foundation of “Nippon C.H. Boehringer Sohn”, the predecessor of Nippon Boehringer Ingelheim
1964	January	Establishment of the Erwin von Belz Prize to support the research activities of the Japan Medical Association, recognizing the growing friendship between Japan and Germany
1969	April	Establishment of the Japan Pharma Research Institute in Kawanishi City, Hyogo Prefecture
1982	March	Completion of the HQ building in Kawanishi City, Hyogo Prefecture Company name changes to Nippon Boehringer Ingelheim
1993	January	Start of in-house sales of human pharmaceuticals
2002	April	Start of operations at Boehringer Ingelheim Shionogi Vetmedica, a joint venture animal health company founded together with SHIONOGI Co., Ltd..
	May	Completion of a new plant in Yamagata.
2005	January	Start of operations at Boehringer Ingelheim Vetmedica Japan, a 100%-owned animal health subsidiary
2008	April	Nippon Boehringer Ingelheim consolidates HQ in Tokyo
	November	Opening of the Kobe Pharma Research Institute as a R&D site in Japan
2011	April	Start of the new group organization as the Boehringer Ingelheim Japan Group
2014	May	Entry into the field of oncology
2017	January	Closing of the business swap with Sanofi to exchange of Sanofi’s animal health business (Merial) and Boehringer Ingelheim’s consumer healthcare (CHC) business
2018	January	Integration of animal health companies of Boehringer Ingelheim in Japan into one legal entity and started its business operation as Boehringer Ingelheim Animal Health Japan Co., Ltd.
2020	January	To optimize the structure of group companies in Japan, Boehringer Ingelheim Japan Co., Ltd. and human pharmaceuticals business Nippon Boehringer Ingelheim Co., Ltd. merge, with the continuing company named Nippon Boehringer Ingelheim Co., Ltd.



Founder
Albert Boehringer



History of the company logo

The logo used by Boehringer Ingelheim today is a stylised depiction of the central section of the imperial palace of Charlemagne. Previously, the emblem was based on a plan of the palace produced in the 16th century. The town of Ingelheim is famous for its association with Charlemagne, King of Franks, who stayed in the town in the late 8th century.



Past company logo





Human monoclonal antibody directed against
the human interleukin IL-4/13 receptor

Listed in the NHI Price List

DUPIXENT[®] S.C.
Dupilumab (genetical recombination) 300 mg Injection Pen
Biological product, powerful drug, prescription-only drug Syringe
(Caution - To be used as prescribed by your physician, etc.)

Please refer to the package insert for indications, dosage and administration, and precautions including warnings and contraindications, etc.

Marketing Authorization Holder : **Sanofi K.K.**

3-20-2, Nishi Shinjuku, Shinjuku-ku, Tokyo 163-1488, Japan

SANOFI GENZYME 

Novartis Pharma K.K.



新しい発想で医療に貢献します

ノバルティスのミッションは、より充実した、
すこやかな毎日のために、新しい発想で医療に貢献することです。
イノベーションを推進することで、
治療法が確立されていない疾患にも積極的に取り組み、
新薬をより多くの患者さんにお届けします。

 **NOVARTIS**

ノバルティス ファーマ株式会社

<http://www.novartis.co.jp/>



Personalize My Healthcare, Please.

The same disease
affects each person differently.
This is true of treatments as well.
Shouldn't the number of treatments
equal the number of patients?

Personalized Healthcare Based on Genetic Information

INNOVATION BEYOND IMAGINATION

Innovation all for the patients



CHUGAI PHARMACEUTICAL CO., LTD.



Roche Group

患者さんのQuality of Lifeの
向上が私たちの理念です。

健保適用

TEIJIN

● 在宅酸素療法



酸素濃縮装置
(テレメトリー式パルスオキシメータ受信機)

ハイサンソⁱ

販売名:ハイサンソⁱ
認証番号:230ADBZX00107000

● 在宅酸素療法



酸素濃縮装置
(呼吸同調式レギュレータ)

ハイサンソ ポータブル^αII

販売名:ハイサンソポータブル^αII
認証番号:227ADBZX00202000

● NPPV療法



汎用人工呼吸器
(二相式気道陽圧ユニット)

NIPネーザル[®] V-E(タイプ名)

販売名:NIPネーザルV
承認番号:22300BZX00433000

● ハイフローセラピー



加熱式加湿器

F&P AIRVO[™] 2

F&P myAIRVO[™] 2

販売名:フロージェネレーターAirvo
フロージェネレーターmyAirvo
承認番号:22500BZX00417000
22800BZX00186000

● ASV療法



二相式気道陽圧ユニット

AirCurve[™] TJ

販売名:レスメドAirCurve 10 CS-A TJ
承認番号:22900BZI00028000

● CPAP療法



持続的自動気道陽圧ユニット
(CPAP装置)

スリープメイト[®] 10

販売名:スリープメイト10
承認番号:22700BZI00027000

ご使用前に添付文書および取扱説明書をよく読み、正しくお使いください。



LIFE EXPLOSION

Our mission is to foster a "Life Explosion" that enriches the lives of people around the world. In pursuit of this mission, we maintain the goal of delivering cures and hope to patients with unmet medical needs.

2021.9

HEALIOS K.K.
<https://www.healios.co.jp/en/>

INVENTING FOR LIFE

人々の生命を救い
人生を健やかにするために、挑みつける。

最先端の医薬品の創造。それは長く険しい道のりです。
懸命な研究開発の99%以上は実を結ばない現実。
でも、決してあきらめない。
あなたや、あなた大切な人の「いのち」のために、
革新的な新薬とワクチンの発見、開発、提供を
私たちは続けていきます。

MSD製薬
INVENTING FOR LIFE

MSD株式会社 www.msd.co.jp 東京都千代田区九段北1-13-12 北の丸スクエア

 大日本住友製薬

ポリエンマクロライド系抗真菌性抗生物質製剤 ————— 薬価基準収載
毒薬・処方箋医薬品 (注意—医師等の処方箋により使用すること)

アムビゾム[®] 点滴静注用50mg
注射用アムホテリシンBリボソーム製剤 (略号:L-AMB) *Ambisome[®]*

効能・効果、用法・用量、禁忌を含む使用上の注意等
については、添付文書をご参照ください。

製造販売元 (文献請求先及び問い合わせ先)

大日本住友製薬株式会社
〒541-0045 大阪市中央区道修町 2-6-8

〈製品に関するお問い合わせ先〉

くすり情報センター
TEL 0120-034-389

受付時間 / 月~金 9:00~17:30 (祝・祭日を除く)
<https://ds-pharma.jp/>

提携

 **GILEAD**

2019.7作成

TB.
TO FIND
IT IS TO
FIGHT IT.

結核
めざして。
ぜろ
を

年間130万人が命を落としている感染症、結核¹⁾。すべての結核検査は、感染を発見し、患者と地域社会を守り、パンデミックに立ち向かうための機会となりえます。

1) World Health Organization, Global tuberculosis report 2019.
License: CC BY-NC-SA 3.0 IGO

医療従事者向け情報サイト開設

<https://tspot.jp/>

会員登録はこちらから



【製品に関するお問い合わせ先】

オックスフォード・イムノテック株式会社

横浜市港北区新横浜 3-8-8 日総第16ビル 8F
TEL. 0120-718-004 FAX. 045-473-8006
e-mail: contact-jp@oxfordimmunotec.com

 **Oxford**
Immunotec

T-スポット[®]、T-SPOT[®]、T-Cell Xtend[®]はOxford Immunotec Limitedの登録商標です。

TB-JP-FLY-NA-0001_0001
© Oxford Immunotec 2021. All rights reserved.

PHILIPS

Healthcare



No bounds. Better healthcare.

Together, we make life better.

innovation  you

Philips Building, 2-13-37 Konan, Minato-ku, Tokyo 108-8507 Japan
www.philips.co.jp
© 2021 Philips Japan, Ltd.

